11. Literaturverzeichnis – Hepatozelluläres Karzinom und biliäre Karzinome
1. Lamarca, Angela, Palmer, Daniel H., Wasan, Harpreet Singh, Ross, Paul J., Ma, Yuk Ting, Arora, Arvind, et.al. ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy, Journal of Clinical Oncology, 2019. 37(15_suppl): p. 4003-4003., https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.4003
2. Bruix, J, Sherman, M, Management of hepatocellular carcinoma: an update., Hepatology, 2011. 53 (3)(3): p. 1020-2., https://pubmed.ncbi.nlm.nih.gov/21374666/
3. World Health Organization, The Global Cancer Observatory, 2021., https://gco.iarc.fr/
4. Robert-Koch-Institut (RKI), Zentrum für Krebsregisterdaten, 2021., https://www.krebsdaten.de/
5. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma, J Hepatol, 2018. 69(1): p. 182-236., https://www.sciencedirect.com/science/article/pii/S0168827818302150
6. Sangiovanni, A., Prati, G. M., Fasani, P., Ronchi, G., Romeo, R., Manini, M., et.al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients, Hepatology, 2006. 43(6): p. 1303-10., https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.21176
7. Ioannou, G. N., Splan, M. F., Weiss, N. S., McDonald, G. B., Beretta, L., Lee, S. P., Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis, Clin Gastroenterol Hepatol, 2007. 5(8): p. 938-45, 945.e1-4.
8. Kanwal, F., Kramer, J. R., Asch, S. M., Cao, Y., Li, L., El-Serag, H. B., Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents, Hepatology, 2020. 71(1): p. 44-55., https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.30823?download=true
9. Kanwal, F., Kramer, J. R., Mapakshi, S., Natarajan, Y., Chayanupatkul, M., Richardson, P. A., et.al. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease, Gastroenterology, 2018. 155(6): p. 1828-1837.e2., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279617/pdf/nihms-1504451.pdf
10. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease, J Hepatol, 2016. 64(6): p. 1388-402., https://pubmed.ncbi.nlm.nih.gov/27062661/
11. Frenette, C. T., Isaacson, A. J., Bargellini, I., Saab, S., Singal, A. G., A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk, Mayo Clin Proc Innov Qual Outcomes, 2019. 3(3): p. 302-310., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713857/pdf/main.pdf
12. Cucchetti, A., Cescon, M., Erroi, V., Pinna, A. D., Cost-effectiveness of liver cancer screening, Best Pract Res Clin Gastroenterol, 2013. 27(6): p. 961-72.
13. Brouwer, W. P., van der Meer, A. J. P., Boonstra, A., Plompen, E. P. C., Pas, S. D., de Knegt, R. J., et.al. Prediction of long-term clinical outcome in a diverse chronic hepatitis B population: Role of the PAGE-B score, J Viral Hepat, 2017. 24(11): p. 1023-1031., https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jvh.12727?download=true
14. Papatheodoridis, G., Dalekos, G., Sypsa, V., Yurdaydin, C., Buti, M., Goulis, J., et.al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy, J Hepatol, 2016. 64(4): p. 800-6., https://www.sciencedirect.com/science/article/pii/S0168827815007953?via%3Dihub
15. Papatheodoridis, G. V., Lampertico, P., Manolakopoulos, S., Lok, A., Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review, J Hepatol, 2010. 53(2): p. 348-56.
16. Yuen, M. F., Tanaka, Y., Fong, D. Y., Fung, J., Wong, D. K., Yuen, J. C., et.al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B, J Hepatol, 2009. 50(1): p. 80-8., https://www.sciencedirect.com/science/article/pii/S0168827808005655?via%3Dihub
17. Yang, H. I., Yuen, M. F., Chan, H. L., Han, K. H., Chen, P. J., Kim, D. Y., et.al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score, Lancet Oncol, 2011. 12(6): p. 568-74., https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70077-8/fulltext
18. Wong, V. W., Chan, S. L., Mo, F., Chan, T. C., Loong, H. H., Wong, G. L., et.al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers, J Clin Oncol, 2010. 28(10): p. 1660-5.
19. Yip, T. C., Wong, G. L., Wong, V. W., Tse, Y. K., Liang, L. Y., Hui, V. W., et.al. Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B, J Hepatol, 2020. 72(5): p. 847-854., https://www.sciencedirect.com/science/article/abs/pii/S0168827819307172?via%3Dihub
20. Marrero, J. A., Kulik, L. M., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., et.al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases, Hepatology, 2018. 68(2): p. 723-750., https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.29913?download=true
21. Mittal, S., El-Serag, H. B., Sada, Y. H., Kanwal, F., Duan, Z., Temple, S., et.al. Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease, Clin Gastroenterol Hepatol, 2016. 14(1): p. 124-31.e1., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690789/pdf/nihms709433.pdf
22. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis, J Hepatol, 2015. 63(1): p. 237-64.
23. Thomas, JA, Kendall, BJ, Dalais, C, Macdonald, GA, Thrift, AP, Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: A systematic review and meta-analysis., Eur J Cancer, 2022. 173 (): p. 250-262., https://pubmed.ncbi.nlm.nih.gov/35944373/
24. Loosen, SH, Kostev, K, Keitel, V, Tacke, F, Roderburg, C, Luedde, T, An elevated FIB-4 score predicts liver cancer development: A longitudinal analysis from 29,999 patients with NAFLD., J Hepatol, 2022. 76 (1)(1): p. 247-248., https://pubmed.ncbi.nlm.nih.gov/34520785/
25. Castera, L., Friedrich-Rust, M., Loomba, R., Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease, Gastroenterology, 2019. 156(5): p. 1264-1281.e4., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505052/pdf/nihms-1567724.pdf
26. Roeb, E., Steffen, H. M., Bantel, H., Baumann, U., Canbay, A., Demir, M., et.al. [S2k Guideline non-alcoholic fatty liver disease], Z Gastroenterol, 2015. 53(7): p. 668-723., https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0035-1553193
27. Roeb, E., Geier, A., Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments, Z Gastroenterol, 2019. 57(4): p. 508-517., https://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-0784-8827
28. Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., et.al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD, Hepatology, 2007. 45(4): p. 846-54., https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.21496?download=true
29. Tanwar, S., Trembling, P. M., Hogan, B. J., Parkes, J., Harris, S., Grant, P., et.al. Biomarkers of Hepatic Fibrosis in Chronic Hepatitis C: A Comparison of 10 Biomarkers Using 2 Different Assays for Hyaluronic Acid, J Clin Gastroenterol, 2017. 51(3): p. 268-277., https://www.ingentaconnect.com/content/wk/jcga/2017/00000051/00000003/art00015;jsessionid=4j79pxsus6e3.x-ic-live-03
30. Kanwal, F., Kramer, J., Asch, S. M., Chayanupatkul, M., Cao, Y., El-Serag, H. B., Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents, Gastroenterology, 2017. 153(4): p. 996-1005.e1., https://pubmed.ncbi.nlm.nih.gov/28642197/
31. Masuzaki, R., Tateishi, R., Yoshida, H., Goto, E., Sato, T., Ohki, T., et.al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography, Hepatology, 2009. 49(6): p. 1954-61., https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.22870
32. El-Serag, H. B., Kanwal, F., Richardson, P., Kramer, J., Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection, Hepatology, 2016. 64(1): p. 130-7., https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.28535?download=true
33. Ioannou, G. N., Beste, L. A., Green, P. K., Singal, A. G., Tapper, E. B., Waljee, A. K., et.al. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores, Gastroenterology, 2019. 157(5): p. 1264-1278.e4., https://www.sciencedirect.com/science/article/abs/pii/S001650851941130X?via%3Dihub
34. Omata, M., Cheng, A. L., Kokudo, N., Kudo, M., Lee, J. M., Jia, J., et.al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update, Hepatol Int, 2017. 11(4): p. 317-370., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491694/pdf/12072_2017_Article_9799.pdf
35. Younes, R., Bugianesi, E., Should we undertake surveillance for HCC in patients with NAFLD?, J Hepatol, 2018. 68(2): p. 326-334., https://www.journal-of-hepatology.eu/article/S0168-8278(17)32353-X/fulltext
36. Simeone, J. C., Bae, J. P., Hoogwerf, B. J., Li, Q., Haupt, A., Ali, A. K., et.al. Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes, Clin Epidemiol, 2017. 9: p. 679-688., https://pubmed.ncbi.nlm.nih.gov/29276410/
37. Fujiwara, N., Friedman, S. L., Goossens, N., Hoshida, Y., Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine, J Hepatol, 2018. 68(3): p. 526-549., https://www.journal-of-hepatology.eu/article/S0168-8278(17)32328-0/pdf
38. Gellert-Kristensen, H, Richardson, TG, Davey Smith, G, Nordestgaard, BG, Tybjaerg-Hansen, A, Stender, S, Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population., Hepatology, 2020. 72 (3)(3): p. 845-856., https://pubmed.ncbi.nlm.nih.gov/32190914/
39. Raffetti, E., Fattovich, G., Donato, F., Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis, Liver Int, 2016. 36(9): p. 1239-51., https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/liv.13142?download=true
40. Papatheodoridis, G. V., Chan, H. L., Hansen, B. E., Janssen, H. L., Lampertico, P., Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy, J Hepatol, 2015. 62(4): p. 956-67., https://air.unimi.it/retrieve/handle/2434/437611/717191/1-s2.0-S0168827815000045-main.pdf
41. Orci, LA, Sanduzzi-Zamparelli, M, Caballol, B, Sapena, V, Colucci, N, Torres, F, et.al. Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression., Clin Gastroenterol Hepatol, 2022. 20 (2)(2): p. 283-292.e10., https://pubmed.ncbi.nlm.nih.gov/33965578/
42. Björkström, K, Widman, L, Hagström, H, Risk of hepatic and extrahepatic cancer in NAFLD: A population-based cohort study., Liver Int, 2022. 42 (4)(4): p. 820-828., https://pubmed.ncbi.nlm.nih.gov/35152526/
43. Huang, DQ, Tan, DJH, Ng, CH, Amangurbanova, M, Sutter, N, Lin Tay, PW, et.al. Hepatocellular Carcinoma Incidence in Alcohol-Associated Cirrhosis: Systematic Review and Meta-analysis., Clin Gastroenterol Hepatol, 2023. 21 (5)(5): p. 1169-1177., https://pubmed.ncbi.nlm.nih.gov/35940513/
44. Lithner, F, Wetterberg, L, Hepatocellular carcinoma in patients with acute intermittent porphyria., Acta Med Scand, 1984. 215 (3)(3): p. 271-4., https://pubmed.ncbi.nlm.nih.gov/6328897/
45. Baravelli, CM, Sandberg, S, Aarsand, AK, Nilsen, RM, Tollånes, MC, Acute hepatic porphyria and cancer risk: a nationwide cohort study., J Intern Med, 2017. 282 (3)(3): p. 229-240., https://pubmed.ncbi.nlm.nih.gov/28730628/
46. Jang, HJ, Yang, HR, Ko, JS, Moon, JS, Chang, JY, Seo, JK, Development of Hepatocellular Carcinoma in Patients with Glycogen Storage Disease: a Single Center Retrospective Study., J Korean Med Sci, 2020. 35 (1)(1): p. e5., https://pubmed.ncbi.nlm.nih.gov/31898434/
47. Bianchi, L, Glycogen storage disease I and hepatocellular tumours., Eur J Pediatr, 1993. 152 Suppl 1 (): p. S63-70., https://pubmed.ncbi.nlm.nih.gov/8391447/
48. de Fost, M, Vom Dahl, S, Weverling, GJ, Brill, N, Brett, S, Häussinger, D, et.al. Increased incidence of cancer in adult Gaucher disease in Western Europe., Blood Cells Mol Dis 36 (1)(1): p. 53-8., https://pubmed.ncbi.nlm.nih.gov/16246599/
49. Regenboog, M, van Dussen, L, Verheij, J, Weinreb, NJ, Santosa, D, Vom Dahl, S, et.al. Hepatocellular carcinoma in Gaucher disease: an international case series., J Inherit Metab Dis, 2018. 41 (5)(5): p. 819-827., https://pubmed.ncbi.nlm.nih.gov/29423829/
50. Bartlett, DC, Lloyd, C, McKiernan, PJ, Newsome, PN, Early nitisinone treatment reduces the need for liver transplantation in children with tyrosinaemia type 1 and improves post-transplant renal function., J Inherit Metab Dis, 2014. 37 (5)(5): p. 745-52., https://pubmed.ncbi.nlm.nih.gov/24515874/
51. Poon, D., Anderson, B. O., Chen, L. T., Tanaka, K., Lau, W. Y., Van Cutsem, E., et.al. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009, Lancet Oncol, 2009. 10(11): p. 1111-8.
52. Chang, M. H., Chen, C. J., Lai, M. S., Hsu, H. M., Wu, T. C., Kong, M. S., et.al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group, N Engl J Med, 1997. 336(26): p. 1855-9., https://www.nejm.org/doi/pdf/10.1056/NEJM199706263362602?articleTools=true
53. Indolfi, G., Easterbrook, P., Dusheiko, G., Siberry, G., Chang, M. H., Thorne, C., et.al. Hepatitis B virus infection in children and adolescents, Lancet Gastroenterol Hepatol, 2019. 4(6): p. 466-476., https://www.sciencedirect.com/science/article/abs/pii/S2468125319300421?via%3Dihub
54. Inoue, M., Yoshimi, I., Sobue, T., Tsugane, S., Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan, J Natl Cancer Inst, 2005. 97(4): p. 293-300., https://pubmed.ncbi.nlm.nih.gov/15713964/
55. Bravi, F., Tavani, A., Bosetti, C., Boffetta, P., La Vecchia, C., Coffee and the risk of hepatocellular carcinoma and chronic liver disease: a systematic review and meta-analysis of prospective studies, Eur J Cancer Prev, 2017. 26(5): p. 368-377.
56. Aleksandrova, K., Bamia, C., Drogan, D., Lagiou, P., Trichopoulou, A., Jenab, M., et.al. The association of coffee intake with liver cancer risk is mediated by biomarkers of inflammation and hepatocellular injury: data from the European Prospective Investigation into Cancer and Nutrition, Am J Clin Nutr, 2015. 102(6): p. 1498-508., http://spiral.imperial.ac.uk/bitstream/10044/1/29882/11/Am%20J%20Clin%20Nutr-2015-Aleksandrova-1498-508.pdf
57. Setiawan, V. W., Wilkens, L. R., Lu, S. C., Hernandez, B. Y., Le Marchand, L., Henderson, B. E., Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort, Gastroenterology, 2015. 148(1): p. 118-25; quiz e15., https://pubmed.ncbi.nlm.nih.gov/25305507/
58. Saab, S., Mallam, D., Cox, G. A., 2nd, Tong, M. J., Impact of coffee on liver diseases: a systematic review, Liver Int, 2014. 34(4): p. 495-504.
59. Bhurwal, A., Rattan, P., Yoshitake, S., Pioppo, L., Reja, D., Dellatore, P., et.al. Inverse Association of Coffee with Liver Cancer Development: An Updated Systematic Review and Meta-analysis, J Gastrointestin Liver Dis, 2020. 29(3): p. 421-428., https://www.jgld.ro/jgld/index.php/jgld/article/download/805/1593
60. Kennedy, O. J., Roderick, P., Buchanan, R., Fallowfield, J. A., Hayes, P. C., Parkes, J., Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: a systematic review and dose-response meta-analysis, BMJ Open, 2017. 7(5): p. e013739., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730000/pdf/bmjopen-2016-013739.pdf
61. Filippini, T., Malavolti, M., Borrelli, F., Izzo, A. A., Fairweather-Tait, S. J., Horneber, M., et.al. Green tea (Camellia sinensis) for the prevention of cancer, Cochrane Database Syst Rev, 2020. 3(3): p. Cd005004.
62. Singh, S., Fujii, L. L., Murad, M. H., Wang, Z., Asrani, S. K., Ehman, R. L., et.al. Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis, Clin Gastroenterol Hepatol, 2013. 11(12): p. 1573-84.e1-2; quiz e88-9., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3900882/pdf/nihms532555.pdf
63. Tseng, C. H., Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes, Liver Int, 2018. 38(11): p. 2018-2027.
64. Cunha, V., Cotrim, H. P., Rocha, R., Carvalho, K., Lins-Kusterer, L., Metformin in the prevention of hepatocellular carcinoma in diabetic patients: A systematic review, Ann Hepatol, 2020. 19(3): p. 232-237.
65. Harris, K., Smith, L., Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C, Ann Pharmacother, 2013. 47(10): p. 1348-52., https://journals.sagepub.com/doi/pdf/10.1177/1060028013503108
66. Inzucchi, S. E., Lipska, K. J., Mayo, H., Bailey, C. J., McGuire, D. K., Metformin in patients with type 2 diabetes and kidney disease: a systematic review, Jama, 2014. 312(24): p. 2668-75., https://jamanetwork.com/journals/jama/articlepdf/2084896/jrv140019.pdf
67. Zhang, X, Harmsen, WS, Mettler, TA, Kim, WR, Roberts, RO, Therneau, TM, et.al. Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes., Hepatology, 2014. 60 (6)(6): p. 2008-16., https://pubmed.ncbi.nlm.nih.gov/24798175/
68. Vandenbulcke, H., Moreno, C., Colle, I., Knebel, J. F., Francque, S., Sersté, T., et.al. Alcohol intake increases the risk of HCC in hepatitis C virus-related compensated cirrhosis: A prospective study, J Hepatol, 2016. 65(3): p. 543-51.
69. Roeb, E, Canbay, A, Bantel, H, Bojunga, J, de Laffolie, J, Demir, M, et.al. [Not Available]., Z Gastroenterol, 2022. 60 (9)(9): p. 1346-1421., https://pubmed.ncbi.nlm.nih.gov/36100202/
70. Ascha, M. S., Hanouneh, I. A., Lopez, R., Tamimi, T. A., Feldstein, A. F., Zein, N. N., The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis, Hepatology, 2010. 51(6): p. 1972-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20209604
71. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease, J Hepatol, 2018. 69(1): p. 154-181.
72. Wang, Z. Y., Tao, Q. F., Wang, Z. H., Lin, K. Y., Huang, G., Yang, Y., et.al. Antiviral therapy improves post-operative survival outcomes in patients with HBV-related hepatocellular carcinoma of less than 3 cm - A retrospective cohort study, Am J Surg, 2020. 219(4): p. 717-725., https://www.sciencedirect.com/science/article/abs/pii/S000296101831609X?via%3Dihub
73. Jang, J. W., Yoo, S. H., Nam, H. C., Jang, B. H., Sung Sung, P. S., Lee, W., et.al. Association of Prophylactic Anti-Hepatitis B Virus Therapy With Improved Long-term Survival in Patients With Hepatocellular Carcinoma Undergoing Transarterial Therapy, Clin Infect Dis, 2020. 71(3): p. 546-555., https://pubmed.ncbi.nlm.nih.gov/31504352/
74. Yang, Y., Wen, F., Li, J., Zhang, P., Yan, W., Hao, P., et.al. A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib, Liver Int, 2015. 35(9): p. 2147-54.
75. Cabibbo, G., Celsa, C., Calvaruso, V., Petta, S., Cacciola, I., Cannavò, M. R., et.al. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients, J Hepatol, 2019. 71(2): p. 265-273., https://www.sciencedirect.com/science/article/abs/pii/S0168827819302211?via%3Dihub
76. Dang, H., Yeo, Y. H., Yasuda, S., Huang, C. F., Iio, E., Landis, C., et.al. Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma From Both East and West, Hepatology, 2020. 71(6): p. 1910-1922., https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.30988?download=true
77. Zhang, B. H., Yang, B. H., Tang, Z. Y., Randomized controlled trial of screening for hepatocellular carcinoma, J Cancer Res Clin Oncol, 2004. 130(7): p. 417-22., https://link.springer.com/content/pdf/10.1007%2Fs00432-004-0552-0.pdf
78. Trevisani, F., Santi, V., Gramenzi, A., Di Nolfo, M. A., Del Poggio, P., Benvegnù, L., et.al. Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis?, Am J Gastroenterol, 2007. 102(11): p. 2448-57; quiz 2458.
79. Trevisani, F., Santi, V., Gramenzi, A., Di Nolfo, M. A., Del Poggio, P., Benvegnu, L., et.al. Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis?, Am J Gastroenterol, 2007. 102(11): p. 2448-57; quiz 2458.
80. Fan, R, Papatheodoridis, G, Sun, J, Innes, H, Toyoda, H, Xie, Q, et.al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis., J Hepatol, 2020. 73 (6)(6): p. 1368-1378., https://pubmed.ncbi.nlm.nih.gov/32707225/
81. Johnson, PJ, Innes, H, Hughes, DM, Kalyuzhnyy, A, Kumada, T, Toyoda, H, Evaluation of the aMAP score for hepatocellular carcinoma surveillance: a realistic opportunity to risk stratify., Br J Cancer, 2022. 127 (7)(7): p. 1263-1269., https://pubmed.ncbi.nlm.nih.gov/35798825/
82. Pocha, C., Dieperink, E., McMaken, K. A., Knott, A., Thuras, P., Ho, S. B., Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography -- a randomised study, Aliment Pharmacol Ther, 2013. 38(3): p. 303-12., https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.12370
83. Trinchet, J. C., Chaffaut, C., Bourcier, V., Degos, F., Henrion, J., Fontaine, H., et.al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities, Hepatology, 2011. 54(6): p. 1987-97., https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.24545
84. Tzartzeva, K., Obi, J., Rich, N. E., Parikh, N. D., Marrero, J. A., Yopp, A., et.al. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis, Gastroenterology, 2018. 154(6): p. 1706-1718.e1., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927818/pdf/nihms940431.pdf
85. Song, B. G., Sinn, D. H., Chi, S., Kim, K., Kang, W., Gwak, G. Y., et.al. Additional role of liver stiffness measurement in stratifying residual hepatocellular carcinoma risk predicted by serum biomarkers in chronic hepatitis B patients under antiviral therapy, Eur J Gastroenterol Hepatol, 2018. 30(12): p. 1447-1452.
86. Singal, A. G., Pillai, A., Tiro, J., Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis, PLoS Med, 2014. 11(4): p. e1001624., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3972088/pdf/pmed.1001624.pdf
87. Feng, H, Li, B, Li, Z, Wei, Q, Ren, L, PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma., BMC Cancer, 2021. 21 (1)(1): p. 401., https://pubmed.ncbi.nlm.nih.gov/33849479/
88. Ricco, G, Cosma, C, Bedogni, G, Biasiolo, A, Guarino, M, Pontisso, P, et.al. Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma., Cancer Biomark, 2020. 29 (2)(2): p. 189-196., https://pubmed.ncbi.nlm.nih.gov/32623383/
89. Hemken, PM, Sokoll, LJ, Yang, X, Dai, J, Elliott, D, Gawel, SH, et.al. Validation of a novel model for the early detection of hepatocellular carcinoma., Clin Proteomics, 2019. 16 (): p. 2., https://pubmed.ncbi.nlm.nih.gov/30675135/
90. Xu, F, Zhang, L, He, W, Song, D, Ji, X, Shao, J, The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients., Dis Markers, 2021. 2021 (): p. 8868370., https://pubmed.ncbi.nlm.nih.gov/33628341/
91. Poté, N, Cauchy, F, Albuquerque, M, Voitot, H, Belghiti, J, Castera, L, et.al. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion., J Hepatol, 2015. 62 (4)(4): p. 848-54., https://pubmed.ncbi.nlm.nih.gov/25450201/
92. Loglio, A, Iavarone, M, Facchetti, F, Di Paolo, D, Perbellini, R, Lunghi, G, et.al. The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy., Liver Int, 2020. 40 (8)(8): p. 1987-1996., https://pubmed.ncbi.nlm.nih.gov/32301212/
93. Best, J, Bechmann, LP, Sowa, JP, Sydor, S, Dechêne, A, Pflanz, K, et.al. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis., Clin Gastroenterol Hepatol, 2020. 18 (3)(3): p. 728-735.e4., https://pubmed.ncbi.nlm.nih.gov/31712073/
94. Yang, JD, Addissie, BD, Mara, KC, Harmsen, WS, Dai, J, Zhang, N, et.al. GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score., Cancer Epidemiol Biomarkers Prev, 2019. 28 (3)(3): p. 531-538., https://pubmed.ncbi.nlm.nih.gov/30464023/
95. Schotten, C, Ostertag, B, Sowa, JP, Manka, P, Bechmann, LP, Hilgard, G, et.al. GALAD Score Detects Early-Stage Hepatocellular Carcinoma in a European Cohort of Chronic Hepatitis B and C Patients., Pharmaceuticals (Basel), 2021. 14 (8)(8):, https://pubmed.ncbi.nlm.nih.gov/34451832/
96. Huang, C, Fang, M, Xiao, X, Wang, H, Gao, Z, Ji, J, et.al. Validation of the GALAD model for early diagnosis and monitoring of hepatocellular carcinoma in Chinese multicenter study., Liver Int, 2022. 42 (1)(1): p. 210-223., https://pubmed.ncbi.nlm.nih.gov/34679250/
97. Tayob, N, Kanwal, F, Alsarraj, A, Hernaez, R, El-Serag, HB, The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States., Clin Gastroenterol Hepatol, 2023. 21 (2)(2): p. 415-423.e4., https://pubmed.ncbi.nlm.nih.gov/35124267/
98. Singal, AG, Tayob, N, Mehta, A, Marrero, JA, El-Serag, H, Jin, Q, et.al. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis., Hepatology, 2022. 75 (3)(3): p. 541-549., https://pubmed.ncbi.nlm.nih.gov/34618932/
99. Chan, HLY, Vogel, A, Berg, T, De Toni, EN, Kudo, M, Trojan, J, et.al. Performance evaluation of the Elecsys PIVKA-II and Elecsys AFP assays for hepatocellular carcinoma diagnosis., JGH Open, 2022. 6 (5)(5): p. 292-300., https://pubmed.ncbi.nlm.nih.gov/35601131/
100. Chalasani, NP, Porter, K, Bhattacharya, A, Book, AJ, Neis, BM, Xiong, KM, et.al. Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma., Clin Gastroenterol Hepatol, 2022. 20 (1)(1): p. 173-182.e7., https://pubmed.ncbi.nlm.nih.gov/34391922/
101. Loomba, R., Lim, J. K., Patton, H., El-Serag, H. B., AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review, Gastroenterology, 2020. 158(6): p. 1822-1830.
102. Petrick, J. L., Thistle, J. E., Zeleniuch-Jacquotte, A., Zhang, X., Wactawski-Wende, J., Van Dyke, A. L., et.al. Body Mass Index, Diabetes and Intrahepatic Cholangiocarcinoma Risk: The Liver Cancer Pooling Project and Meta-analysis, Am J Gastroenterol, 2018. 113(10): p. 1494-1505., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521884/pdf/nihms-1027973.pdf
103. Loomba, R., Adams, L. A., Advances in non-invasive assessment of hepatic fibrosis, Gut, 2020. 69(7): p. 1343-1352., https://gut.bmj.com/content/69/7/1343.long
104. Singh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., Loomba, R., Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies, Clin Gastroenterol Hepatol, 2015. 13(4): p. 643-54.e1-9; quiz e39-40., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4208976/pdf/nihms-604814.pdf
105. Sterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., et.al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection, Hepatology, 2006. 43(6): p. 1317-25.
106. Taylor, R. S., Taylor, R. J., Bayliss, S., Hagström, H., Nasr, P., Schattenberg, J. M., et.al. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis, Gastroenterology, 2020. 158(6): p. 1611-1625.e12.
107. Rockey, D. C., Caldwell, S. H., Goodman, Z. D., Nelson, R. C., Smith, A. D., Liver biopsy, Hepatology, 2009. 49(3): p. 1017-44., https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.22742?download=true
108. Silva, M. A., Hegab, B., Hyde, C., Guo, B., Buckels, J. A., Mirza, D. F., Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis, Gut, 2008. 57(11): p. 1592-6., https://gut.bmj.com/content/gutjnl/57/11/1592.full.pdf
109. Müllhaupt, B., Durand, F., Roskams, T., Dutkowski, P., Heim, M., Is tumor biopsy necessary?, Liver Transpl, 2011. 17 Suppl 2: p. S14-25., https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lt.22374?download=true
110. Fuks, D., Cauchy, F., Fusco, G., Paradis, V., Durand, F., Belghiti, J., Preoperative tumour biopsy does not affect the oncologic course of patients with transplantable HCC, J Hepatol, 2014. 61(3): p. 589-93.
111. Paradis V, Fukayama M, Park YN, Schirmacher P, Tumors of the liver and intrahepatic bile ducts., In: WHO Classification of Tumours Editorial Board WHO-Classification of Tumours (5th ed.) Digestive System Tumours. International Agency for Research on Cancer, Lyon 2019. p. 215-264.
112. Terminology of nodular hepatocellular lesions, Hepatology, 1995. 22(3): p. 983-93., https://www.sciencedirect.com/science/article/abs/pii/0270913995903240?via%3Dihub
113. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia, Hepatology, 2009. 49(2): p. 658-64., https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.22709?download=true
114. Burt, A. D., Alves, V., Bedossa, P., Clouston, A., Guido, M., Hübscher, S., et.al. Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR), Histopathology, 2018. 73(3): p. 369-385., https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/his.13520?download=true
115. Edmondson, Hugh A., Steiner, Paul E., Primary carcinoma of the liver. A study of 100 cases among 48,900 necropsies, Cancer, 1954. 7(3): p. 462-503., https://acsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142%28195405%297%3A3%3C462%3A%3AAID-CNCR2820070308%3E3.0.CO%3B2-E
116. Nzeako, U. C., Goodman, Z. D., Ishak, K. G., Comparison of tumor pathology with duration of survival of North American patients with hepatocellular carcinoma, Cancer, 1995. 76(4): p. 579-88., https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/1097-0142%2819950815%2976%3A4%3C579%3A%3AAID-CNCR2820760407%3E3.0.CO%3B2-D?download=true
117. Di Tommaso, L., Franchi, G., Park, Y. N., Fiamengo, B., Destro, A., Morenghi, E., et.al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis, Hepatology, 2007. 45(3): p. 725-34., https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.21531?download=true
118. Di Tommaso, L., Destro, A., Seok, J. Y., Balladore, E., Terracciano, L., Sangiovanni, A., et.al. The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma, J Hepatol, 2009. 50(4): p. 746-54.
119. Lee, Y. J., Lee, J. M., Lee, J. S., Lee, H. Y., Park, B. H., Kim, Y. H., et.al. Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis, Radiology, 2015. 275(1): p. 97-109.
120. Chen, N., Motosugi, U., Morisaka, H., Ichikawa, S., Sano, K., Ichikawa, T., et.al. Added Value of a Gadoxetic Acid-enhanced Hepatocyte-phase Image to the LI-RADS System for Diagnosing Hepatocellular Carcinoma, Magn Reson Med Sci, 2016. 15(1): p. 49-59., https://www.jstage.jst.go.jp/article/mrms/15/1/15_2014-0149/_pdf
121. Granito, A., Galassi, M., Piscaglia, F., Romanini, L., Lucidi, V., Renzulli, M., et.al. Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study, Aliment Pharmacol Ther, 2013. 37(3): p. 355-63., https://www.onlinelibrary.wiley.com/doi/pdf/10.1111/apt.12166
122. Haradome, H., Grazioli, L., Tinti, R., Morone, M., Motosugi, U., Sano, K., et.al. Additional value of gadoxetic acid-DTPA-enhanced hepatobiliary phase MR imaging in the diagnosis of early-stage hepatocellular carcinoma: comparison with dynamic triple-phase multidetector CT imaging, J Magn Reson Imaging, 2011. 34(1): p. 69-78., https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmri.22588
123. Inoue, T., Kudo, M., Komuta, M., Hayaishi, S., Ueda, T., Takita, M., et.al. Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCT, J Gastroenterol, 2012. 47(9): p. 1036-47., https://link.springer.com/content/pdf/10.1007%2Fs00535-012-0571-6.pdf
124. Maiwald, B., Lobsien, D., Kahn, T., Stumpp, P., Is 3-Tesla Gd-EOB-DTPA-enhanced MRI with diffusion-weighted imaging superior to 64-slice contrast-enhanced CT for the diagnosis of hepatocellular carcinoma?, PLoS One, 2014. 9(11): p. e111935., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223069/pdf/pone.0111935.pdf
125. Park, V. Y., Choi, J. Y., Chung, Y. E., Kim, H., Park, M. S., Lim, J. S., et.al. Dynamic enhancement pattern of HCC smaller than 3 cm in diameter on gadoxetic acid-enhanced MRI: comparison with multiphasic MDCT, Liver Int, 2014. 34(10): p. 1593-602., https://onlinelibrary.wiley.com/doi/pdf/10.1111/liv.12550
126. Sun, H. Y., Lee, J. M., Shin, C. I., Lee, D. H., Moon, S. K., Kim, K. W., et.al. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging, Invest Radiol, 2010. 45(2): p. 96-103., https://www.ncbi.nlm.nih.gov/pubmed/20057319
127. Tsurusaki, M., Sofue, K., Isoda, H., Okada, M., Kitajima, K., Murakami, T., Comparison of gadoxetic acid-enhanced magnetic resonance imaging and contrast-enhanced computed tomography with histopathological examinations for the identification of hepatocellular carcinoma: a multicenter phase III study, J Gastroenterol, 2016. 51(1): p. 71-9., https://link.springer.com/content/pdf/10.1007%2Fs00535-015-1097-5.pdf
128. Burrel, M., Llovet, J. M., Ayuso, C., Iglesias, C., Sala, M., Miquel, R., et.al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation, Hepatology, 2003. 38(4): p. 1034-42., https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.1840380430
129. Di Martino, M., De Filippis, G., De Santis, A., Geiger, D., Del Monte, M., Lombardo, C. V., et.al. Hepatocellular carcinoma in cirrhotic patients: prospective comparison of US, CT and MR imaging, Eur Radiol, 2013. 23(4): p. 887-96., https://link.springer.com/content/pdf/10.1007%2Fs00330-012-2691-z.pdf
130. Schellhaas, B, Bernatik, T, Bohle, W, Borowitzka, F, Chang, J, Dietrich, CF, et.al. Contrast-Enhanced Ultrasound Algorithms (CEUS-LIRADS/ESCULAP) for the Noninvasive Diagnosis of Hepatocellular Carcinoma - A Prospective Multicenter DEGUM Study., Ultraschall Med, 2021. 42 (2)(2): p. e20., https://pubmed.ncbi.nlm.nih.gov/32717752/
131. Strobel, D, Jung, EM, Ziesch, M, Praktiknjo, M, Link, A, Dietrich, CF, et.al. Real-life assessment of standardized contrast-enhanced ultrasound (CEUS) and CEUS algorithms (CEUS LI-RADS®/ESCULAP) in hepatic nodules in cirrhotic patients-a prospective multicenter study., Eur Radiol, 2021. 31 (10)(10): p. 7614-7625., https://pubmed.ncbi.nlm.nih.gov/33855588/
132. Schellhaas, B, Bernatik, T, Dirks, K, Jesper, D, Mauch, M, Potthoff, A, et.al. Contrast-Enhanced Ultrasound Patterns for the Non-invasive Diagnosis of Hepatocellular Carcinoma: A Prospective Multicenter Study in Histologically Proven Liver Lesions in a Real-Life Setting Demonstrating the Benefit of Extended Late Phase Observation., Ultrasound Med Biol, 2021. 47 (11)(11): p. 3170-3180., https://pubmed.ncbi.nlm.nih.gov/34417066/
133. Chen, X, Li, M, Guo, R, Liu, W, Li, J, Zong, X, et.al. The diagnostic performance of contrast-enhanced CT versus extracellular contrast agent-enhanced MRI in detecting hepatocellular carcinoma: direct comparison and a meta-analysis., Abdom Radiol (NY), 2022. 47 (6)(6): p. 2057-2070., https://pubmed.ncbi.nlm.nih.gov/35312822/
134. Lee, S, Kim, YY, Shin, J, Roh, YH, Choi, JY, Chernyak, V, et.al. Liver Imaging Reporting and Data System version 2018 category 5 for diagnosing hepatocellular carcinoma: an updated meta-analysis., Eur Radiol, 2024. 34 (3)(3): p. 1502-1514., https://pubmed.ncbi.nlm.nih.gov/37656177/
135. V2018, CT/MRT LI-RADS®, CT/MRT LI-RADS® v2018
136. Elsayes, KM, Kielar, AZ, Elmohr, MM, Chernyak, V, Masch, WR, Furlan, A, et.al. White paper of the Society of Abdominal Radiology hepatocellular carcinoma diagnosis disease-focused panel on LI-RADS v2018 for CT and MRI., Abdom Radiol (NY), 2018. 43 (10)(10): p. 2625-2642., https://pubmed.ncbi.nlm.nih.gov/30155697/
137. Castilla-Lievre, M. A., Franco, D., Gervais, P., Kuhnast, B., Agostini, H., Marthey, L., et.al. Diagnostic value of combining (1)(1)C-choline and (1)(8)F-FDG PET/CT in hepatocellular carcinoma, Eur J Nucl Med Mol Imaging, 2016. 43(5): p. 852-859., https://www.ncbi.nlm.nih.gov/pubmed/26577938
138. Chotipanich, C., Kunawudhi, A., Promteangtrong, C., Tungsuppawattanakit, P., Sricharunrat, T., Wongsa, P., Diagnosis of Hepatocellular Carcinoma Using C11 Choline PET/CT: Comparison with F18 FDG, ContrastEnhanced MRI and MDCT, Asian Pac J Cancer Prev, 2016. 17(7): p. 3569-73., https://www.ncbi.nlm.nih.gov/pubmed/27510010
139. Hong, G., Suh, K. S., Suh, S. W., Yoo, T., Kim, H., Park, M. S., et.al. Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation, J Hepatol, 2016. 64(4): p. 852-9., https://www.ncbi.nlm.nih.gov/pubmed/26658686
140. Lin, C. Y., Liao, C. W., Chu, L. Y., Yen, K. Y., Jeng, L. B., Hsu, C. N., et.al. Predictive Value of 18F-FDG PET/CT for Vascular Invasion in Patients With Hepatocellular Carcinoma Before Liver Transplantation, Clin Nucl Med, 2017. 42(4): p. e183-e187., https://www.ncbi.nlm.nih.gov/pubmed/28114226
141. Khalili, K., Kim, T. K., Jang, H. J., Haider, M. A., Khan, L., Guindi, M., et.al. Optimization of imaging diagnosis of 1-2 cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization, J Hepatol, 2011. 54(4): p. 723-8., https://www.sciencedirect.com/science/article/pii/S0168827810008147?via%3Dihub
142. Giorgio, A., Montesarchio, L., Gatti, P., Amendola, F., Matteucci, P., Santoro, B., et.al. Contrast-Enhanced Ultrasound: a Simple and Effective Tool in Defining a Rapid Diagnostic Work-up for Small Nodules Detected in Cirrhotic Patients during Surveillance, J Gastrointestin Liver Dis, 2016. 25(2): p. 205-11., https://www.ncbi.nlm.nih.gov/pubmed/27308652
143. Schellhaas, B., Gortz, R. S., Pfeifer, L., Kielisch, C., Neurath, M. F., Strobel, D., Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS, Eur J Gastroenterol Hepatol, 2017. 29(9): p. 1036-1044., https://www.ncbi.nlm.nih.gov/pubmed/28562394
144. Mitchell, D. G., Bruix, J., Sherman, M., Sirlin, C. B., LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions, Hepatology, 2015. 61(3): p. 1056-65., https://www.ncbi.nlm.nih.gov/pubmed/25041904
145. Llovet, J. M., Bru, C., Bruix, J., Prognosis of hepatocellular carcinoma: the BCLC staging classification, Semin Liver Dis, 1999. 19(3): p. 329-38., https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2007-1007122
146. Chan, A. C., Fan, S. T., Poon, R. T., Cheung, T. T., Chok, K. S., Chan, S. C., et.al. Evaluation of the seventh edition of the American Joint Committee on Cancer tumour-node-metastasis (TNM) staging system for patients undergoing curative resection of hepatocellular carcinoma: implications for the development of a refined staging system, HPB (Oxford), 2013. 15(6): p. 439-48., https://www.hpbonline.org/article/S1365-182X(15)31417-9/pdf
147. Chevret, S., Trinchet, J. C., Mathieu, D., Rached, A. A., Beaugrand, M., Chastang, C., A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire, J Hepatol, 1999. 31(1): p. 133-41., https://www.journal-of-hepatology.eu/article/S0168-8278(99)80173-1/fulltext
148. Johnson, P. J., Berhane, S., Kagebayashi, C., Satomura, S., Teng, M., Reeves, H. L., et.al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade, J Clin Oncol, 2015. 33(6): p. 550-8., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322258/pdf/zlj550.pdf
149. Kitai, S., Kudo, M., Minami, Y., Haji, S., Osaki, Y., Oka, H., et.al. Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score, Oncology, 2008. 75 Suppl 1: p. 83-90., https://www.karger.com/Article/Abstract/173428
150. Leung, T. W., Tang, A. M., Zee, B., Lau, W. Y., Lai, P. B., Leung, K. L., et.al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients, Cancer, 2002. 94(6): p. 1760-9., https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.10384
151. Marrero, J. A., Fontana, R. J., Barrat, A., Askari, F., Conjeevaram, H. S., Su, G. L., et.al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort, Hepatology, 2005. 41(4): p. 707-16., https://pubmed.ncbi.nlm.nih.gov/15795889/
152. Pinato, D. J., Sharma, R., Allara, E., Yen, C., Arizumi, T., Kubota, K., et.al. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma, J Hepatol, 2017. 66(2): p. 338-346., https://www.journal-of-hepatology.eu/article/S0168-8278(16)30535-9/pdf
153. Vitale, A., Saracino, E., Boccagni, P., Brolese, A., D'Amico, F., Gringeri, E., et.al. Validation of the BCLC prognostic system in surgical hepatocellular cancer patients, Transplant Proc, 2009. 41(4): p. 1260-3., https://www.sciencedirect.com/science/article/pii/S0041134509004850?via%3Dihub
154. Yau, T., Tang, V. Y., Yao, T. J., Fan, S. T., Lo, C. M., Poon, R. T., Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma, Gastroenterology, 2014. 146(7): p. 1691-700.e3., https://www.gastrojournal.org/article/S0016-5085(14)00243-1/pdf
155. Sohn, J. H., Duran, R., Zhao, Y., Fleckenstein, F., Chapiro, J., Sahu, S., et.al. Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy, Clin Gastroenterol Hepatol, 2017. 15(5): p. 746-755.e4., https://www.cghjournal.org/article/S1542-3565(16)31049-7/pdf
156. Yang, A., Ju, W., Yuan, X., Han, M., Wang, X., Guo, Z., et.al. Comparison between liver resection and liver transplantation on outcomes in patients with solitary hepatocellular carcinoma meeting UNOS criteria: a population-based study of the SEER database, Oncotarget, 2017. 8(57): p. 97428-97438., https://www.oncotarget.com/article/22134/pdf/
157. Krenzien, F., Schmelzle, M., Struecker, B., Raschzok, N., Benzing, C., Jara, M., et.al. Liver Transplantation and Liver Resection for Cirrhotic Patients with Hepatocellular Carcinoma: Comparison of Long-Term Survivals, J Gastrointest Surg, 2018. 22(5): p. 840-848., https://link.springer.com/content/pdf/10.1007/s11605-018-3690-4.pdf
158. Cherqui, D., Laurent, A., Mocellin, N., Tayar, C., Luciani, A., Van Nhieu, J. T., et.al. Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation, Ann Surg, 2009. 250(5): p. 738-46.
159. Eguchi, S., Kanematsu, T., Arii, S., Omata, M., Kudo, M., Sakamoto, M., et.al. Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma, Br J Surg, 2011. 98(4): p. 552-7., https://bjssjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/bjs.7393?download=true
160. Sapisochin, G., Goldaracena, N., Laurence, J. M., Dib, M., Barbas, A., Ghanekar, A., et.al. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study, Hepatology, 2016. 64(6): p. 2077-2088., https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.28643
161. Mazzaferro, V., Battiston, C., Sposito, C., Pro (With Caution): Extended oncologic indications in liver transplantation, Liver Transpl, 2018. 24(1): p. 98-103., https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/lt.24963
162. Mazzaferro, V., Regalia, E., Doci, R., Andreola, S., Pulvirenti, A., Bozzetti, F., et.al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis, N Engl J Med, 1996. 334(11): p. 693-9., https://www.nejm.org/doi/pdf/10.1056/NEJM199603143341104?articleTools=true
163. Agopian, V. G., Harlander-Locke, M. P., Ruiz, R. M., Klintmalm, G. B., Senguttuvan, S., Florman, S. S., et.al. Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium, Ann Surg, 2017. 266(3): p. 525-535.
164. Bundesärztekammer, Richtlinien zur Organtransplantation gem. § 16 TPG, Deutsches Ärzteblatt | DOI: 10.3238/arztebl.2019.rili_baek_OrgaWlOvLeberTx2019092, 2019.
165. von Felden, J., Villanueva, A., Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma, Liver Transpl, 2020. 26(6): p. 823-831.
166. Yao, F. Y., Ferrell, L., Bass, N. M., Watson, J. J., Bacchetti, P., Venook, A., et.al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival, Hepatology, 2001. 33(6): p. 1394-403.
167. Mazzaferro, V., Llovet, J. M., Miceli, R., Bhoori, S., Schiavo, M., Mariani, L., et.al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis, Lancet Oncol, 2009. 10(1): p. 35-43., https://www.sciencedirect.com/science/article/pii/S1470204508702845?via%3Dihub
168. Sinha, J., Mehta, N., Dodge, J. L., Poltavskiy, E., Roberts, J., Yao, F., Are There Upper Limits in Tumor Burden for Down-Staging of Hepatocellular Carcinoma to Liver Transplant? Analysis of the All-Comers Protocol, Hepatology, 2019. 70(4): p. 1185-1196., https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.30570
169. Lai, Q., Vitale, A., Halazun, K., Iesari, S., Viveiros, A., Bhangui, P., et.al. Identification of an Upper Limit of Tumor Burden for Downstaging in Candidates with Hepatocellular Cancer Waiting for Liver Transplantation: A West-East Collaborative Effort, Cancers (Basel), 2020. 12(2):, https://res.mdpi.com/d_attachment/cancers/cancers-12-00452/article_deploy/cancers-12-00452-v2.pdf
170. Mehta, N., Guy, J., Frenette, C. T., Dodge, J. L., Osorio, R. W., Minteer, W. B., et.al. Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study, Clin Gastroenterol Hepatol, 2018. 16(6): p. 955-964., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6053266/pdf/nihms922574.pdf
171. Otto, G., Herber, S., Heise, M., Lohse, A. W., Mönch, C., Bittinger, F., et.al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma, Liver Transpl, 2006. 12(8): p. 1260-7., https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lt.20837?download=true
172. Di Sandro, S., Sposito, C., Lauterio, A., Najjar, M., Droz Dit Busset, M., Buscemi, V., et.al. Proposal of Prognostic Survival Models before and after Liver Resection for Hepatocellular Carcinoma in Potentially Transplantable Patients, J Am Coll Surg, 2018. 226(6): p. 1147-1159., https://www.sciencedirect.com/science/article/abs/pii/S1072751518302199?via%3Dihub
173. Ferrer-Fàbrega, J., Forner, A., Liccioni, A., Miquel, R., Molina, V., Navasa, M., et.al. Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection, Hepatology, 2016. 63(3): p. 839-49., https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.28339?download=true
174. Scatton, O., Goumard, C., Cauchy, F., Fartoux, L., Perdigao, F., Conti, F., et.al. Early and resectable HCC: Definition and validation of a subgroup of patients who could avoid liver transplantation, J Surg Oncol, 2015. 111(8): p. 1007-15., https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jso.23916?download=true
175. de Haas, R. J., Lim, C., Bhangui, P., Salloum, C., Compagnon, P., Feray, C., et.al. Curative salvage liver transplantation in patients with cirrhosis and hepatocellular carcinoma: An intention-to-treat analysis, Hepatology, 2018. 67(1): p. 204-215., https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.29468?download=true
176. Bhangui, P., Allard, M. A., Vibert, E., Cherqui, D., Pelletier, G., Cunha, A. S., et.al. Salvage Versus Primary Liver Transplantation for Early Hepatocellular Carcinoma: Do Both Strategies Yield Similar Outcomes?, Ann Surg, 2016. 264(1): p. 155-63., https://www.ingentaconnect.com/content/wk/sla/2016/00000264/00000001/art00029;jsessionid=5ees0b4oapp5t.x-ic-live-02
177. Pichlmayr, R., Is there a place for liver grafting for malignancy?, Transplant Proc, 1988. 20(1 Suppl 1): p. 478-82.
178. Roayaie, S., Schwartz, J. D., Sung, M. W., Emre, S. H., Miller, C. M., Gondolesi, G. E., et.al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis, Liver Transpl, 2004. 10(4): p. 534-40., https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lt.20128?download=true
179. Shetty, K., Timmins, K., Brensinger, C., Furth, E. E., Rattan, S., Sun, W., et.al. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome, Liver Transpl, 2004. 10(7): p. 911-8., https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lt.20140?download=true
180. Lee, H. W., Song, G. W., Lee, S. G., Kim, J. M., Joh, J. W., Han, D. H., et.al. Patient Selection by Tumor Markers in Liver Transplantation for Advanced Hepatocellular Carcinoma, Liver Transpl, 2018. 24(9): p. 1243-1251., https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/lt.25056
181. Berry, K., Ioannou, G. N., Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma, Liver Transpl, 2013. 19(6): p. 634-45., https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/lt.23652
182. Vibert, E., Azoulay, D., Hoti, E., Iacopinelli, S., Samuel, D., Salloum, C., et.al. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor, Am J Transplant, 2010. 10(1): p. 129-37., https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1600-6143.2009.02750.x
183. Yao, F. Y., Mehta, N., Flemming, J., Dodge, J., Hameed, B., Fix, O., et.al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria, Hepatology, 2015. 61(6): p. 1968-77., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4809192/pdf/nihms667031.pdf
184. Hameed, B., Mehta, N., Sapisochin, G., Roberts, J. P., Yao, F. Y., Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria, Liver Transpl, 2014. 20(8): p. 945-51., https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lt.23904?download=true
185. Heimbach, J. K., Kulik, L. M., Finn, R. S., Sirlin, C. B., Abecassis, M. M., Roberts, L. R., et.al. AASLD guidelines for the treatment of hepatocellular carcinoma, Hepatology, 2018. 67(1): p. 358-380., https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.29086
186. Mehta, N., Dodge, J. L., Roberts, J. P., Hirose, R., Yao, F. Y., Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes, Hepatology, 2019. 69(3): p. 1193-1205., https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.30413?download=true
187. EASL Clinical Practice Guidelines: Liver transplantation, J Hepatol, 2016. 64(2): p. 433-485.
188. Martin, P., DiMartini, A., Feng, S., Brown, R., Jr., Fallon, M., Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation, Hepatology, 2014. 59(3): p. 1144-65., https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.26972?download=true
189. Adani, G. L., Baccarani, U., Lorenzin, D., Rossetto, A., Nicolini, D., Vecchi, A., et.al. Elderly versus young liver transplant recipients: patient and graft survival, Transplant Proc, 2009. 41(4): p. 1293-4.
190. Cross, T. J., Antoniades, C. G., Muiesan, P., Al-Chalabi, T., Aluvihare, V., Agarwal, K., et.al. Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outcomes and survival, Liver Transpl, 2007. 13(10): p. 1382-8., https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lt.21181?download=true
191. Grąt, M., Kornasiewicz, O., Grąt, K., Antczak, A., Ligocka, J., Hołówko, W., et.al. Short and long-term outcomes after primary liver transplantation in elderly patients, Pol Przegl Chir, 2013. 85(10): p. 581-8.
192. Aduen, J. F., Sujay, B., Dickson, R. C., Heckman, M. G., Hewitt, W. R., Stapelfeldt, W. H., et.al. Outcomes after liver transplant in patients aged 70 years or older compared with those younger than 60 years, Mayo Clin Proc, 2009. 84(11): p. 973-8., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2770908/pdf/mayoclinproc_84_11_004.pdf
193. Lipshutz, G. S., Hiatt, J., Ghobrial, R. M., Farmer, D. G., Martinez, M. M., Yersiz, H., et.al. Outcome of liver transplantation in septuagenarians: a single-center experience, Arch Surg, 2007. 142(8): p. 775-81; discussion 781-4., https://jamanetwork.com/journals/jamasurgery/articlepdf/400501/spc70006_775_784.pdf
194. Oezcelik, A., Dayangac, M., Guler, N., Yaprak, O., Erdogan, Y., Akyildiz, M., et.al. Living Donor Liver Transplantation in Patients 70 Years or Older, Transplantation, 2015. 99(7): p. 1436-40.
195. Taner, C. B., Ung, R. L., Rosser, B. G., Aranda-Michel, J., Age is not a contraindication for orthotopic liver transplantation: a single institution experience with recipients older than 75 years, Hepatol Int, 2012. 6(1): p. 403-7., https://link.springer.com/content/pdf/10.1007/s12072-011-9286-7.pdf
196. Huang, X., Lu, S., Impact of preoperative locoregional therapy on recurrence and patient survival following liver transplantation for hepatocellular carcinoma: a meta-analysis, Scand J Gastroenterol, 2017. 52(2): p. 143-149., https://www.tandfonline.com/doi/full/10.1080/00365521.2016.1236396
197. Kulik, L., Heimbach, J. K., Zaiem, F., Almasri, J., Prokop, L. J., Wang, Z., et.al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis, Hepatology, 2018. 67(1): p. 381-400., https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.29485
198. Sneiders, D., Houwen, T., Pengel, L. H. M., Polak, W. G., Dor, Fjmf, Hartog, H., Systematic Review and Meta-Analysis of Posttransplant Hepatic Artery and Biliary Complications in Patients Treated With Transarterial Chemoembolization Before Liver Transplantation, Transplantation, 2018. 102(1): p. 88-96.
199. Clavien, P. A., Lesurtel, M., Bossuyt, P. M., Gores, G. J., Langer, B., Perrier, A., Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report, Lancet Oncol, 2012. 13(1): p. e11-22., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3417764/pdf/nihms392425.pdf
200. Beal, E. W., Dittmar, K. M., Hanje, A. J., Michaels, A. J., Conteh, L., Davidson, G., et.al. Pretransplant Locoregional Therapy for Hepatocellular Carcinoma: Evaluation of Explant Pathology and Overall Survival, Front Oncol, 2016. 6: p. 143.
201. Cascales-Campos, P., Martinez-Insfran, L. A., Ramirez, P., Ferreras, D., Gonzalez-Sanchez, M. R., Sanchez-Bueno, F., et.al. Liver Transplantation in Patients With Hepatocellular Carcinoma Outside the Milan Criteria After Downstaging: Is It Worth It?, Transplant Proc, 2018. 50(2): p. 591-594., https://www.sciencedirect.com/science/article/abs/pii/S0041134517309284
202. Finkenstedt, A., Vikoler, A., Portenkirchner, M., Mülleder, K., Maglione, M., Margreiter, C., et.al. Excellent post-transplant survival in patients with intermediate stage hepatocellular carcinoma responding to neoadjuvant therapy, Liver Int, 2016. 36(5): p. 688-95., https://onlinelibrary.wiley.com/doi/full/10.1111/liv.12966
203. Györi, G. P., Felsenreich, D. M., Silberhumer, G. R., Soliman, T., Berlakovich, G. A., Multimodality locoregional treatment strategies for bridging HCC patients before liver transplantation, Eur Surg, 2017. 49(5): p. 236-243., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5653748/pdf/10353_2017_Article_487.pdf
204. Jianyong, L., Jinjing, Z., Lunan, Y., Jingqiang, Z., Wentao, W., Yong, Z., et.al. Preoperative adjuvant transarterial chemoembolization cannot improve the long term outcome of radical therapies for hepatocellular carcinoma, Sci Rep, 2017. 7: p. 41624., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5290748/pdf/srep41624.pdf
205. Nicolini, D., Agostini, A., Montalti, R., Mocchegiani, F., Mincarelli, C., Mandolesi, A., et.al. Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation, World J Gastroenterol, 2017. 23(20): p. 3690-3701., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5449426/pdf/WJG-23-3690.pdf
206. Gabr, A., Abouchaleh, N., Ali, R., Vouche, M., Atassi, R., Memon, K., et.al. Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization, Eur J Radiol, 2017. 93: p. 100-106., https://www.sciencedirect.com/science/article/abs/pii/S0720048X17302012
207. Lai, Q., Vitale, A., Iesari, S., Finkenstedt, A., Mennini, G., Onali, S., et.al. The Intention-to-Treat Effect of Bridging Treatments in the Setting of Milan Criteria-In Patients Waiting for Liver Transplantation, Liver Transpl, 2019. 25(7): p. 1023-1033., https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lt.25492?download=true
208. Oligane, H. C., Xing, M., Kim, H. S., Effect of Bridging Local-Regional Therapy on Recurrence of Hepatocellular Carcinoma and Survival after Orthotopic Liver Transplantation, Radiology, 2017. 282(3): p. 869-879.
209. Millonig, G., Graziadei, I. W., Freund, M. C., Jaschke, W., Stadlmann, S., Ladurner, R., et.al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma, Liver Transpl, 2007. 13(2): p. 272-9., https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lt.21033?download=true
210. Cucchetti, A., Cescon, M., Bigonzi, E., Piscaglia, F., Golfieri, R., Ercolani, G., et.al. Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy, Liver Transpl, 2011. 17(11): p. 1344-54., https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lt.22397?download=true
211. Lai, Q., Avolio, A. W., Graziadei, I., Otto, G., Rossi, M., Tisone, G., et.al. Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation, Liver Transpl, 2013. 19(10): p. 1108-18., https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lt.23706?download=true
212. Kim, D. J., Clark, P. J., Heimbach, J., Rosen, C., Sanchez, W., Watt, K., et.al. Recurrence of hepatocellular carcinoma: importance of mRECIST response to chemoembolization and tumor size, Am J Transplant, 2014. 14(6): p. 1383-90., https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ajt.12684?download=true
213. Riaz, A., Miller, F. H., Kulik, L. M., Nikolaidis, P., Yaghmai, V., Lewandowski, R. J., et.al. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma, Jama, 2010. 303(11): p. 1062-9., https://jamanetwork.com/journals/jama/articlepdf/185545/joc05021_1062_1069.pdf
214. Wong, TC, Lee, VH, Law, AL, Pang, HH, Lam, KO, Lau, V, et.al. Prospective Study of Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma on Waitlist for Liver Transplant., Hepatology, 2021. 74 (5)(5): p. 2580-2594., https://pubmed.ncbi.nlm.nih.gov/34091914/
215. Sapisochin, G, Barry, A, Doherty, M, Fischer, S, Goldaracena, N, Rosales, R, et.al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis., J Hepatol, 2017. 67 (1)(1): p. 92-99., https://pubmed.ncbi.nlm.nih.gov/28257902/
216. Bush, DA, Volk, M, Smith, JC, Reeves, ME, Sanghvi, S, Slater, JD, et.al. Proton beam radiotherapy versus transarterial chemoembolization for hepatocellular carcinoma: Results of a randomized clinical trial., Cancer, 2023. 129 (22)(22): p. 3554-3563., https://pubmed.ncbi.nlm.nih.gov/37503907/
217. Degroote, H., Callebout, E., Iesari, S., Dekervel, J., Schreiber, J., Pirenne, J., et.al. Extended criteria for liver transplantation in hepatocellular carcinoma. A retrospective, multicentric validation study in Belgium, Surg Oncol, 2019., https://pubmed.ncbi.nlm.nih.gov/31630912/
218. Parikh, N. D., Waljee, A. K., Singal, A. G., Downstaging hepatocellular carcinoma: A systematic review and pooled analysis, Liver Transpl, 2015. 21(9): p. 1142-52., https://deepblue.lib.umich.edu/bitstream/handle/2027.42/113108/lt24169.pdf?sequence=1
219. Mazzaferro, V, Citterio, D, Bhoori, S, Bongini, M, Miceli, R, De Carlis, L, et.al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial., Lancet Oncol, 2020. 21 (7)(7): p. 947-956., https://pubmed.ncbi.nlm.nih.gov/32615109/
220. Chapman, W. C., Garcia-Aroz, S., Vachharajani, N., Fowler, K., Saad, N., Lin, Y., et.al. Liver Transplantation for Advanced Hepatocellular Carcinoma after Downstaging Without Up-Front Stage Restrictions, J Am Coll Surg, 2017. 224(4): p. 610-621., https://www.sciencedirect.com/science/article/abs/pii/S1072751516317240
221. Graziadei, I., Zoller, H., Fickert, P., Schneeberger, S., Finkenstedt, A., Peck-Radosavljevic, M., et.al. Indications for liver transplantation in adults : Recommendations of the Austrian Society for Gastroenterology and Hepatology (ÖGGH) in cooperation with the Austrian Society for Transplantation, Transfusion and Genetics (ATX), Wien Klin Wochenschr, 2016. 128(19-20): p. 679-690., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052293/pdf/508_2016_Article_1046.pdf
222. Mazzaferro, V., Sposito, C., Zhou, J., Pinna, A. D., De Carlis, L., Fan, J., et.al. Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma, Gastroenterology, 2018. 154(1): p. 128-139., https://www.gastrojournal.org/article/S0016-5085(17)36184-X/fulltext
223. Halazun, K. J., Tabrizian, P., Najjar, M., Florman, S., Schwartz, M., Michelassi, F., et.al. Is it Time to Abandon the Milan Criteria?: Results of a Bicoastal US Collaboration to Redefine Hepatocellular Carcinoma Liver Transplantation Selection Policies, Ann Surg, 2018. 268(4): p. 690-699.
224. Hong, S. K., Lee, K. W., Kim, H. S., Yoon, K. C., Yi, N. J., Suh, K. S., Living donor liver transplantation for hepatocellular carcinoma in Seoul National University, Hepatobiliary Surg Nutr, 2016. 5(6): p. 453-460.
225. Kornberg, A., Schernhammer, M., Friess, H., (18)F-FDG-PET for Assessing Biological Viability and Prognosis in Liver Transplant Patients with Hepatocellular Carcinoma, J Clin Transl Hepatol, 2017. 5(3): p. 224-234.
226. Assalino, M., Terraz, S., Grat, M., Lai, Q., Vachharajani, N., Gringeri, E., et.al. Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion - a multi-center retrospective cohort study, Transpl Int, 2020. 33(5): p. 567-575.
227. Parikh, N. D., Yopp, A., Singal, A. G., Controversies in criteria for liver transplantation in hepatocellular carcinoma, Curr Opin Gastroenterol, 2016. 32(3): p. 182-8.
228. Salem, R., Gordon, A. C., Mouli, S., Hickey, R., Kallini, J., Gabr, A., et.al. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma, Gastroenterology, 2016. 151(6): p. 1155-1163.e2., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5124387/pdf/nihms813288.pdf
229. Ettorre, G. M., Levi Sandri, G. B., Laurenzi, A., Colasanti, M., Meniconi, R. L., Lionetti, R., et.al. Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation, World J Surg, 2017. 41(1): p. 241-249., https://link.springer.com/content/pdf/10.1007/s00268-016-3682-z.pdf
230. Schwacha-Eipper, B., Minciuna, I., Banz, V., Dufour, J. F., Immunotherapy as a downstaging therapy for liver transplantation, Hepatology, 2020., https://aasldpubs.onlinelibrary.wiley.com/doi/abs/10.1002/hep.31234
231. Golse, N., Radenne, S., Rode, A., Ducerf, C., Mabrut, J. Y., Merle, P., Liver Transplantation After Neoadjuvant Sorafenib Therapy: Preliminary Experience and Literature Review, Exp Clin Transplant, 2018. 16(2): p. 227-236.
232. Hoffmann, K., Ganten, T., Gotthardtp, D., Radeleff, B., Settmacher, U., Kollmar, O., et.al. Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial, BMC Cancer, 2015. 15: p. 392., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449604/pdf/12885_2015_Article_1373.pdf
233. Berenguer, M., Burra, P., Ghobrial, M., Hibi, T., Metselaar, H., Sapisochin, G., et.al. Posttransplant Management of Recipients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Working Group Report From the ILTS Transplant Oncology Consensus Conference, Transplantation, 2020. 104(6): p. 1143-1149.
234. Verna, E. C., Patel, Y. A., Aggarwal, A., Desai, A. P., Frenette, C., Pillai, A. A., et.al. Liver transplantation for hepatocellular carcinoma: Management after the transplant, Am J Transplant, 2020. 20(2): p. 333-347., https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ajt.15697?download=true
235. Vivarelli, M., Cucchetti, A., Piscaglia, F., La Barba, G., Bolondi, L., Cavallari, A., et.al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression, Liver Transpl, 2005. 11(5): p. 497-503., https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lt.20391?download=true
236. Vivarelli, M., Cucchetti, A., La Barba, G., Ravaioli, M., Del Gaudio, M., Lauro, A., et.al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence, Ann Surg, 2008. 248(5): p. 857-62.
237. Rodríguez-Perálvarez, M., Tsochatzis, E., Naveas, M. C., Pieri, G., García-Caparrós, C., O'Beirne, J., et.al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma, J Hepatol, 2013. 59(6): p. 1193-9.
238. Decaens, T., Roudot-Thoraval, F., Bresson-Hadni, S., Meyer, C., Gugenheim, J., Durand, F., et.al. Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients, World J Gastroenterol, 2006. 12(45): p. 7319-25., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4087490/pdf/WJG-12-7319.pdf
239. Tan, P. S., Muthiah, M. D., Koh, T., Teoh, Y. L., Chan, A., Kow, A., et.al. Asian Liver Transplant Network Clinical Guidelines on Immunosuppression in Liver Transplantation, Transplantation, 2019. 103(3): p. 470-480.
240. Duvoux, C., Toso, C., mTOR inhibitor therapy: Does it prevent HCC recurrence after liver transplantation?, Transplant Rev (Orlando), 2015. 29(3): p. 168-74.
241. Tarantino, G., Magistri, P., Ballarin, R., Di Francia, R., Berretta, M., Di Benedetto, F., Oncological Impact of M-Tor Inhibitor Immunosuppressive Therapy after Liver Transplantation for Hepatocellular Carcinoma: Review of the Literature, Front Pharmacol, 2016. 7: p. 387., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5073152/pdf/fphar-07-00387.pdf
242. Teperman, L., Moonka, D., Sebastian, A., Sher, L., Marotta, P., Marsh, C., et.al. Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial, Liver Transpl, 2013. 19(7): p. 675-89., https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lt.23658?download=true
243. De Simone, P., Metselaar, H. J., Fischer, L., Dumortier, J., Boudjema, K., Hardwigsen, J., et.al. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial, Liver Transpl, 2009. 15(10): p. 1262-9., https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lt.21827?download=true
244. Fischer, L., Saliba, F., Kaiser, G. M., De Carlis, L., Metselaar, H. J., De Simone, P., et.al. Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study, Transplantation, 2015. 99(7): p. 1455-62.
245. Geissler, E. K., Schnitzbauer, A. A., Zülke, C., Lamby, P. E., Proneth, A., Duvoux, C., et.al. Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial, Transplantation, 2016. 100(1): p. 116-25.
246. Schnitzbauer, AA, Filmann, N, Adam, R, Bachellier, P, Bechstein, WO, Becker, T, et.al. mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors., Ann Surg, 2020. 272 (5)(5): p. 855-862., https://pubmed.ncbi.nlm.nih.gov/32889867/
247. Trevisani, F., Frigerio, M., Santi, V., Grignaschi, A., Bernardi, M., Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal, Dig Liver Dis, 2010. 42(5): p. 341-7.
248. Paradis, V., Zalinski, S., Chelbi, E., Guedj, N., Degos, F., Vilgrain, V., et.al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis, Hepatology, 2009. 49(3): p. 851-9., https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.22734
249. Piscaglia, F., Svegliati-Baroni, G., Barchetti, A., Pecorelli, A., Marinelli, S., Tiribelli, C., et.al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study, Hepatology, 2016. 63(3): p. 827-38., https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.28368
250. Ertle, J., Dechêne, A., Sowa, J. P., Penndorf, V., Herzer, K., Kaiser, G., et.al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis, Int J Cancer, 2011. 128(10): p. 2436-43., https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.25797?download=true
251. Zhou, Y., Lei, X., Wu, L., Wu, X., Xu, D., Li, B., Outcomes of hepatectomy for noncirrhotic hepatocellular carcinoma: a systematic review, Surg Oncol, 2014. 23(4): p. 236-42.
252. Faber, W., Sharafi, S., Stockmann, M., Denecke, T., Sinn, B., Puhl, G., et.al. Long-term results of liver resection for hepatocellular carcinoma in noncirrhotic liver, Surgery, 2013. 153(4): p. 510-7.
253. Cauchy, F., Zalinski, S., Dokmak, S., Fuks, D., Farges, O., Castera, L., et.al. Surgical treatment of hepatocellular carcinoma associated with the metabolic syndrome, Br J Surg, 2013. 100(1): p. 113-21., https://bjssjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/bjs.8963?download=true
254. Dasari, B. V., Kamarajah, S. K., Hodson, J., Pawlik, T. M., Vauthey, J. N., Ma, Y. T., et.al. Development and validation of a risk score to predict the overall survival following surgical resection of hepatocellular carcinoma in non-cirrhotic liver, HPB (Oxford), 2020. 22(3): p. 383-390., https://www.sciencedirect.com/science/article/abs/pii/S1365182X19306215?via%3Dihub
255. Ju, M., Yopp, A. C., The Utility of Anatomical Liver Resection in Hepatocellular Carcinoma: Associated with Improved Outcomes or Lack of Supportive Evidence?, Cancers (Basel), 2019. 11(10):, https://res.mdpi.com/d_attachment/cancers/cancers-11-01441/article_deploy/cancers-11-01441.pdf
256. Moris, D., Tsilimigras, D. I., Kostakis, I. D., Ntanasis-Stathopoulos, I., Shah, K. N., Felekouras, E., et.al. Anatomic versus non-anatomic resection for hepatocellular carcinoma: A systematic review and meta-analysis, Eur J Surg Oncol, 2018. 44(7): p. 927-938., https://www.sciencedirect.com/science/article/abs/pii/S0748798318310242?via%3Dihub
257. Arnaoutakis, D. J., Mavros, M. N., Shen, F., Alexandrescu, S., Firoozmand, A., Popescu, I., et.al. Recurrence patterns and prognostic factors in patients with hepatocellular carcinoma in noncirrhotic liver: a multi-institutional analysis, Ann Surg Oncol, 2014. 21(1): p. 147-154., https://link.springer.com/content/pdf/10.1245/s10434-013-3211-3.pdf
258. Lang, H., Sotiropoulos, G. C., Brokalaki, E. I., Schmitz, K. J., Bertona, C., Meyer, G., et.al. Survival and recurrence rates after resection for hepatocellular carcinoma in noncirrhotic livers, J Am Coll Surg, 2007. 205(1): p. 27-36.
259. Bège, T., Le Treut, Y. P., Hardwigsen, J., Ananian, P., Richa, H., Campan, P., et.al. Prognostic factors after resection for hepatocellular carcinoma in nonfibrotic or moderately fibrotic liver. A 116-case European series, J Gastrointest Surg, 2007. 11(5): p. 619-25., https://link.springer.com/content/pdf/10.1007/s11605-006-0023-9.pdf
260. Teegen, E. M., Mogl, M. T., Pratschke, J., Rayes, N., Adrenal Metastasis of Hepatocellular Carcinoma in Patients following Liver Resection or Liver Transplantation: Experience from a Tertiary Referral Center, Int J Surg Oncol, 2018. 2018: p. 4195076., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6087597/pdf/IJSO2018-4195076.pdf
261. Wang, Y. Y., Zhao, X. H., Ma, L., Ye, J. Z., Wu, F. X., Tang, J., et.al. Comparison of the ability of Child-Pugh score, MELD score, and ICG-R15 to assess preoperative hepatic functional reserve in patients with hepatocellular carcinoma, J Surg Oncol, 2018. 118(3): p. 440-445., https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jso.25184?download=true
262. Rubin, T. M., Heyne, K., Luchterhand, A., Jan, Bednarsch, F, W. R. Vondran, Polychronidis, G., et.al. Kinetic validation of the LiMAx test during 10 000 intravenous (13)C-methacetin breath tests, J Breath Res, 2017. 12(1): p. 016005., https://iopscience.iop.org/article/10.1088/1752-7163/aa820b
263. Stockmann, M., Lock, J. F., Riecke, B., Heyne, K., Martus, P., Fricke, M., et.al. Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity, Ann Surg, 2009. 250(1): p. 119-25.
264. Huang, Z., Huang, J., Zhou, T., Cao, H., Tan, B., Prognostic value of liver stiffness measurement for the liver-related surgical outcomes of patients under hepatic resection: A meta-analysis, PLoS One, 2018. 13(1): p. e0190512., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5764309/pdf/pone.0190512.pdf
265. Simonetto, D. A., Liu, M., Kamath, P. S., Portal Hypertension and Related Complications: Diagnosis and Management, Mayo Clin Proc, 2019. 94(4): p. 714-726., https://www.sciencedirect.com/science/article/abs/pii/S0025619618310085?via%3Dihub
266. Roayaie, S., Jibara, G., Tabrizian, P., Park, J. W., Yang, J., Yan, L., et.al. The role of hepatic resection in the treatment of hepatocellular cancer, Hepatology, 2015. 62(2): p. 440-51., https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.27745
267. Ishizawa, T., Hasegawa, K., Aoki, T., Takahashi, M., Inoue, Y., Sano, K., et.al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma, Gastroenterology, 2008. 134(7): p. 1908-16., https://www.sciencedirect.com/science/article/pii/S0016508508004277?via%3Dihub
268. Torzilli, G., Belghiti, J., Kokudo, N., Takayama, T., Capussotti, L., Nuzzo, G., et.al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group, Ann Surg, 2013. 257(5): p. 929-37.
269. Koh, Y. X., Tan, H. L., Lye, W. K., Kam, J. H., Chiow, A. K. H., Tan, S. S., et.al. Systematic review of the outcomes of surgical resection for intermediate and advanced Barcelona Clinic Liver Cancer stage hepatocellular carcinoma: A critical appraisal of the evidence, World J Hepatol, 2018. 10(6): p. 433-447., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033716/pdf/WJH-10-433.pdf
270. Zaydfudim, V. M., Vachharajani, N., Klintmalm, G. B., Jarnagin, W. R., Hemming, A. W., Doyle, M. B., et.al. Liver Resection and Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria, Ann Surg, 2016. 264(4): p. 650-8., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5279918/pdf/nihms-835604.pdf
271. Tsilimigras, D. I., Bagante, F., Moris, D., Hyer, J. M., Sahara, K., Paredes, A. Z., et.al. Recurrence Patterns and Outcomes after Resection of Hepatocellular Carcinoma within and beyond the Barcelona Clinic Liver Cancer Criteria, Ann Surg Oncol, 2020. 27(7): p. 2321-2331., https://link.springer.com/content/pdf/10.1245/s10434-020-08452-3.pdf
272. Pang, T. C., Lam, V. W., Surgical management of hepatocellular carcinoma, World J Hepatol, 2015. 7(2): p. 245-52., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342606/pdf/WJH-7-245.pdf
273. Feng, X., Su, Y., Zheng, S., Xia, F., Ma, K., Yan, J., et.al. A double blinded prospective randomized trial comparing the effect of anatomic versus non-anatomic resection on hepatocellular carcinoma recurrence, HPB (Oxford), 2017. 19(8): p. 667-674.
274. Wakabayashi, G., Cherqui, D., Geller, D. A., Buell, J. F., Kaneko, H., Han, H. S., et.al. Recommendations for laparoscopic liver resection: a report from the second international consensus conference held in Morioka, Ann Surg, 2015. 261(4): p. 619-29.
275. Cherqui, D., Soubrane, O., Laparoscopic Liver Resection: An Ongoing Revolution, Ann Surg, 2017. 265(5): p. 864-865., https://www.ingentaconnect.com/content/wk/sla/2017/00000265/00000005/art00019
276. Andreou, A., Struecker, B., Raschzok, N., Krenzien, F., Haber, P., Wabitsch, S., et.al. Minimal-invasive versus open hepatectomy for hepatocellular carcinoma: Comparison of postoperative outcomes and long-term survivals using propensity score matching analysis, Surg Oncol, 2018. 27(4): p. 751-758., https://www.sciencedirect.com/science/article/abs/pii/S0960740418302512?via%3Dihub
277. Haber, P. K., Wabitsch, S., Krenzien, F., Benzing, C., Andreou, A., Schöning, W., et.al. Laparoscopic liver surgery in cirrhosis - Addressing lesions in posterosuperior segments, Surg Oncol, 2019. 28: p. 140-144., https://www.sciencedirect.com/science/article/abs/pii/S0960740418304614?via%3Dihub
278. Levi Sandri, G. B., Ettorre, G. M., Aldrighetti, L., Cillo, U., Dalla Valle, R., Guglielmi, A., et.al. Laparoscopic liver resection of hepatocellular carcinoma located in unfavorable segments: a propensity score-matched analysis from the I Go MILS (Italian Group of Minimally Invasive Liver Surgery) Registry, Surg Endosc, 2019. 33(5): p. 1451-1458., https://link.springer.com/content/pdf/10.1007/s00464-018-6426-3.pdf
279. Felli, E., Cillo, U., Pinna, A. D., De Carlis, L., Ercolani, G., Santoro, R., et.al. Salvage liver transplantation after laparoscopic resection for hepatocellular carcinoma: a multicenter experience, Updates Surg, 2015. 67(2): p. 215-22., https://link.springer.com/content/pdf/10.1007/s13304-015-0323-2.pdf
280. Chen, M. S., Li, J. Q., Zheng, Y., Guo, R. P., Liang, H. H., Zhang, Y. Q., et.al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma, Ann Surg, 2006. 243(3): p. 321-8., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1448947/pdf/20060300s00006p321.pdf
281. Feng, K., Yan, J., Li, X., Xia, F., Ma, K., Wang, S., et.al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma, J Hepatol, 2012. 57(4): p. 794-802., https://www.sciencedirect.com/science/article/pii/S0168827812003613?via%3Dihub
282. Huang, J., Yan, L., Cheng, Z., Wu, H., Du, L., Wang, J., et.al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria, Ann Surg, 2010. 252(6): p. 903-12.
283. Ng, K. K. C., Chok, K. S. H., Chan, A. C. Y., Cheung, T. T., Wong, T. C. L., Fung, J. Y. Y., et.al. Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma, Br J Surg, 2017. 104(13): p. 1775-1784., https://onlinelibrary.wiley.com/doi/pdf/10.1002/bjs.10677
284. Yin, L., Li, H., Li, A. J., Lau, W. Y., Pan, Z. Y., Lai, E. C., et.al. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT, J Hepatol, 2014. 61(1): p. 82-8., https://www.sciencedirect.com/science/article/pii/S0168827814001561?via%3Dihub
285. Lencioni, R., Llovet, J. M., Modified RECIST (mRECIST) assessment for hepatocellular carcinoma, Semin Liver Dis, 2010. 30(1): p. 52-60., https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0030-1247132.pdf
286. Wahab, M. A., Shehta, A., Hamed, H., El Nakeeb, A., Salah, T., Predictors of recurrence in hepatitis C virus related hepatocellular carcinoma after hepatic resection: a retrospective cohort study, Eurasian J Med, 2014. 46(1): p. 36-41., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4261437/pdf/eajm-46-1-36.pdf
287. Ramacciato, G., Mercantini, P., Nigri, G. R., Ravaioli, M., Cautero, N., Di Benedetto, F., et.al. Univariate and multivariate analysis of prognostic factors in the surgical treatment of hepatocellular carcinoma in cirrhotic patients, Hepatogastroenterology, 2006. 53(72): p. 898-903.
288. Di Costanzo, G. G., Tortora, R., D'Adamo, G., De Luca, M., Lampasi, F., Addario, L., et.al. Radiofrequency ablation versus laser ablation for the treatment of small hepatocellular carcinoma in cirrhosis: a randomized trial, J Gastroenterol Hepatol, 2015. 30(3): p. 559-65., https://onlinelibrary.wiley.com/doi/abs/10.1111/jgh.12791
289. Cucchetti, A., Piscaglia, F., Cescon, M., Serra, C., Colecchia, A., Maroni, L., et.al. An explorative data-analysis to support the choice between hepatic resection and radiofrequency ablation in the treatment of hepatocellular carcinoma, Dig Liver Dis, 2014. 46(3): p. 257-63.
290. Nishikawa, H., Inuzuka, T., Takeda, H., Nakajima, J., Matsuda, F., Sakamoto, A., et.al. Comparison of percutaneous radiofrequency thermal ablation and surgical resection for small hepatocellular carcinoma, BMC Gastroenterol, 2011. 11: p. 143., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3260104/pdf/1471-230X-11-143.pdf
291. Uhlig, J., Sellers, C. M., Stein, S. M., Kim, H. S., Radiofrequency ablation versus surgical resection of hepatocellular carcinoma: contemporary treatment trends and outcomes from the United States National Cancer Database, Eur Radiol, 2019. 29(5): p. 2679-2689., https://link.springer.com/article/10.1007/s00330-018-5902-4
292. Salmi, A., Turrini, R., Lanzani, G., Savio, A., Anglani, L., Radiofrequency ablation of hepatocellular carcinoma in patients with and without cirrhosis, J Ultrasound, 2009. 12(3): p. 118-24., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552707/pdf/main.pdf
293. Mohanty, S., Rajaram, R., Bilimoria, K. Y., Salem, R., Pawlik, T. M., Bentrem, D. J., Assessment of non-surgical versus surgical therapy for localized hepatocellular carcinoma, J Surg Oncol, 2016. 113(2): p. 175-80., https://onlinelibrary.wiley.com/doi/abs/10.1002/jso.24113
294. Yamauchi, R., Takata, K., Shinagawa, Y., Tanaka, T., Fukuda, H., Fukuda, S., et.al. Hepatocellular Carcinoma Arising in a Non-cirrhotic Liver with Secondary Hemochromatosis, Intern Med, 2019. 58(5): p. 661-665., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443541/pdf/1349-7235-58-0661.pdf
295. Livraghi, T., Goldberg, S. N., Lazzaroni, S., Meloni, F., Solbiati, L., Gazelle, G. S., Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection, Radiology, 1999. 210(3): p. 655-61.
296. Lencioni, R. A., Allgaier, H. P., Cioni, D., Olschewski, M., Deibert, P., Crocetti, L., et.al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection, Radiology, 2003. 228(1): p. 235-40.
297. Lin, S. M., Lin, C. J., Lin, C. C., Hsu, C. W., Chen, Y. C., Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm, Gastroenterology, 2004. 127(6): p. 1714-23., https://www.sciencedirect.com/science/article/abs/pii/S0016508504015720?via%3Dihub
298. Bruix, J., Sherman, M., Llovet, J. M., Beaugrand, M., Lencioni, R., Burroughs, A. K., et.al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver, J Hepatol, 2001. 35(3): p. 421-30.
299. Shiina, S., Teratani, T., Obi, S., Sato, S., Tateishi, R., Fujishima, T., et.al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma, Gastroenterology, 2005. 129(1): p. 122-30., https://www.sciencedirect.com/science/article/abs/pii/S0016508505006918?via%3Dihub
300. Brunello, F., Veltri, A., Carucci, P., Pagano, E., Ciccone, G., Moretto, P., et.al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial, Scand J Gastroenterol, 2008. 43(6): p. 727-35., https://www.tandfonline.com/doi/pdf/10.1080/00365520701885481?needAccess=true
301. Lin, S. M., Lin, C. J., Lin, C. C., Hsu, C. W., Chen, Y. C., Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less, Gut, 2005. 54(8): p. 1151-6., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1774888/pdf/gut05401151.pdf
302. Shiina, S., Teratani, T., Obi, S., Hamamura, K., Koike, Y., Omata, M., Nonsurgical treatment of hepatocellular carcinoma: from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation, Oncology, 2002. 62 Suppl 1: p. 64-8., https://www.karger.com/Article/Pdf/48278
303. Hara, K., Takeda, A., Tsurugai, Y., Saigusa, Y., Sanuki, N., Eriguchi, T., et.al. Radiotherapy for Hepatocellular Carcinoma Results in Comparable Survival to Radiofrequency Ablation: A Propensity Score Analysis, Hepatology, 2019. 69(6): p. 2533-2545., https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.30591?download=true
304. Peng, Z. W., Zhang, Y. J., Chen, M. S., Xu, L., Liang, H. H., Lin, X. J., et.al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial, J Clin Oncol, 2013. 31(4): p. 426-32.
305. Liu, H., Wang, Z. G., Fu, S. Y., Li, A. J., Pan, Z. Y., Zhou, W. P., et.al. Randomized clinical trial of chemoembolization plus radiofrequency ablation versus partial hepatectomy for hepatocellular carcinoma within the Milan criteria, Br J Surg, 2016. 103(4): p. 348-56., https://bjssjournals.onlinelibrary.wiley.com/doi/full/10.1002/bjs.10061
306. Endo, K., Kuroda, H., Oikawa, T., Okada, Y., Fujiwara, Y., Abe, T., et.al. Efficacy of combination therapy with transcatheter arterial chemoembolization and radiofrequency ablation for intermediate-stage hepatocellular carcinoma, Scand J Gastroenterol, 2018. 53(12): p. 1575-1583., https://www.tandfonline.com/doi/full/10.1080/00365521.2018.1548645
307. Fukutomi, S., Nomura, Y., Nakashima, O., Yano, H., Tanaka, H., Akagi, Y., et.al. Evaluation of hepatocellular carcinoma spread via the portal system by 3-dimensional mapping, HPB (Oxford), 2017. 19(12): p. 1119-1125.
308. Hendriks, P, Sudiono, DR, Schaapman, JJ, Coenraad, MJ, Tushuizen, ME, Takkenberg, RB, et.al. Thermal ablation combined with transarterial chemoembolization for hepatocellular carcinoma: What is the right treatment sequence?, Eur J Radiol, 2021. 144 (): p. 110006., https://pubmed.ncbi.nlm.nih.gov/34717187/
309. Smolock, A. R., Cristescu, M. M., Hinshaw, A., Woo, K. M., Wells, S. A., Ziemlewicz, T. J., et.al. Combination transarterial chemoembolization and microwave ablation improves local tumor control for 3- to 5-cm hepatocellular carcinoma when compared with transarterial chemoembolization alone, Abdom Radiol (NY), 2018. 43(9): p. 2497-2504., https://link.springer.com/content/pdf/10.1007/s00261-018-1464-9.pdf
310. Bonomo, G., Della Vigna, P., Monfardini, L., Orgera, G., Chiappa, A., Bianchi, P. P., et.al. Combined therapies for the treatment of technically unresectable liver malignancies: bland embolization and radiofrequency thermal ablation within the same session, Cardiovasc Intervent Radiol, 2012. 35(6): p. 1372-9., https://link.springer.com/content/pdf/10.1007/s00270-012-0341-0.pdf
311. Lo, C. M., Ngan, H., Tso, W. K., Liu, C. L., Lam, C. M., Poon, R. T., et.al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma, Hepatology, 2002. 35(5): p. 1164-71., https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1053/jhep.2002.33156
312. Lammer, J., Malagari, K., Vogl, T., Pilleul, F., Denys, A., Watkinson, A., et.al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study, Cardiovasc Intervent Radiol, 2010. 33(1): p. 41-52., https://www.zora.uzh.ch/id/eprint/24207/1/Lammer_CardiovascInterventRadiol_2010_V.pdf
313. Golfieri, R., Giampalma, E., Renzulli, M., Cioni, R., Bargellini, I., Bartolozzi, C., et.al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma, Br J Cancer, 2014. 111(2): p. 255-64., https://iris.unito.it/retrieve/handle/2318/149077/25760/art%20Doxorubicina-Tace%202014.pdf
314. Yamada, R., Bassaco, B., Bracewell, S., Gillen, K., Kocher, M., Collins, H., et.al. Long-term follow-up after conventional transarterial chemoembolization (c-TACE) with mitomycin for hepatocellular carcinoma (HCC), J Gastrointest Oncol, 2019. 10(2): p. 348-353.
315. Llovet, J. M., Real, M. I., Montana, X., Planas, R., Coll, S., Aponte, J., et.al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial, Lancet, 2002. 359(9319): p. 1734-9., https://www.sciencedirect.com/science/article/pii/S014067360208649X?via%3Dihub
316. Abdel-Rahman, O., Elsayed, Z., Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma, Cochrane Database Syst Rev, 2020. 1(1): p. Cd011313.
317. Yang, J., Wang, J., Zhou, H., Zhou, Y., Wang, Y., Jin, H., et.al. Efficacy and safety of endoscopic radiofrequency ablation for unresectable extrahepatic cholangiocarcinoma: a randomized trial, Endoscopy, 2018. 50(8): p. 751-760., https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0043-124870.pdf
318. Ludwig, J. M., Zhang, D., Xing, M., Kim, H. S., Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus (90)Y-radioembolization for hepatocellular carcinoma, Eur Radiol, 2017. 27(5): p. 2031-2041., https://link.springer.com/content/pdf/10.1007%2Fs00330-016-4548-3.pdf
319. Casadei Gardini, A., Tamburini, E., Inarrairaegui, M., Frassineti, G. L., Sangro, B., Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials, Onco Targets Ther, 2018. 11: p. 7315-7321., https://www.dovepress.com/getfile.php?fileID=45631
320. Garin, E, Tselikas, L, Guiu, B, Chalaye, J, Edeline, J, de Baere, T, et.al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial., Lancet Gastroenterol Hepatol, 2021. 6 (1)(1): p. 17-29., https://pubmed.ncbi.nlm.nih.gov/33166497/
321. Hermann, AL, Dieudonné, A, Ronot, M, Sanchez, M, Pereira, H, Chatellier, G, et.al. Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with , Radiology, 2020. 296 (3)(3): p. 673-684., https://pubmed.ncbi.nlm.nih.gov/32602828/
322. Kolligs, F. T., Bilbao, J. I., Jakobs, T., Iñarrairaegui, M., Nagel, J. M., Rodriguez, M., et.al. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma, Liver Int, 2015. 35(6): p. 1715-21., https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/liv.12750?download=true
323. Katsanos, K., Kitrou, P., Spiliopoulos, S., Maroulis, I., Petsas, T., Karnabatidis, D., Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials, PLoS One, 2017. 12(9): p. e0184597., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5608206/pdf/pone.0184597.pdf
324. Pitton, M. B., Kloeckner, R., Ruckes, C., Wirth, G. M., Eichhorn, W., Wörns, M. A., et.al. Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma, Cardiovasc Intervent Radiol, 2015. 38(2): p. 352-60., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355443/pdf/270_2014_Article_1012.pdf
325. Lobo, L., Yakoub, D., Picado, O., Ripat, C., Pendola, F., Sharma, R., et.al. Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis, Cardiovasc Intervent Radiol, 2016. 39(11): p. 1580-1588., https://link.springer.com/content/pdf/10.1007/s00270-016-1426-y.pdf
326. Salem, R., Gilbertsen, M., Butt, Z., Memon, K., Vouche, M., Hickey, R., et.al. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization, Clin Gastroenterol Hepatol, 2013. 11(10): p. 1358-1365.e1., https://www.sciencedirect.com/science/article/abs/pii/S1542356513005971?via%3Dihub
327. Sangro, B., Maini, C. L., Ettorre, G. M., Cianni, R., Golfieri, R., Gasparini, D., et.al. Radioembolisation in patients with hepatocellular carcinoma that have previously received liver-directed therapies, Eur J Nucl Med Mol Imaging, 2018. 45(10): p. 1721-1730., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097757/pdf/259_2018_Article_3968.pdf
328. Johnson, G. E., Monsky, W. L., Valji, K., Hippe, D. S., Padia, S. A., Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma, J Vasc Interv Radiol, 2016. 27(8): p. 1123-9.
329. Hilgard, P., Hamami, M., Fouly, A. E., Scherag, A., Müller, S., Ertle, J., et.al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival, Hepatology, 2010. 52(5): p. 1741-9., https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.23944?download=true
330. Sangro, B., Carpanese, L., Cianni, R., Golfieri, R., Gasparini, D., Ezziddin, S., et.al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation, Hepatology, 2011. 54(3): p. 868-78., https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.24451?download=true
331. Kulik, L. M., Carr, B. I., Mulcahy, M. F., Lewandowski, R. J., Atassi, B., Ryu, R. K., et.al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis, Hepatology, 2008. 47(1): p. 71-81., https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.21980?download=true
332. Mazzaferro, V., Sposito, C., Bhoori, S., Romito, R., Chiesa, C., Morosi, C., et.al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study, Hepatology, 2013. 57(5): p. 1826-37., https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.26014?download=true
333. Salem, R., Lewandowski, R. J., Mulcahy, M. F., Riaz, A., Ryu, R. K., Ibrahim, S., et.al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes, Gastroenterology, 2010. 138(1): p. 52-64.
334. Rim, C. H., Kim, C. Y., Yang, D. S., Yoon, W. S., Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: A meta-analysis and systematic review, Radiother Oncol, 2018. 129(1): p. 112-122., https://www.sciencedirect.com/science/article/abs/pii/S0167814017327305?via%3Dihub
335. Salem, R, Padia, SA, Lam, M, Bell, J, Chiesa, C, Fowers, K, et.al. Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group., Eur J Nucl Med Mol Imaging, 2019. 46 (8)(8): p. 1695-1704., https://pubmed.ncbi.nlm.nih.gov/31098749/
336. Levillain, H, Bagni, O, Deroose, CM, Dieudonné, A, Gnesin, S, Grosser, OS, et.al. International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres., Eur J Nucl Med Mol Imaging, 2021. 48 (5)(5): p. 1570-1584., https://pubmed.ncbi.nlm.nih.gov/33433699/
337. Salem, R, Johnson, GE, Kim, E, Riaz, A, Bishay, V, Boucher, E, et.al. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study., Hepatology, 2021. 74 (5)(5): p. 2342-2352., https://pubmed.ncbi.nlm.nih.gov/33739462/
338. Vilgrain, Valérie, Pereira, Helena, Assenat, Eric, Guiu, Boris, Ilonca, Alina Diana, Pageaux, Georges-Philippe, et.al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial, The Lancet Oncology, 2017. 18(12): p. 1624-1636.
339. Chow, P. K. H., Gandhi, M., Tan, S. B., Khin, M. W., Khasbazar, A., Ong, J., et.al. SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma, J Clin Oncol, 2018. 36(19): p. 1913-1921., https://www.ncbi.nlm.nih.gov/pubmed/29498924
340. Sapir, E., Tao, Y., Schipper, M. J., Bazzi, L., Novelli, P. M., Devlin, P., et.al. Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma, Int J Radiat Oncol Biol Phys, 2018. 100(1): p. 122-130., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818982/pdf/nihms942371.pdf
341. Eriguchi, T, Takeda, A, Tateishi, Y, Tsurugai, Y, Sanuki, N, Ebinuma, H, et.al. Comparison of stereotactic body radiotherapy and radiofrequency ablation for hepatocellular carcinoma: Systematic review and meta-analysis of propensity score studies., Hepatol Res, 2021. 51 (7)(7): p. 813-822., https://pubmed.ncbi.nlm.nih.gov/33856722/
342. Rim, CH, Lee, JS, Kim, SY, Seong, J, Comparison of radiofrequency ablation and ablative external radiotherapy for the treatment of intrahepatic malignancies: A hybrid meta-analysis., JHEP Rep, 2023. 5 (1)(1): p. 100594., https://pubmed.ncbi.nlm.nih.gov/36561128/
343. Craig, T, Xiao, Y, McNulty, S, Dawson, LA, Insights From Image Guided Radiation Therapy Credentialing for the NRG Oncology RTOG 1112 Liver Stereotactic Body Radiation Therapy Trial., Pract Radiat Oncol, 2022. ():, https://pubmed.ncbi.nlm.nih.gov/36581199/
344. Rim, CH, Kim, HJ, Seong, J, Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studies., Radiother Oncol, 2019. 131 (): p. 135-144., https://pubmed.ncbi.nlm.nih.gov/30773180/
345. Brunner, TB, Bettinger, D, Schultheiss, M, Maruschke, L, Sturm, L, Bartl, N, et.al. Efficacy of Stereotactic Body Radiotherapy in Patients With Hepatocellular Carcinoma Not Suitable for Transarterial Chemoembolization (HERACLES: HEpatocellular Carcinoma Stereotactic RAdiotherapy CLinical Efficacy Study)., Front Oncol, 2021. 11 (): p. 653141., https://pubmed.ncbi.nlm.nih.gov/33816309/
346. Omata, M, Cheng, AL, Kokudo, N, Kudo, M, Lee, JM, Jia, J, et.al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update., Hepatol Int, 2017. 11 (4)(4): p. 317-370., https://pubmed.ncbi.nlm.nih.gov/28620797/
347. Vogel, A., Cervantes, A., Chau, I., Daniele, B., Llovet, J. M., Meyer, T., et.al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 2018. 29(Suppl 4): p. iv238-iv255.
348. Guckenberger, M, Baus, WW, Blanck, O, Combs, SE, Debus, J, Engenhart-Cabillic, R, et.al. Definition and quality requirements for stereotactic radiotherapy: consensus statement from the DEGRO/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery., Strahlenther Onkol, 2020. 196 (5)(5): p. 417-420., https://pubmed.ncbi.nlm.nih.gov/32211940/
349. Mizumoto, M., Tokuuye, K., Sugahara, S., Nakayama, H., Fukumitsu, N., Ohara, K., et.al. Proton beam therapy for hepatocellular carcinoma adjacent to the porta hepatis, Int J Radiat Oncol Biol Phys, 2008. 71(2): p. 462-7.
350. Fukumitsu, N., Sugahara, S., Nakayama, H., Fukuda, K., Mizumoto, M., Abei, M., et.al. A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma, Int J Radiat Oncol Biol Phys, 2009. 74(3): p. 831-6.
351. Sugahara, S., Oshiro, Y., Nakayama, H., Fukuda, K., Mizumoto, M., Abei, M., et.al. Proton beam therapy for large hepatocellular carcinoma, Int J Radiat Oncol Biol Phys, 2010. 76(2): p. 460-6.
352. Kim, TH, Park, JW, Kim, YJ, Kim, BH, Woo, SM, Moon, SH, et.al. Phase I dose-escalation study of proton beam therapy for inoperable hepatocellular carcinoma., Cancer Res Treat, 2015. 47 (1)(1): p. 34-45., https://pubmed.ncbi.nlm.nih.gov/25381830/
353. Nakayama, H., Sugahara, S., Fukuda, K., Abei, M., Shoda, J., Sakurai, H., et.al. Proton beam therapy for hepatocellular carcinoma located adjacent to the alimentary tract, Int J Radiat Oncol Biol Phys, 2011. 80(4): p. 992-5.
354. Bush, D. A., Smith, J. C., Slater, J. D., Volk, M. L., Reeves, M. E., Cheng, J., et.al. Randomized Clinical Trial Comparing Proton Beam Radiation Therapy with Transarterial Chemoembolization for Hepatocellular Carcinoma: Results of an Interim Analysis, Int J Radiat Oncol Biol Phys, 2016. 95(1): p. 477-482.
355. Hong, T. S., Wo, J. Y., Yeap, B. Y., Ben-Josef, E., McDonnell, E. I., Blaszkowsky, L. S., et.al. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma, J Clin Oncol, 2016. 34(5): p. 460-8., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872014/pdf/JCO642710.pdf
356. Mizumoto, M, Oshiro, Y, Okumura, T, Fukumitsu, N, Numajiri, H, Ohnishi, K, et.al. Proton Beam Therapy for Hepatocellular Carcinoma: A Review of the University of Tsukuba Experience., Int J Part Ther, 2016. 2 (4)(4): p. 570-578., https://pubmed.ncbi.nlm.nih.gov/31772968/
357. Mohnike, K., Wieners, G., Schwartz, F., Seidensticker, M., Pech, M., Ruehl, R., et.al. Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival, Int J Radiat Oncol Biol Phys, 2010. 78(1): p. 172-9.
358. Mohnike, K., Steffen, I. G., Seidensticker, M., Hass, P., Damm, R., Peters, N., et.al. Radioablation by Image-Guided (HDR) Brachytherapy and Transarterial Chemoembolization in Hepatocellular Carcinoma: A Randomized Phase II Trial, Cardiovasc Intervent Radiol, 2019. 42(2): p. 239-249., https://link.springer.com/content/pdf/10.1007/s00270-018-2127-5.pdf
359. Collettini, F., Schreiber, N., Schnapauff, D., Denecke, T., Wust, P., Schott, E., et.al. CT-guided high-dose-rate brachytherapy of unresectable hepatocellular carcinoma, Strahlenther Onkol, 2015. 191(5): p. 405-12., https://link.springer.com/content/pdf/10.1007/s00066-014-0781-3.pdf
360. Comito, T, Loi, M, Franzese, C, Clerici, E, Franceschini, D, Badalamenti, M, et.al. Stereotactic Radiotherapy after Incomplete Transarterial (Chemo-) Embolization (TAE\TACE) versus Exclusive TAE or TACE for Treatment of Inoperable HCC: A Phase III Trial (NCT02323360)., Curr Oncol, 2022. 29 (11)(11): p. 8802-8813., https://pubmed.ncbi.nlm.nih.gov/36421345/
361. Buckstein, M, Kim, E, Özbek, U, Tabrizian, P, Gunasekaran, G, Facciuto, M, et.al. Combination Transarterial Chemoembolization and Stereotactic Body Radiation Therapy for Unresectable Single Large Hepatocellular Carcinoma: Results From a Prospective Phase 2 Trial., Int J Radiat Oncol Biol Phys, 2022. 114 (2)(2): p. 221-230., https://pubmed.ncbi.nlm.nih.gov/35643250/
362. Yoon, SM, Ryoo, BY, Lee, SJ, Kim, JH, Shin, JH, An, JH, et.al. Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial., JAMA Oncol, 2018. 4 (5)(5): p. 661-669., https://pubmed.ncbi.nlm.nih.gov/29543938/
363. Huo, YR, Eslick, GD, Transcatheter Arterial Chemoembolization Plus Radiotherapy Compared With Chemoembolization Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis., JAMA Oncol, 2015. 1 (6)(6): p. 756-65., https://pubmed.ncbi.nlm.nih.gov/26182200/
364. Bargellini, I, Bozzi, E, Campani, D, Carrai, P, De Simone, P, Pollina, L, et.al. Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants., Eur J Radiol, 2013. 82 (5)(5): p. e212-8., https://pubmed.ncbi.nlm.nih.gov/23332890/
365. Yu, H, Bai, Y, Xie, X, Feng, Y, Yang, Y, Zhu, Q, RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis., BMJ Open, 2022. 12 (6)(6): p. e052294., https://pubmed.ncbi.nlm.nih.gov/35649603/
366. Kim, DH, Kim, B, Choi, JI, Oh, SN, Rha, SE, LI-RADS Treatment Response versus Modified RECIST for Diagnosing Viable Hepatocellular Carcinoma after Locoregional Therapy: A Systematic Review and Meta-Analysis of Comparative Studies., Taehan Yongsang Uihakhoe Chi, 2022. 83 (2)(2): p. 331-343., https://pubmed.ncbi.nlm.nih.gov/36237934/
367. Santillan, C., Chernyak, V., Sirlin, C., LI-RADS categories: concepts, definitions, and criteria, Abdom Radiol (NY), 2018. 43(1): p. 101-110.
368. Santillan, C., Fowler, K., Kono, Y., Chernyak, V., LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents, Abdom Radiol (NY), 2018. 43(1): p. 75-81.
369. Takahashi, S., Kudo, M., Chung, H., Inoue, T., Ishikawa, E., Kitai, S., et.al. Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy, Oncology, 2007. 72 Suppl 1: p. 98-103., https://www.karger.com/Article/Pdf/111714
370. Guglielmi, A., Ruzzenente, A., Pachera, S., Valdegamberi, A., Sandri, M., D'Onofrio, M., et.al. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response, Am J Gastroenterol, 2008. 103(3): p. 597-604.
371. Yoon, J. H., Lee, E. J., Cha, S. S., Han, S. S., Choi, S. J., Juhn, J. R., et.al. Comparison of gadoxetic acid-enhanced MR imaging versus four-phase multi-detector row computed tomography in assessing tumor regression after radiofrequency ablation in subjects with hepatocellular carcinomas, J Vasc Interv Radiol, 2010. 21(3): p. 348-56.
372. Vauthey, J. N., Dixon, E., Abdalla, E. K., Helton, W. S., Pawlik, T. M., Taouli, B., et.al. Pretreatment assessment of hepatocellular carcinoma: expert consensus statement, HPB (Oxford), 2010. 12(5): p. 289-99., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2951814/pdf/hpb0012-0289.pdf
373. Schima, W., Ba-Ssalamah, A., Kurtaran, A., Schindl, M., Gruenberger, T., Post-treatment imaging of liver tumours, Cancer Imaging, 2007. 7 Spec No A(Special issue A): p. S28-36., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727978/pdf/ci079047.pdf
374. Frieser, M., Kiesel, J., Lindner, A., Bernatik, T., Haensler, J. M., Janka, R., et.al. Efficacy of contrast-enhanced US versus CT or MRI for the therapeutic control of percutaneous radiofrequency ablation in the case of hepatic malignancies, Ultraschall Med, 2011. 32(2): p. 148-53., https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0029-1245934.pdf
375. Schacherer, D., Girlich, C., Jung, M. E., Wiest, R., Scholmerich, J., Transabdominal ultrasound with echoenhancement by contrast media in the diagnosis of hepatocellular carcinoma, Dig Dis, 2009. 27(2): p. 109-13., https://www.karger.com/Article/Pdf/218342
376. Lencioni, R., Piscaglia, F., Bolondi, L., Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma, J Hepatol, 2008. 48(5): p. 848-57., https://www.sciencedirect.com/science/article/pii/S0168827808001244?via%3Dihub
377. Crocetti, L., de Baere, T., Lencioni, R., Quality improvement guidelines for radiofrequency ablation of liver tumours, Cardiovasc Intervent Radiol, 2010. 33(1): p. 11-7., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2816824/pdf/270_2009_Article_9736.pdf
378. Tsai, M. C., Wang, J. H., Hung, C. H., Kee, K. M., Yen, Y. H., Lee, C. M., et.al. Favorable alpha-fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation, J Gastroenterol Hepatol, 2010. 25(3): p. 605-12., https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1440-1746.2009.06115.x?download=true
379. Lencioni, R., New data supporting modified RECIST (mRECIST) for Hepatocellular Carcinoma, Clin Cancer Res, 2013. 19(6): p. 1312-4., https://clincancerres.aacrjournals.org/content/clincanres/19/6/1312.full.pdf
380. Vincenzi, B., Di Maio, M., Silletta, M., D'Onofrio, L., Spoto, C., Piccirillo, M. C., et.al. Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis, PLoS One, 2015. 10(7): p. e0133488., https://iris.unito.it/retrieve/handle/2318/1572009/162002/pone.0133488.pdf
381. Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T. Y., et.al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma, N Engl J Med, 2020. 382(20): p. 1894-1905., https://www.nejm.org/doi/pdf/10.1056/NEJMoa1915745?articleTools=true
382. Cheng, A. L., Kang, Y. K., Chen, Z., Tsao, C. J., Qin, S., Kim, J. S., et.al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial, Lancet Oncol, 2009. 10(1): p. 25-34., https://www.sciencedirect.com/science/article/pii/S1470204508702857?via%3Dihub
383. Kudo, Masatoshi, Finn, Richard S., Qin, Shukui, Han, Kwang-Hyub, Ikeda, Kenji, Piscaglia, Fabio, et.al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial, The Lancet, 2018. 391(10126): p. 1163-1173.
384. Bruix, Jordi, Qin, Shukui, Merle, Philippe, Granito, Alessandro, Huang, Yi-Hsiang, Bodoky, György, et.al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial, The Lancet, 2017. 389(10064): p. 56-66.
385. Abou-Alfa, G. K., Meyer, T., Cheng, A. L., El-Khoueiry, A. B., Rimassa, L., Ryoo, B. Y., et.al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma, N Engl J Med, 2018. 379(1): p. 54-63., https://www.nejm.org/doi/pdf/10.1056/NEJMoa1717002?articleTools=true
386. Zhu, A. X., Kang, Y. K., Yen, C. J., Finn, R. S., Galle, P. R., Llovet, J. M., et.al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol, 2019. 20(2): p. 282-296.
387. Facciorusso, A, Tartaglia, N, Villani, R, Serviddio, G, Ramai, D, Mohan, BP, et.al. Lenvatinib versus sorafenib as first-line therapy of advanced hepatocellular carcinoma: a systematic review and meta-analysis., Am J Transl Res, 2021. 13 (4)(4): p. 2379-2387., https://pubmed.ncbi.nlm.nih.gov/34017396/
388. Abou-Alfa Ghassan K., Lau George, Kudo Masatoshi, Chan Stephen L., Kelley Robin Kate, Furuse Junji, et.al. Tremelimumab plus Durvalumab in Unresectable Hepatocellular CarcinomaMassachusetts Medical Society, NEJM Evidence, 2022. 1(8): p. EVIDoa2100070., https://doi.org/10.1056/EVIDoa2100070
389. Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J. F., et.al. Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 2008. 359(4): p. 378-90., https://www.nejm.org/doi/pdf/10.1056/NEJMoa0708857?articleTools=true
390. Zhu, Andrew X., Kang, Yoon-Koo, Yen, Chia-Jui, Finn, Richard S., Galle, Peter R., Llovet, Josep M., et.al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial, The Lancet Oncology, 2019. 20(2): p. 282-296.
391. Cheng, AL, Qin, S, Ikeda, M, Galle, PR, Ducreux, M, Kim, TY, et.al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma., J Hepatol, 2022. 76 (4)(4): p. 862-873., https://pubmed.ncbi.nlm.nih.gov/34902530/
392. Galle, PR, Finn, RS, Qin, S, Ikeda, M, Zhu, AX, Kim, TY, et.al. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial., Lancet Oncol, 2021. 22 (7)(7): p. 991-1001., https://pubmed.ncbi.nlm.nih.gov/34051880/
393. Yau, T, Park, JW, Finn, RS, Cheng, AL, Mathurin, P, Edeline, J, et.al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial., Lancet Oncol, 2022. 23 (1)(1): p. 77-90., https://pubmed.ncbi.nlm.nih.gov/34914889/
394. Qin, S, Kudo, M, Meyer, T, Bai, Y, Guo, Y, Meng, Z, et.al. Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial., JAMA Oncol, 2023. 9 (12)(12): p. 1651-1659., https://pubmed.ncbi.nlm.nih.gov/37796513/
395. Cainap, C., Qin, S., Huang, W. T., Chung, I. J., Pan, H., Cheng, Y., et.al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial, J Clin Oncol, 2015. 33(2): p. 172-9., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279237/pdf/zlj172.pdf
396. Johnson, P. J., Qin, S., Park, J. W., Poon, R. T., Raoul, J. L., Philip, P. A., et.al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study, J Clin Oncol, 2013. 31(28): p. 3517-24.
397. Zhu, A. X., Rosmorduc, O., Evans, T. R., Ross, P. J., Santoro, A., Carrilho, F. J., et.al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma, J Clin Oncol, 2015. 33(6): p. 559-66., http://diposit.ub.edu/dspace/bitstream/2445/117402/1/649304.pdf
398. Cheng, A. L., Kang, Y. K., Lin, D. Y., Park, J. W., Kudo, M., Qin, S., et.al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial, J Clin Oncol, 2013. 31(32): p. 4067-75.
399. Llovet, JM, Kudo, M, Merle, P, Meyer, T, Qin, S, Ikeda, M, et.al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial., Lancet Oncol, 2023. 24 (12)(12): p. 1399-1410., https://pubmed.ncbi.nlm.nih.gov/38039993/
400. Marrero, J. A., Kudo, M., Venook, A. P., Ye, S. L., Bronowicki, J. P., Chen, X. P., et.al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study, J Hepatol, 2016. 65(6): p. 1140-1147., https://www.journal-of-hepatology.eu/article/S0168-8278(16)30346-4/pdf
401. Ganten, T. M., Stauber, R. E., Schott, E., Malfertheiner, P., Buder, R., Galle, P. R., et.al. Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT Study, Clin Cancer Res, 2017. 23(19): p. 5720-5728., https://clincancerres.aacrjournals.org/content/clincanres/23/19/5720.full.pdf
402. Leal, C. R. G., Magalhães, C., Barbosa, D., Aquino, D., Carvalho, B., Balbi, E., et.al. Survival and tolerance to sorafenib in Child-Pugh B patients with hepatocellular carcinoma: a prospective study, Invest New Drugs, 2018. 36(5): p. 911-918., https://link.springer.com/article/10.1007/s10637-018-0621-x
403. Pressiani, T., Boni, C., Rimassa, L., Labianca, R., Fagiuoli, S., Salvagni, S., et.al. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis, Ann Oncol, 2013. 24(2): p. 406-411., https://www.annalsofoncology.org/article/S0923-7534(19)36863-2/pdf
404. Ogasawara, S., Chiba, T., Ooka, Y., Kanogawa, N., Saito, T., Motoyama, T., et.al. Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors, Invest New Drugs, 2015. 33(3): p. 729-39., https://link.springer.com/article/10.1007%2Fs10637-015-0237-3
405. Rimini, M, Persano, M, Tada, T, Suda, G, Shimose, S, Kudo, M, et.al. Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients., J Cancer Res Clin Oncol, 2023. 149 (10)(10): p. 7565-7577., https://pubmed.ncbi.nlm.nih.gov/36976353/
406. Kudo, M, Matilla, A, Santoro, A, Melero, I, Gracián, AC, Acosta-Rivera, M, et.al. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis., J Hepatol, 2021. 75 (3)(3): p. 600-609., https://pubmed.ncbi.nlm.nih.gov/34051329/
407. El-Khoueiry, AB, Meyer, T, Cheng, AL, Rimassa, L, Sen, S, Milwee, S, et.al. Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial., BMC Cancer, 2022. 22 (1)(1): p. 377., https://pubmed.ncbi.nlm.nih.gov/35397508/
408. Huynh, J, Cho, MT, Kim, EJ, Ren, M, Ramji, Z, Vogel, A, Lenvatinib in patients with unresectable hepatocellular carcinoma who progressed to Child-Pugh B liver function., Ther Adv Med Oncol, 2022. 14 (): p. 17588359221116608., https://pubmed.ncbi.nlm.nih.gov/36051472/
409. Xie, E, Yeo, YH, Scheiner, B, Zhang, Y, Hiraoka, A, Tantai, X, et.al. Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis., JAMA Oncol, 2023. 9 (10)(10): p. 1423-1431., https://pubmed.ncbi.nlm.nih.gov/37615958/
410. D'Alessio, A, Fulgenzi, CAM, Nishida, N, Schönlein, M, von Felden, J, Schulze, K, et.al. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study., Hepatology, 2022. 76 (4)(4): p. 1000-1012., https://pubmed.ncbi.nlm.nih.gov/35313048/
411. Jost-Brinkmann, F, Demir, M, Wree, A, Luedde, T, Loosen, SH, Müller, T, et.al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real-world cohort., Aliment Pharmacol Ther, 2023. 57 (11)(11): p. 1313-1325., https://pubmed.ncbi.nlm.nih.gov/36883351/
412. de Castro, T, Jochheim, LS, Bathon, M, Welland, S, Scheiner, B, Shmanko, K, et.al. Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience., Ther Adv Med Oncol, 2022. 14 (): p. 17588359221080298., https://pubmed.ncbi.nlm.nih.gov/35251317/
413. Vilgrain, V., Pereira, H., Assenat, E., Guiu, B., Ilonca, A. D., Pageaux, G. P., et.al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial, Lancet Oncol, 2017. 18(12): p. 1624-1636., https://www.sciencedirect.com/science/article/abs/pii/S1470204517306836
414. Lencioni, R., Llovet, J. M., Han, G., Tak, W. Y., Yang, J., Guglielmi, A., et.al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial, J Hepatol, 2016. 64(5): p. 1090-8., https://www.ncbi.nlm.nih.gov/pubmed/26809111
415. Meyer, T., Fox, R., Ma, Y. T., Ross, P. J., James, M. W., Sturgess, R., et.al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial, Lancet Gastroenterol Hepatol, 2017. 2(8): p. 565-575., https://www.thelancet.com/pdfs/journals/langas/PIIS2468-1253(17)30156-5.pdf
416. Cai, R, Song, R, Pang, P, Yan, Y, Liao, Y, Zhou, C, et.al. Transcatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization alone to treat advanced hepatocellular carcinoma: a meta-analysis., BMC Cancer, 2017. 17 (1)(1): p. 714., https://pubmed.ncbi.nlm.nih.gov/29110700/
417. Dai, Y, Jiang, H, Jiang, H, Zhao, S, Zeng, X, Sun, R, et.al. Optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis., Transl Oncol, 2021. 14 (12)(12): p. 101238., https://pubmed.ncbi.nlm.nih.gov/34628285/
418. Duan, R, Gong, F, Wang, Y, Huang, C, Wu, J, Hu, L, et.al. Transarterial chemoembolization (TACE) plus tyrosine kinase inhibitors versus TACE in patients with hepatocellular carcinoma: a systematic review and meta-analysis., World J Surg Oncol, 2023. 21 (1)(1): p. 120., https://pubmed.ncbi.nlm.nih.gov/37004052/
419. Zhao, S, Zhang, T, Dou, W, Wang, E, Wang, M, Wang, C, et.al. A comparison of transcatheter arterial chemoembolization used with and without apatinib for intermediate- to advanced-stage hepatocellular carcinoma: a systematic review and meta-analysis., Ann Transl Med, 2020. 8 (8)(8): p. 542., https://pubmed.ncbi.nlm.nih.gov/32411765/
420. Gu, H, Li, J, You, N, Wu, K, Wang, Z, Wang, L, et.al. Efficacy and safety of apatinib combined with transarterial chemoembolization (TACE) in treating patients with recurrent hepatocellular carcinoma., Ann Transl Med, 2020. 8 (24)(24): p. 1677., https://pubmed.ncbi.nlm.nih.gov/33490189/
421. Kudo, M, Ueshima, K, Ikeda, M, Torimura, T, Tanabe, N, Aikata, H, et.al. Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma., Liver Cancer, 2022. 11 (4)(4): p. 354-367., https://pubmed.ncbi.nlm.nih.gov/35978604/
422. Kudo, M, Ueshima, K, Ikeda, M, Torimura, T, Tanabe, N, Aikata, H, et.al. Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma., Liver Cancer, 2022. 11 (4)(4): p. 354-367., https://pubmed.ncbi.nlm.nih.gov/35978604/
423. Ding, X, Sun, W, Li, W, Shen, Y, Guo, X, Teng, Y, et.al. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study., Cancer, 2021. 127 (20)(20): p. 3782-3793., https://pubmed.ncbi.nlm.nih.gov/34237154/
424. Cai, M, Huang, W, Huang, J, Shi, W, Guo, Y, Liang, L, et.al. Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study., Front Immunol, 2022. 13 (): p. 848387., https://pubmed.ncbi.nlm.nih.gov/35300325/
425. Marinelli, B, Kim, E, D'Alessio, A, Cedillo, M, Sinha, I, Debnath, N, et.al. Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study., J Immunother Cancer, 2022. 10 (6)(6):, https://pubmed.ncbi.nlm.nih.gov/35710293/
426. Fan, W, Zhu, B, Yue, S, Zheng, X, Zou, X, Li, F, et.al. Idarubicin-Loaded DEB-TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score-matching analysis., Cancer Med, 2023. 12 (1)(1): p. 61-72., https://pubmed.ncbi.nlm.nih.gov/35698292, /
427. Ricke, J., Klümpen, H. J., Amthauer, H., Bargellini, I., Bartenstein, P., de Toni, E. N., et.al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma, J Hepatol, 2019. 71(6): p. 1164-1174., https://www.journal-of-hepatology.eu/article/S0168-8278(19)30472-6/fulltext
428. Kudo, M., Ueshima, K., Ikeda, M., Torimura, T., Tanabe, N., Aikata, H., et.al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial, Gut, 2020. 69(8): p. 1492-1501., https://www.ncbi.nlm.nih.gov/pubmed/31801872
429. Kudo, M., Ikeda, M., Ueshima, K., Sakamoto, M., Shiina, S., Tateishi, R., et.al. Response Evaluation Criteria in Cancer of the Liver version 5 (RECICL 2019 revised version), Hepatol Res, 2019. 49(9): p. 981-989., https://www.ncbi.nlm.nih.gov/pubmed/31231916
430. Kudo, Masatoshi, Ueshima, Kazuomi, Ikeda, Masafumi, Torimura, Takuji, Aikata, Hiroshi, Izumi, Namiki, et.al. TACTICS: Final overall survival (OS) data from a randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients (pts) with hepatocellular carcinoma (HCC), Journal of Clinical Oncology, 2021. 39(3_suppl): p. 270-270., https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.3_suppl.270
431. Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y. H., Bodoky, G., et.al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 2017. 389(10064): p. 56-66., https://www.sciencedirect.com/science/article/pii/S0140673616324539?via%3Dihub
432. Finn, RS, Ryoo, BY, Merle, P, Kudo, M, Bouattour, M, Lim, HY, et.al. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial., J Clin Oncol, 2020. 38 (3)(3): p. 193-202., https://pubmed.ncbi.nlm.nih.gov/31790344/
433. Rao, Q, Li, M, Xu, W, Pang, K, Guo, X, Wang, D, et.al. Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis., Hepatol Int, 2020. 14 (5)(5): p. 765-775., https://pubmed.ncbi.nlm.nih.gov/32572818/
434. Parikh, ND, Marshall, A, Betts, KA, Song, J, Zhao, J, Yuan, M, et.al. Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinoma., J Comp Eff Res, 2021. 10 (5)(5): p. 343-352., https://pubmed.ncbi.nlm.nih.gov/33442996/
435. He, S, Jiang, W, Fan, K, Wang, X, The Efficacy and Safety of Programmed Death-1 and Programmed Death Ligand 1 Inhibitors for the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis., Front Oncol, 2021. 11 (): p. 626984., https://pubmed.ncbi.nlm.nih.gov/33833987/
436. Kudo, M, Finn, RS, Edeline, J, Cattan, S, Ogasawara, S, Palmer, DH, et.al. Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib., Eur J Cancer, 2022. 167 (): p. 1-12., https://pubmed.ncbi.nlm.nih.gov/35364421/
437. Yau, T, Kang, YK, Kim, TY, El-Khoueiry, AB, Santoro, A, Sangro, B, et.al. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial., JAMA Oncol, 2020. 6 (11)(11): p. e204564., https://pubmed.ncbi.nlm.nih.gov/33001135/
438. El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., et.al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial, Lancet, 2017. 389(10088): p. 2492-2502., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539326/pdf/nihms-1623792.pdf
439. Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., et.al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial, Lancet Oncol, 2018. 19(7): p. 940-952., https://www.ncbi.nlm.nih.gov/pubmed/29875066
440. Finn, R. S., Ryoo, B. Y., Merle, P., Kudo, M., Bouattour, M., Lim, H. Y., et.al. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial, J Clin Oncol, 2020. 38(3): p. 193-202., https://www.ncbi.nlm.nih.gov/pubmed/31790344
441. Qin, Shukui, Chen, Zhendong, Fang, Weijia, Ren, Zhenggang, Xu, Ruocai, Ryoo, Baek-Yeol, et.al. Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.Wolters Kluwer, Journal of Clinical Oncology, 2022. 40(4_suppl): p. 383 - 383., https://doi.org/10.1200/JCO.2022.40.4_suppl.383
442. Dinh, TA, Utria, AF, Barry, KC, Ma, R, Abou-Alfa, GK, Gordan, JD, et.al. A framework for fibrolamellar carcinoma research and clinical trials., Nat Rev Gastroenterol Hepatol, 2022. 19 (5)(5): p. 328-342., https://pubmed.ncbi.nlm.nih.gov/35190728/
443. Honeyman, JN, Simon, EP, Robine, N, Chiaroni-Clarke, R, Darcy, DG, Lim, II, et.al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma., Science, 2014. 343 (6174)(6174): p. 1010-4., https://pubmed.ncbi.nlm.nih.gov/24578576/
444. Ramai, D, Ofosu, A, Lai, JK, Gao, ZH, Adler, DG, Fibrolamellar Hepatocellular Carcinoma: A Population-Based Observational Study., Dig Dis Sci, 2021. 66 (1)(1): p. 308-314., https://pubmed.ncbi.nlm.nih.gov/32052215/
445. Rimassa, L, Personeni, N, Czauderna, C, Foerster, F, Galle, P, Systemic treatment of HCC in special populations., J Hepatol, 2021. 74 (4)(4): p. 931-943., https://pubmed.ncbi.nlm.nih.gov/33248171/
446. Wege, H, Schulze, K, von Felden, J, Calderaro, J, Reig, M, Rare variants of primary liver cancer: Fibrolamellar, combined, and sarcomatoid hepatocellular carcinomas., Eur J Med Genet, 2021. 64 (11)(11): p. 104313., https://pubmed.ncbi.nlm.nih.gov/34418585/
447. Da Fonseca, LG, Yamamoto, VJ, Trinconi Cunha, M, Torre, GS, Araujo, RLC, Fonseca, GM, et.al. Treatment Outcomes in Patients with Advanced Fibrolamellar Hepatocellular Carcinoma Under Systemic Treatment: Analysis of Clinical Characteristics, Management, and Radiomics., J Hepatocell Carcinoma, 2023. 10 (): p. 1923-1933., https://pubmed.ncbi.nlm.nih.gov/37933267/
448. Chakrabarti, S, Tella, SH, Kommalapati, A, Huffman, BM, Yadav, S, Riaz, IB, et.al. Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma., J Gastrointest Oncol, 2019. 10 (3)(3): p. 554-561., https://pubmed.ncbi.nlm.nih.gov/31183207/
449. Gras, P, Truant, S, Boige, V, Ladrat, L, Rougier, P, Pruvot, FR, et.al. Prolonged Complete Response after GEMOX Chemotherapy in a Patient with Advanced Fibrolamellar Hepatocellular Carcinoma., Case Rep Oncol, 2012. 5 (1)(1): p. 169-72., https://pubmed.ncbi.nlm.nih.gov/22666208/
450. Patt, YZ, Hassan, MM, Lozano, RD, Brown, TD, Vauthey, JN, Curley, SA, et.al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma., J Clin Oncol, 2003. 21 (3)(3): p. 421-7., https://pubmed.ncbi.nlm.nih.gov/12560429/
451. Kim, AK, Gani, F, Layman, AJ, Besharati, S, Zhu, Q, Succaria, F, et.al. Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma., Cancer Immunol Res, 2019. 7 (5)(5): p. 805-812., https://pubmed.ncbi.nlm.nih.gov/30902819/
452. Chen, KY, Popovic, A, Hsiehchen, D, Baretti, M, Griffith, P, Bista, R, et.al. Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors., Cancers (Basel), 2022. 14 (21)(21):, https://pubmed.ncbi.nlm.nih.gov/36358766/
453. Berger, R, Dinstag, G, Tirosh, O, Schiff, E, Kleiner, D, Aldape, KD, et.al. Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab., J Immunother Cancer, 2022. 10 (12)(12):, https://pubmed.ncbi.nlm.nih.gov/36600603/
454. De Toni, EN, Roessler, D, Using dual checkpoint blockade to treat fibrolamellar hepatocellular carcinoma., Gut, 2020. 69 (11)(11): p. 2056-2058., https://pubmed.ncbi.nlm.nih.gov/32051207/
455. Kang, S, Magliocca, J, Sellers, M, Roccaro, G, Zheng, W, Pectasides, M, et.al. Successful Liver Transplantation of Recurrent Fibrolamellar Carcinoma following Clinical and Pathologic Complete Response to Triple Immunochemotherapy: A Case Report., Oncol Res Treat, 2022. 45 (7-8)(7-8): p. 430-437., https://pubmed.ncbi.nlm.nih.gov/35537414/
456. Gottlieb, S, O'Grady, C, Gliksberg, A, Kent, P, Early Experiences with Triple Immunochemotherapy in Adolescents and Young Adults with High-Risk Fibrolamellar Carcinoma., Oncology, 2021. 99 (5)(5): p. 310-317., https://pubmed.ncbi.nlm.nih.gov/33690232/
457. Bauer, J, Köhler, N, Maringer, Y, Bucher, P, Bilich, T, Zwick, M, et.al. The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma., Nat Commun, 2022. 13 (1)(1): p. 6401., https://pubmed.ncbi.nlm.nih.gov/36302754/
458. Nagtegaal, ID, Odze, RD, Klimstra, D, Paradis, V, Rugge, M, Schirmacher, P, et.al. The 2019 WHO classification of tumours of the digestive system., Histopathology, 2020. 76 (2)(2): p. 182-188., https://pubmed.ncbi.nlm.nih.gov/31433515/
459. Eschrich, J, Kobus, Z, Geisel, D, Halskov, S, Roßner, F, Roderburg, C, et.al. The Diagnostic Approach towards Combined Hepatocellular-Cholangiocarcinoma-State of the Art and Future Perspectives., Cancers (Basel), 2023. 15 (1)(1):, https://pubmed.ncbi.nlm.nih.gov/36612297/
460. Gigante, E, Paradis, V, Ronot, M, Cauchy, F, Soubrane, O, Ganne-Carrié, N, et.al. New insights into the pathophysiology and clinical care of rare primary liver cancers., JHEP Rep, 2021. 3 (1)(1): p. 100174., https://pubmed.ncbi.nlm.nih.gov/33205035/
461. Xue, R, Chen, L, Zhang, C, Fujita, M, Li, R, Yan, SM, et.al. Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes., Cancer Cell, 2019. 35 (6)(6): p. 932-947.e8., https://pubmed.ncbi.nlm.nih.gov/31130341/
462. Gigante, E, Hobeika, C, Le Bail, B, Paradis, V, Tougeron, D, Lequoy, M, et.al. Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma., Liver Cancer, 2022. 11 (5)(5): p. 460-473., https://pubmed.ncbi.nlm.nih.gov/36158591/
463. Pomej, K, Balcar, L, Shmanko, K, Welland, S, Himmelsbach, V, Scheiner, B, et.al. Clinical characteristics and outcome of patients with combined hepatocellular-cholangiocarcinoma-a European multicenter cohort., ESMO Open, 2023. 8 (1)(1): p. 100783., https://pubmed.ncbi.nlm.nih.gov/36753993/
464. Jang, YJ, Kim, EJ, Kim, HD, Kim, KP, Ryu, MH, Park, SR, et.al. Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellular-cholangiocarcinoma., J Cancer Res Clin Oncol, 2023. 149 (10)(10): p. 7547-7555., https://pubmed.ncbi.nlm.nih.gov/36971796/
465. Rizell, M, Åberg, F, Perman, M, Ny, L, Stén, L, Hashimi, F, et.al. Checkpoint Inhibition Causing Complete Remission of Metastatic Combined Hepatocellular-Cholangiocarcinoma after Hepatic Resection., Case Rep Oncol, 2020. 13 (1)(1): p. 478-484., https://pubmed.ncbi.nlm.nih.gov/32508620/
466. Satake, T, Shibuki, T, Watanabe, K, Sasaki, M, Imaoka, H, Mitsunaga, S, et.al. Case Report: Atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma., Front Oncol, 2023. 13 (): p. 1234113., https://pubmed.ncbi.nlm.nih.gov/37546425/
467. Kim, EJ, Yoo, C, Kang, HJ, Kim, KP, Ryu, MH, Park, SR, et.al. Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular-cholangiocarcinoma., Liver Int, 2021. 41 (6)(6): p. 1398-1408., https://pubmed.ncbi.nlm.nih.gov/33548073/
468. Kobayashi, S, Terashima, T, Shiba, S, Yoshida, Y, Yamada, I, Iwadou, S, et.al. Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma., Cancer Sci, 2018. 109 (8)(8): p. 2549-2557., https://pubmed.ncbi.nlm.nih.gov/29856900/
469. Rogers, JE, Bolonesi, RM, Rashid, A, Elsayes, KM, Elbanan, MG, Law, L, et.al. Systemic therapy for unresectable, mixed hepatocellular-cholangiocarcinoma: treatment of a rare malignancy., J Gastrointest Oncol, 2017. 8 (2)(2): p. 347-351., https://pubmed.ncbi.nlm.nih.gov/28480073/
470. Trikalinos, NA, Zhou, A, Doyle, MBM, Fowler, KJ, Morton, A, Vachharajani, N, et.al. Systemic Therapy for Combined Hepatocellular-Cholangiocarcinoma: A Single-Institution Experience., J Natl Compr Canc Netw, 2018. 16 (10)(10): p. 1193-1199., https://pubmed.ncbi.nlm.nih.gov/30323089/
471. Salimon, M, Prieux-Klotz, C, Tougeron, D, Hautefeuille, V, Caulet, M, Gournay, J, et.al. Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study., Br J Cancer, 2018. 118 (3)(3): p. 325-330., https://pubmed.ncbi.nlm.nih.gov/29169182/
472. Qin, S, Chen, M, Cheng, AL, Kaseb, AO, Kudo, M, Lee, HC, et.al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial., Lancet, 2023. 402 (10415)(10415): p. 1835-1847., https://pubmed.ncbi.nlm.nih.gov/37871608/
473. Bruix, J., Takayama, T., Mazzaferro, V., Chau, G. Y., Yang, J., Kudo, M., et.al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial, Lancet Oncol, 2015. 16(13): p. 1344-54., https://www.sciencedirect.com/science/article/pii/S1470204515001989?via%3Dihub
474. Vogel, A, Grant, RC, Meyer, T, Sapisochin, G, O'Kane, GM, Saborowski, A, Adjuvant and neoadjuvant therapies for hepatocellular carcinoma., Hepatology, 2023. ():, https://pubmed.ncbi.nlm.nih.gov/38108634/
475. Ho, WJ, Zhu, Q, Durham, J, Popovic, A, Xavier, S, Leatherman, J, et.al. Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity., Nat Cancer, 2021. 2 (9)(9): p. 891-903., https://pubmed.ncbi.nlm.nih.gov/34796337/
476. Kaseb, AO, Hasanov, E, Cao, HST, Xiao, L, Vauthey, JN, Lee, SS, et.al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial., Lancet Gastroenterol Hepatol, 2022. 7 (3)(3): p. 208-218., https://pubmed.ncbi.nlm.nih.gov/35065057/
477. Marron, TU, Fiel, MI, Hamon, P, Fiaschi, N, Kim, E, Ward, SC, et.al. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial., Lancet Gastroenterol Hepatol, 2022. 7 (3)(3): p. 219-229., https://pubmed.ncbi.nlm.nih.gov/35065058/
478. Xia, Y, Tang, W, Qian, X, Li, X, Cheng, F, Wang, K, et.al. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial., J Immunother Cancer, 2022. 10 (4)(4):, https://pubmed.ncbi.nlm.nih.gov/35379737/
479. Katzenstein, H. M., Krailo, M. D., Malogolowkin, M. H., Ortega, J. A., Liu-Mares, W., Douglass, E. C., et.al. Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children's Cancer Group intergroup study, J Clin Oncol, 2002. 20(12): p. 2789-97.
480. Czauderna, P., Mackinlay, G., Perilongo, G., Brown, J., Shafford, E., Aronson, D., et.al. Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group, J Clin Oncol, 2002. 20(12): p. 2798-804., https://www.ncbi.nlm.nih.gov/pubmed/12065556
481. Schmid, I., von Schweinitz, D., Pediatric hepatocellular carcinoma: challenges and solutions, J Hepatocell Carcinoma, 2017. 4: p. 15-21., https://pubmed.ncbi.nlm.nih.gov/28144610/
482. Schmid, I., Häberle, B., Albert, M. H., Corbacioglu, S., Fröhlich, B., Graf, N., et.al. Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma, Pediatr Blood Cancer, 2012. 58(4): p. 539-44., https://onlinelibrary.wiley.com/doi/abs/10.1002/pbc.23295
483. Villani, A, Davidson, S, Kanwar, N, Lo, WW, Li, Y, Cohen-Gogo, S, et.al. The clinical utility of integrative genomics in childhood cancer extends beyond targetable mutations., Nat Cancer, 2023. 4 (2)(2): p. 203-221., https://pubmed.ncbi.nlm.nih.gov/36585449/
484. Schroeder, C, Faust, U, Krauße, L, Liebmann, A, Abele, M, Demidov, G, et.al. Clinical trio genome sequencing facilitates the interpretation of variants in cancer predisposition genes in paediatric tumour patients., Eur J Hum Genet, 2023. 31 (10)(10): p. 1139-1146., https://pubmed.ncbi.nlm.nih.gov/37507557/
485. Cohen-Gogo, S, Denburg, AE, Villani, A, Thacker, N, Egan, G, Simao Rafael, M, et.al. Precision oncology for children: A primer for paediatricians., Paediatr Child Health, 2023. 28 (5)(5): p. 278-284., https://pubmed.ncbi.nlm.nih.gov/37484033/
486. Parsons, DW, Roy, A, Yang, Y, Wang, T, Scollon, S, Bergstrom, K, et.al. Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors., JAMA Oncol, 2016. 2 (5)(5): p. 616-624., https://pubmed.ncbi.nlm.nih.gov/26822237/
487. Atchison, E. A., Gridley, G., Carreon, J. D., Leitzmann, M. F., McGlynn, K. A., Risk of cancer in a large cohort of U.S. veterans with diabetes, Int J Cancer, 2011. 128(3): p. 635-43., https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.25362?download=true
488. de Valle, M. B., Björnsson, E., Lindkvist, B., Mortality and cancer risk related to primary sclerosing cholangitis in a Swedish population-based cohort, Liver Int, 2012. 32(3): p. 441-8., https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1478-3231.2011.02614.x?download=true
489. El-Serag, H. B., Engels, E. A., Landgren, O., Chiao, E., Henderson, L., Amaratunge, H. C., et.al. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans, Hepatology, 2009. 49(1): p. 116-23., https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.22606?download=true
490. Huang, Y., You, L., Xie, W., Ning, L., Lang, J., Smoking and risk of cholangiocarcinoma: a systematic review and meta-analysis, Oncotarget, 2017. 8(59): p. 100570-100581., https://www.oncotarget.com/article/20141/pdf/
491. Jing, W., Jin, G., Zhou, X., Zhou, Y., Zhang, Y., Shao, C., et.al. Diabetes mellitus and increased risk of cholangiocarcinoma: a meta-analysis, Eur J Cancer Prev, 2012. 21(1): p. 24-31.
492. Palmer, W. C., Patel, T., Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma, J Hepatol, 2012. 57(1): p. 69-76., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3804834/pdf/nihms363811.pdf
493. Wongjarupong, N., Assavapongpaiboon, B., Susantitaphong, P., Cheungpasitporn, W., Treeprasertsuk, S., Rerknimitr, R., et.al. Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis, BMC Gastroenterol, 2017. 17(1): p. 149., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721586/pdf/12876_2017_Article_696.pdf
494. Park, J. Y., Hong, S. P., Kim, Y. J., Kim, H. J., Kim, H. M., Cho, J. H., et.al. Long-term follow up of gallbladder polyps, J Gastroenterol Hepatol, 2009. 24(2): p. 219-22., https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1440-1746.2008.05689.x?download=true
495. Nagaraja, V., Eslick, G. D., Systematic review with meta-analysis: the relationship between chronic Salmonella typhi carrier status and gall-bladder cancer, Aliment Pharmacol Ther, 2014. 39(8): p. 745-50., https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/apt.12655?download=true
496. Zalevskaja, K, Mecklin, JP, Seppälä, TT, Clinical characteristics of pancreatic and biliary tract cancers in Lynch syndrome: A retrospective analysis from the Finnish National Lynch Syndrome Research Registry., Front Oncol, 2023. 13 (): p. 1123901., https://pubmed.ncbi.nlm.nih.gov/36816932/
497. Golan, T, Raitses-Gurevich, M, Kelley, RK, Bocobo, AG, Borgida, A, Shroff, RT, et.al. Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study., Oncologist, 2017. 22 (7)(7): p. 804-810., https://pubmed.ncbi.nlm.nih.gov/28487467/
498. Razumilava, N., Gores, G. J., Cholangiocarcinoma, Lancet, 2014. 383(9935): p. 2168-79., https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(13)61903-0.pdf
499. Rizvi, S., Khan, S. A., Hallemeier, C. L., Kelley, R. K., Gores, G. J., Cholangiocarcinoma - evolving concepts and therapeutic strategies, Nat Rev Clin Oncol, 2018. 15(2): p. 95-111.
500. Valle, J. W., Borbath, I., Khan, S. A., Huguet, F., Gruenberger, T., Arnold, D., Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 2016. 27(suppl 5): p. v28-v37., https://pubmed.ncbi.nlm.nih.gov/27664259/
501. Rizvi, S., Gores, G. J., Pathogenesis, diagnosis, and management of cholangiocarcinoma, Gastroenterology, 2013. 145(6): p. 1215-29., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862291/pdf/nihms535439.pdf
502. Kamsa-ard, S., Kamsa-ard, S., Luvira, V., Suwanrungruang, K., Vatanasapt, P., Wiangnon, S., Risk Factors for Cholangiocarcinoma in Thailand: A Systematic Review and Meta-Analysis, Asian Pac J Cancer Prev, 2018. 19(3): p. 605-614., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980830/pdf/APJCP-19-605.pdf
503. Qian, M. B., Utzinger, J., Keiser, J., Zhou, X. N., Clonorchiasis, Lancet, 2016. 387(10020): p. 800-10.
504. Qian, M. B., Zhou, X. N., Global burden of cancers attributable to liver flukes, Lancet Glob Health, 2017. 5(2): p. e139.
505. You, M. S., Lee, S. H., Kang, J., Choi, Y. H., Choi, J. H., Shin, B. S., et.al. Natural Course and Risk of Cholangiocarcinoma in Patients with Recurrent Pyogenic Cholangitis: A Retrospective Cohort Study, Gut Liver, 2019. 13(3): p. 373-379., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529165/pdf/gnl-13-373.pdf
506. Ten Hove, A., de Meijer, V. E., Hulscher, J. B. F., de Kleine, R. H. J., Meta-analysis of risk of developing malignancy in congenital choledochal malformation, Br J Surg, 2018. 105(5): p. 482-490., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5900735/pdf/BJS-105-482.pdf
507. Fahrner, R., Dennler, S. G., Inderbitzin, D., Risk of malignancy in Caroli disease and syndrome: A systematic review, World J Gastroenterol, 2020. 26(31): p. 4718-4728., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445861/pdf/WJG-26-4718.pdf
508. Claessen, M. M., Vleggaar, F. P., Tytgat, K. M., Siersema, P. D., van Buuren, H. R., High lifetime risk of cancer in primary sclerosing cholangitis, J Hepatol, 2009. 50(1): p. 158-64.
509. Tyson, G. L., El-Serag, H. B., Risk factors for cholangiocarcinoma, Hepatology, 2011. 54(1): p. 173-84., https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.24351?download=true
510. McGee, E. E., Jackson, S. S., Petrick, J. L., Van Dyke, A. L., Adami, H. O., Albanes, D., et.al. Smoking, Alcohol, and Biliary Tract Cancer Risk: A Pooling Project of 26 Prospective Studies, J Natl Cancer Inst, 2019. 111(12): p. 1263-1278., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6910180/pdf/djz103.pdf
511. Clements, O., Eliahoo, J., Kim, J. U., Taylor-Robinson, S. D., Khan, S. A., Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis, J Hepatol, 2020. 72(1): p. 95-103.
512. Schmidt, M. A., Marcano-Bonilla, L., Roberts, L. R., Gallbladder cancer: epidemiology and genetic risk associations, Chin Clin Oncol, 2019. 8(4): p. 31., http://cco.amegroups.com/article/view/28517/25064
513. Rawla, P., Sunkara, T., Thandra, K. C., Barsouk, A., Epidemiology of gallbladder cancer, Clin Exp Hepatol, 2019. 5(2): p. 93-102., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6728871/pdf/CEH-5-36699.pdf
514. Kratzer, W., Schmid, A., Akinli, A. S., Thiel, R., Mason, R. A., Schuler, A., et.al. [Gallbladder polyps: prevalence and risk factors], Ultraschall Med, 2011. 32 Suppl 1: p. S68-73., https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0029-1245265.pdf
515. Schnelldorfer, T., Porcelain gallbladder: a benign process or concern for malignancy?, J Gastrointest Surg, 2013. 17(6): p. 1161-8., https://link.springer.com/content/pdf/10.1007/s11605-013-2170-0.pdf
516. DesJardins, H., Duy, L., Scheirey, C., Schnelldorfer, T., Porcelain Gallbladder: Is Observation a Safe Option in Select Populations?, J Am Coll Surg, 2018. 226(6): p. 1064-1069., https://www.sciencedirect.com/science/article/abs/pii/S1072751518301571?via%3Dihub
517. Patel, S., Roa, J. C., Tapia, O., Dursun, N., Bagci, P., Basturk, O., et.al. Hyalinizing cholecystitis and associated carcinomas: clinicopathologic analysis of a distinctive variant of cholecystitis with porcelain-like features and accompanying diagnostically challenging carcinomas, Am J Surg Pathol, 2011. 35(8): p. 1104-13.
518. Gutt, C., Jenssen, C., Barreiros, A. P., Götze, T. O., Stokes, C. S., Jansen, P. L., et.al. [Updated S3-Guideline for Prophylaxis, Diagnosis and Treatment of Gallstones. German Society for Digestive and Metabolic Diseases (DGVS) and German Society for Surgery of the Alimentary Tract (DGAV) - AWMF Registry 021/008], Z Gastroenterol, 2018. 56(8): p. 912-966., https://www.thieme-connect.com/products/ejournals/pdf/10.1055/a-0644-2972.pdf
519. Eaton, J. E., Thackeray, E. W., Lindor, K. D., Likelihood of malignancy in gallbladder polyps and outcomes following cholecystectomy in primary sclerosing cholangitis, Am J Gastroenterol, 2012. 107(3): p. 431-9.
520. [Practice guideline autoimmune liver diseases - AWMF-Reg. No. 021-27], Z Gastroenterol, 2017. 55(11): p. 1135-1226., https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0043-120199
521. Wiles, R., Thoeni, R. F., Barbu, S. T., Vashist, Y. K., Rafaelsen, S. R., Dewhurst, C., et.al. Management and follow-up of gallbladder polyps : Joint guidelines between the European Society of Gastrointestinal and Abdominal Radiology (ESGAR), European Association for Endoscopic Surgery and other Interventional Techniques (EAES), International Society of Digestive Surgery - European Federation (EFISDS) and European Society of Gastrointestinal Endoscopy (ESGE), Eur Radiol, 2017. 27(9): p. 3856-3866., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5544788/pdf/330_2017_Article_4742.pdf
522. Fung, B. M., Lindor, K. D., Tabibian, J. H., Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies, World J Gastroenterol, 2019. 25(6): p. 659-671., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378537/pdf/WJG-25-659.pdf
523. Charatcharoenwitthaya, P., Enders, F. B., Halling, K. C., Lindor, K. D., Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis, Hepatology, 2008. 48(4): p. 1106-17., https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.22441?download=true
524. Naitoh, I., Nakazawa, T., Kato, A., Hayashi, K., Miyabe, K., Shimizu, S., et.al. Predictive factors for positive diagnosis of malignant biliary strictures by transpapillary brush cytology and forceps biopsy, J Dig Dis, 2016. 17(1): p. 44-51., https://onlinelibrary.wiley.com/doi/abs/10.1111/1751-2980.12311
525. Navaneethan, U., Njei, B., Lourdusamy, V., Konjeti, R., Vargo, J. J., Parsi, M. A., Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures: a systematic review and meta-analysis, Gastrointest Endosc, 2015. 81(1): p. 168-76., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824293/pdf/nihms773255.pdf
526. Klimstra DS, Lam AK, Paradis V, Schirmacher P., Tumors of the gallbladder and extrahepatic bile ducts., In: WHO Classification of Tumours Editorial Board WHO-Classification of Tumours (5th ed.) Digestive System Tumours. International Agency for Research on Cancer, Lyon 2019. p. 265-294.
527. Moeini, A., Sia, D., Zhang, Z., Camprecios, G., Stueck, A., Dong, H., et.al. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity, J Hepatol, 2017. 66(5): p. 952-961.
528. Paradis V, Schirmacher P, Singh R., Other tumours of the digestive system., In: WHO Classification of Tumours Editorial Board WHO-Classification of Tumours (5th ed.) Digestive System Tumours. International Agency for Research on Cancer, Lyon 2019. p. 499-510.
529. C, Wittekind, TNM-Klassifikation maligner Tumoren. (8. Auflage, korrigierter Nachdruck)., Wiley-VCH, Weinheim, 2020.
530. Wagner G, Hermanek P, Organspezifische Tumordokumentation – Prinzipien und Verschlüsselungsanweisungen für Klinik und Praxis, Online-version: deutsche Krebsgesellschaft. Frankfurt (Main), 1995.
531. Khuntikeo, N., Chamadol, N., Yongvanit, P., Loilome, W., Namwat, N., Sithithaworn, P., et.al. Cohort profile: cholangiocarcinoma screening and care program (CASCAP), BMC Cancer, 2015. 15: p. 459., https://www.ncbi.nlm.nih.gov/pubmed/26054405
532. Li, R., Zhang, X., Ma, K. S., Li, X. W., Xia, F., Zhong, H., et.al. Dynamic enhancing vascular pattern of intrahepatic peripheral cholangiocarcinoma on contrast-enhanced ultrasound: the influence of chronic hepatitis and cirrhosis, Abdom Imaging, 2013. 38(1): p. 112-9., https://link.springer.com/content/pdf/10.1007%2Fs00261-012-9854-x.pdf
533. Xu, H. X., Chen, L. D., Liu, L. N., Zhang, Y. F., Guo, L. H., Liu, C., Contrast-enhanced ultrasound of intrahepatic cholangiocarcinoma: correlation with pathological examination, Br J Radiol, 2012. 85(1016): p. 1029-37., https://www.ncbi.nlm.nih.gov/pubmed/22374276
534. Wildner, D., Bernatik, T., Greis, C., Seitz, K., Neurath, M. F., Strobel, D., CEUS in hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in 320 patients - early or late washout matters: a subanalysis of the DEGUM multicenter trial, Ultraschall Med, 2015. 36(2): p. 132-9., https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0034-1399147.pdf
535. Bach, A. M., Hann, L. E., Brown, K. T., Getrajdman, G. I., Herman, S. K., Fong, Y., et.al. Portal vein evaluation with US: comparison to angiography combined with CT arterial portography, Radiology, 1996. 201(1): p. 149-54., https://www.ncbi.nlm.nih.gov/pubmed/8816536
536. Wennmacker, S. Z., Lamberts, M. P., Di Martino, M., Drenth, J. P., Gurusamy, K. S., van Laarhoven, C. J., Transabdominal ultrasound and endoscopic ultrasound for diagnosis of gallbladder polyps, Cochrane Database Syst Rev, 2018. 8: p. CD012233., https://www.ncbi.nlm.nih.gov/pubmed/30109701
537. Zhang, Y., Uchida, M., Abe, T., Nishimura, H., Hayabuchi, N., Nakashima, Y., Intrahepatic peripheral cholangiocarcinoma: comparison of dynamic CT and dynamic MRI, J Comput Assist Tomogr, 1999. 23(5): p. 670-7., https://www.ncbi.nlm.nih.gov/pubmed/10524843
538. Johnson, P. T., Fishman, E. K., Routine use of precontrast and delayed acquisitions in abdominal CT: time for change, Abdom Imaging, 2013. 38(2): p. 215-23., https://www.ncbi.nlm.nih.gov/pubmed/23132390
539. Fabrega-Foster, K., Ghasabeh, M. A., Pawlik, T. M., Kamel, I. R., Multimodality imaging of intrahepatic cholangiocarcinoma, Hepatobiliary Surg Nutr, 2017. 6(2): p. 67-78., https://www.ncbi.nlm.nih.gov/pubmed/28503554
540. Valls, C., Guma, A., Puig, I., Sanchez, A., Andia, E., Serrano, T., et.al. Intrahepatic peripheral cholangiocarcinoma: CT evaluation, Abdom Imaging, 2000. 25(5): p. 490-6., https://www.ncbi.nlm.nih.gov/pubmed/10931983
541. Kim, J. H., Won, H. J., Shin, Y. M., Kim, K. A., Kim, P. N., Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma, AJR Am J Roentgenol, 2011. 196(2): p. W205-9., https://www.ajronline.org/doi/pdfplus/10.2214/AJR.10.4937
542. Bridgewater, J., Galle, P. R., Khan, S. A., Llovet, J. M., Park, J. W., Patel, T., et.al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma, J Hepatol, 2014. 60(6): p. 1268-89., https://www.ncbi.nlm.nih.gov/pubmed/24681130
543. Jhaveri, K. S., Hosseini-Nik, H., MRI of cholangiocarcinoma, J Magn Reson Imaging, 2015. 42(5): p. 1165-79., https://www.ncbi.nlm.nih.gov/pubmed/25447417
544. Murakami, T., Nakamura, H., Tsuda, K., Ishida, T., Tomoda, K., Hori, S., et.al. Contrast-enhanced MR imaging of intrahepatic cholangiocarcinoma: pathologic correlation study, J Magn Reson Imaging, 1995. 5(2): p. 165-70., https://www.ncbi.nlm.nih.gov/pubmed/7766977
545. Hamrick-Turner, J., Abbitt, P. L., Ros, P. R., Intrahepatic cholangiocarcinoma: MR appearance, AJR Am J Roentgenol, 1992. 158(1): p. 77-9., https://www.ncbi.nlm.nih.gov/pubmed/1309221
546. Fan, Z. M., Yamashita, Y., Harada, M., Baba, Y., Yamamoto, H., Matsukawa, T., et.al. Intrahepatic cholangiocarcinoma: spin-echo and contrast-enhanced dynamic MR imaging, AJR Am J Roentgenol, 1993. 161(2): p. 313-7., https://www.ncbi.nlm.nih.gov/pubmed/8392787
547. Sheng, R. F., Zeng, M. S., Rao, S. X., Ji, Y., Chen, L. L., MRI of small intrahepatic mass-forming cholangiocarcinoma and atypical small hepatocellular carcinoma (, Clin Imaging, 2014. 38(3): p. 265-72., https://www.ncbi.nlm.nih.gov/pubmed/24559750
548. Chung, Y. E., Kim, M. J., Park, Y. N., Choi, J. Y., Pyo, J. Y., Kim, Y. C., et.al. Varying appearances of cholangiocarcinoma: radiologic-pathologic correlation, Radiographics, 2009. 29(3): p. 683-700., https://www.ncbi.nlm.nih.gov/pubmed/19448110
549. Park, H. J., Kim, Y. K., Park, M. J., Lee, W. J., Small intrahepatic mass-forming cholangiocarcinoma: target sign on diffusion-weighted imaging for differentiation from hepatocellular carcinoma, Abdom Imaging, 2013. 38(4): p. 793-801., https://www.ncbi.nlm.nih.gov/pubmed/22829097
550. Fattach, H. E., Dohan, A., Guerrache, Y., Dautry, R., Boudiaf, M., Hoeffel, C., et.al. Intrahepatic and hilar mass-forming cholangiocarcinoma: Qualitative and quantitative evaluation with diffusion-weighted MR imaging, Eur J Radiol, 2015. 84(8): p. 1444-1451., https://www.ncbi.nlm.nih.gov/pubmed/26022518
551. Navaneethan, U., Njei, B., Venkatesh, P. G., Lourdusamy, V., Sanaka, M. R., Endoscopic ultrasound in the diagnosis of cholangiocarcinoma as the etiology of biliary strictures: a systematic review and meta-analysis, Gastroenterol Rep (Oxf), 2015. 3(3): p. 209-15., https://www.ncbi.nlm.nih.gov/pubmed/25169922
552. Pahade, J. K., Juice, D., Staib, L., Israel, G., Cornfeld, D., Mitchell, K., et.al. Is there an added value of a hepatobiliary phase with gadoxetate disodium following conventional MRI with an extracellular gadolinium agent in a single imaging session for detection of primary hepatic malignancies?, Abdom Radiol (NY), 2016. 41(7): p. 1270-84., https://link.springer.com/content/pdf/10.1007%2Fs00261-016-0635-9.pdf
553. Park, H. J., Kim, S. H., Jang, K. M., Choi, S. Y., Lee, S. J., Choi, D., The role of diffusion-weighted MR imaging for differentiating benign from malignant bile duct strictures, Eur Radiol, 2014. 24(4): p. 947-58., https://www.ncbi.nlm.nih.gov/pubmed/24487774
554. Lee, J., Kim, S. H., Kang, T. W., Song, K. D., Choi, D., Jang, K. T., Mass-forming Intrahepatic Cholangiocarcinoma: Diffusion-weighted Imaging as a Preoperative Prognostic Marker, Radiology, 2016. 281(1): p. 119-28., https://www.ncbi.nlm.nih.gov/pubmed/27115053
555. Rupp, C., Hippchen, T., Bruckner, T., Kloters-Plachky, P., Schaible, A., Koschny, R., et.al. Effect of scheduled endoscopic dilatation of dominant strictures on outcome in patients with primary sclerosing cholangitis, Gut, 2019. 68(12): p. 2170-2178., https://www.ncbi.nlm.nih.gov/pubmed/30910856
556. Zhang, H., Zhu, J., Ke, F., Weng, M., Wu, X., Li, M., et.al. Radiological Imaging for Assessing the Respectability of Hilar Cholangiocarcinoma: A Systematic Review and Meta-Analysis, Biomed Res Int, 2015. 2015: p. 497942., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4569758/pdf/BMRI2015-497942.pdf
557. Lamarca, A, Barriuso, J, Chander, A, McNamara, MG, Hubner, RA, ÓReilly, D, et.al. 18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) for patients with biliary tract cancer: Systematic review and meta-analysis, J Hepatol, 2019. 71 (1)(1): p. 115-129., https://pubmed.ncbi.nlm.nih.gov/30797051/
558. Feng, S. T., Wu, L., Cai, H., Chan, T., Luo, Y., Dong, Z., et.al. Cholangiocarcinoma: spectrum of appearances on Gd-EOB-DTPA-enhanced MR imaging and the effect of biliary function on signal intensity, BMC Cancer, 2015. 15: p. 38., https://www.ncbi.nlm.nih.gov/pubmed/25655565
559. Kim, S. H., Lee, C. H., Kim, B. H., Kim, W. B., Yeom, S. K., Kim, K. A., et.al. Typical and atypical imaging findings of intrahepatic cholangiocarcinoma using gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging, J Comput Assist Tomogr, 2012. 36(6): p. 704-9., https://www.ncbi.nlm.nih.gov/pubmed/23192208
560. Kiefer, Lena Sophie, Sekler, Julia, Gückel, Brigitte, Kraus, Mareen Sarah, la Fougère, Christian, Nikolaou, Konstantin, et.al. Impact of 18F-FDG-PET/CT on Clinical Management in Patients with Cholangiocellular CarcinomaThe British Institute of Radiology, BJR|Open, 2021. 3(1): p. 20210008., https://doi.org/10.1259/bjro.20210008
561. De Moura, D. T. H., Moura, E. G. H., Bernardo, W. M., De Moura, E. T. H., Baraca, F. I., Kondo, A., et.al. Endoscopic retrograde cholangiopancreatography versus endoscopic ultrasound for tissue diagnosis of malignant biliary stricture: Systematic review and meta-analysis, Endosc Ultrasound, 2018. 7(1): p. 10-19., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838722/pdf/EUS-7-10.pdf
562. Heimbach, J. K., Sanchez, W., Rosen, C. B., Gores, G. J., Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination, HPB (Oxford), 2011. 13(5): p. 356-60., https://www.ncbi.nlm.nih.gov/pubmed/21492336
563. El Chafic, A. H., Dewitt, J., Leblanc, J. K., El, Hajj, II, Cote, G., House, M. G., et.al. Impact of preoperative endoscopic ultrasound-guided fine needle aspiration on postoperative recurrence and survival in cholangiocarcinoma patients, Endoscopy, 2013. 45(11): p. 883-9., https://www.ncbi.nlm.nih.gov/pubmed/24165813
564. Korc, P., Sherman, S., ERCP tissue sampling, Gastrointest Endosc, 2016. 84(4): p. 557-71., https://www.ncbi.nlm.nih.gov/pubmed/27156656
565. Fogel, E. L., deBellis, M., McHenry, L., Watkins, J. L., Chappo, J., Cramer, H., et.al. Effectiveness of a new long cytology brush in the evaluation of malignant biliary obstruction: a prospective study, Gastrointest Endosc, 2006. 63(1): p. 71-7., https://www.ncbi.nlm.nih.gov/pubmed/16377319
566. Shieh, F. K., Luong-Player, A., Khara, H. S., Liu, H., Lin, F., Shellenberger, M. J., et.al. Improved endoscopic retrograde cholangiopancreatography brush increases diagnostic yield of malignant biliary strictures, World J Gastrointest Endosc, 2014. 6(7): p. 312-7., https://www.ncbi.nlm.nih.gov/pubmed/25031790
567. Glasbrenner, B., Ardan, M., Boeck, W., Preclik, G., Moller, P., Adler, G., Prospective evaluation of brush cytology of biliary strictures during endoscopic retrograde cholangiopancreatography, Endoscopy, 1999. 31(9): p. 712-7., https://www.ncbi.nlm.nih.gov/pubmed/10604612
568. Macken, E., Drijkoningen, M., Van Aken, E., Van Steenbergen, W., Brush cytology of ductal strictures during ERCP, Acta Gastroenterol Belg, 2000. 63(3): p. 254-9., https://www.ncbi.nlm.nih.gov/pubmed/11189981
569. Mansfield, J. C., Griffin, S. M., Wadehra, V., Matthewson, K., A prospective evaluation of cytology from biliary strictures, Gut, 1997. 40(5): p. 671-7., https://www.ncbi.nlm.nih.gov/pubmed/9203949
570. Trikudanathan, G., Navaneethan, U., Njei, B., Vargo, J. J., Parsi, M. A., Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis, Gastrointest Endosc, 2014. 79(5): p. 783-9., https://www.ncbi.nlm.nih.gov/pubmed/24140129
571. Draganov, P. V., Chauhan, S., Wagh, M. S., Gupte, A. R., Lin, T., Hou, W., et.al. Diagnostic accuracy of conventional and cholangioscopy-guided sampling of indeterminate biliary lesions at the time of ERCP: a prospective, long-term follow-up study, Gastrointest Endosc, 2012. 75(2): p. 347-53., https://www.ncbi.nlm.nih.gov/pubmed/22248602
572. Sugiyama, M., Atomi, Y., Wada, N., Kuroda, A., Muto, T., Endoscopic transpapillary bile duct biopsy without sphincterotomy for diagnosing biliary strictures: a prospective comparative study with bile and brush cytology, Am J Gastroenterol, 1996. 91(3): p. 465-7., https://www.ncbi.nlm.nih.gov/pubmed/8633492
573. Jailwala, J., Fogel, E. L., Sherman, S., Gottlieb, K., Flueckiger, J., Bucksot, L. G., et.al. Triple-tissue sampling at ERCP in malignant biliary obstruction, Gastrointest Endosc, 2000. 51(4 Pt 1): p. 383-90., https://www.ncbi.nlm.nih.gov/pubmed/10744806
574. Hartman, D. J., Slivka, A., Giusto, D. A., Krasinskas, A. M., Tissue yield and diagnostic efficacy of fluoroscopic and cholangioscopic techniques to assess indeterminate biliary strictures, Clin Gastroenterol Hepatol, 2012. 10(9): p. 1042-6., https://www.ncbi.nlm.nih.gov/pubmed/22677575
575. Pugliese, V., Conio, M., Nicolo, G., Saccomanno, S., Gatteschi, B., Endoscopic retrograde forceps biopsy and brush cytology of biliary strictures: a prospective study, Gastrointest Endosc, 1995. 42(6): p. 520-6., https://www.ncbi.nlm.nih.gov/pubmed/8674921
576. Kitajima, Y., Ohara, H., Nakazawa, T., Ando, T., Hayashi, K., Takada, H., et.al. Usefulness of transpapillary bile duct brushing cytology and forceps biopsy for improved diagnosis in patients with biliary strictures, J Gastroenterol Hepatol, 2007. 22(10): p. 1615-20., https://www.ncbi.nlm.nih.gov/pubmed/17573833
577. Navaneethan, U., Hasan, M. K., Lourdusamy, V., Njei, B., Varadarajulu, S., Hawes, R. H., Single-operator cholangioscopy and targeted biopsies in the diagnosis of indeterminate biliary strictures: a systematic review, Gastrointest Endosc, 2015. 82(4): p. 608-14 e2., https://www.ncbi.nlm.nih.gov/pubmed/26071061
578. Gerges, C., Beyna, T., Tang, R. S. Y., Bahin, F., Lau, J. Y. W., van Geenen, E., et.al. Digital single-operator peroral cholangioscopy-guided biopsy versus ERCP-guided brushing for indeterminate biliary strictures: a prospective, randomized multicenter trial (with video), Gastrointest Endosc, 2019., https://www.ncbi.nlm.nih.gov/pubmed/31778656
579. Aabakken, L., Karlsen, T. H., Albert, J., Arvanitakis, M., Chazouilleres, O., Dumonceau, J. M., et.al. Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline, Endoscopy, 2017. 49(6): p. 588-608., https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0043-107029.pdf
580. Bagante, F., Spolverato, G., Weiss, M., Alexandrescu, S., Marques, H. P., Aldrighetti, L., et.al. Assessment of the Lymph Node Status in Patients Undergoing Liver Resection for Intrahepatic Cholangiocarcinoma: the New Eighth Edition AJCC Staging System, J Gastrointest Surg, 2018. 22(1): p. 52-59., https://link.springer.com/content/pdf/10.1007/s11605-017-3426-x.pdf
581. Bagante, F., Spolverato, G., Weiss, M., Alexandrescu, S., Marques, H. P., Aldrighetti, L., et.al. Surgical Management of Intrahepatic Cholangiocarcinoma in Patients with Cirrhosis: Impact of Lymphadenectomy on Peri-Operative Outcomes, World J Surg, 2018. 42(8): p. 2551-2560., https://link.springer.com/content/pdf/10.1007/s00268-017-4453-1.pdf
582. Ebata, T., Mizuno, T., Yokoyama, Y., Igami, T., Sugawara, G., Nagino, M., Surgical resection for Bismuth type IV perihilar cholangiocarcinoma, Br J Surg, 2018. 105(7): p. 829-838., https://bjssjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/bjs.10556?download=true
583. El-Diwany, R., Pawlik, T. M., Ejaz, A., Intrahepatic Cholangiocarcinoma, Surg Oncol Clin N Am, 2019. 28(4): p. 587-599., https://www.sciencedirect.com/science/article/abs/pii/S1055320719300444?via%3Dihub
584. Lang, H., Sotiropoulos, G. C., Sgourakis, G., Schmitz, K. J., Paul, A., Hilgard, P., et.al. Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patients, J Am Coll Surg, 2009. 208(2): p. 218-28.
585. Schnitzbauer, A. A., Eberhard, J., Bartsch, F., Brunner, S. M., Ceyhan, G. O., Walter, D., et.al. The MEGNA Score and Preoperative Anemia are Major Prognostic Factors After Resection in the German Intrahepatic Cholangiocarcinoma Cohort, Ann Surg Oncol, 2020. 27(4): p. 1147-1155., https://link.springer.com/content/pdf/10.1245/s10434-019-07968-7.pdf
586. Zhang, X. F., Bagante, F., Chakedis, J., Moris, D., Beal, E. W., Weiss, M., et.al. Perioperative and Long-Term Outcome for Intrahepatic Cholangiocarcinoma: Impact of Major Versus Minor Hepatectomy, J Gastrointest Surg, 2017. 21(11): p. 1841-1850., https://link.springer.com/content/pdf/10.1007/s11605-017-3499-6.pdf
587. Bartsch, F., Tripke, V., Baumgart, J., Hoppe-Lotichius, M., Heinrich, S., Lang, H., Extended resection of intrahepatic cholangiocarcinoma: A retrospective single-center cohort study, Int J Surg, 2019. 67: p. 62-69., https://www.sciencedirect.com/science/article/abs/pii/S1743919119301116?via%3Dihub
588. Mizuno, T., Ebata, T., Nagino, M., Advanced hilar cholangiocarcinoma: An aggressive surgical approach for the treatment of advanced hilar cholangiocarcinoma: Perioperative management, extended procedures, and multidisciplinary approaches, Surg Oncol, 2020. 33: p. 201-206., https://www.sciencedirect.com/science/article/abs/pii/S0960740419302439?via%3Dihub
589. Rassam, F., Roos, E., van Lienden, K. P., van Hooft, J. E., Klümpen, H. J., van Tienhoven, G., et.al. Modern work-up and extended resection in perihilar cholangiocarcinoma: the AMC experience, Langenbecks Arch Surg, 2018. 403(3): p. 289-307., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5986829/pdf/423_2018_Article_1649.pdf
590. Primrose, J. N., Fox, R. P., Palmer, D. H., Malik, H. Z., Prasad, R., Mirza, D., et.al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study, Lancet Oncol, 2019. 20(5): p. 663-673., https://www.sciencedirect.com/science/article/abs/pii/S147020451830915X?via%3Dihub
591. Le Roy, B., Gelli, M., Pittau, G., Allard, M. A., Pereira, B., Serji, B., et.al. Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma, Br J Surg, 2018. 105(7): p. 839-847., https://bjssjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/bjs.10641?download=true
592. Chang, Y., Li, Q., Wu, Q., Chi, L., Bi, X., Zeng, Q., et.al. Impact of surgical strategies on the survival of gallbladder cancer patients: analysis of 715 cases, World J Surg Oncol, 2020. 18(1): p. 142., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320575/pdf/12957_2020_Article_1915.pdf
593. Coimbra, F. J. F., Torres, O. J. M., Alikhanov, R., Agarwal, A., Pessaux, P., Fernandes, E. S. M., et.al. BRAZILIAN CONSENSUS ON INCIDENTAL GALLBLADDER CARCINOMA, Arq Bras Cir Dig, 2020. 33(1): p. e1496., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357549/pdf/0102-6720-abcd-33-01-e1496.pdf
594. Sikora, S. S., Singh, R. K., Surgical strategies in patients with gallbladder cancer: nihilism to optimism, J Surg Oncol, 2006. 93(8): p. 670-81., https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jso.20535?download=true
595. Søreide, K., Guest, R. V., Harrison, E. M., Kendall, T. J., Garden, O. J., Wigmore, S. J., Systematic review of management of incidental gallbladder cancer after cholecystectomy, Br J Surg, 2019. 106(1): p. 32-45., https://bjssjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/bjs.11035?download=true
596. Benson, A. B., 3rd, Abrams, T. A., Ben-Josef, E., Bloomston, P. M., Botha, J. F., Clary, B. M., et.al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers, J Natl Compr Canc Netw, 2009. 7(4): p. 350-91., https://jnccn.org/downloadpdf/journals/jnccn/7/4/article-p350.pdf
597. Yuza, K., Sakata, J., Prasoon, P., Hirose, Y., Ohashi, T., Toge, K., et.al. Long-term outcomes of surgical resection for T1b gallbladder cancer: an institutional evaluation, BMC Cancer, 2020. 20(1): p. 20., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945689/pdf/12885_2019_Article_6507.pdf
598. Lee, S. E., Jang, J. Y., Kim, S. W., Han, H. S., Kim, H. J., Yun, S. S., et.al. Surgical strategy for T1 gallbladder cancer: a nationwide multicenter survey in South Korea, Ann Surg Oncol, 2014. 21(11): p. 3654-60., https://link.springer.com/content/pdf/10.1245/s10434-014-3527-7.pdf
599. Bartsch, F., Paschold, M., Baumgart, J., Hoppe-Lotichius, M., Heinrich, S., Lang, H., Surgical Resection for Recurrent Intrahepatic Cholangiocarcinoma, World J Surg, 2019. 43(4): p. 1105-1116., https://link.springer.com/content/pdf/10.1007/s00268-018-04876-x.pdf
600. Spolverato, G., Kim, Y., Alexandrescu, S., Marques, H. P., Lamelas, J., Aldrighetti, L., et.al. Management and Outcomes of Patients with Recurrent Intrahepatic Cholangiocarcinoma Following Previous Curative-Intent Surgical Resection, Ann Surg Oncol, 2016. 23(1): p. 235-43., https://link.springer.com/content/pdf/10.1245/s10434-015-4642-9.pdf
601. Seidensticker, R., Seidensticker, M., Doegen, K., Mohnike, K., Schütte, K., Stübs, P., et.al. Extensive Use of Interventional Therapies Improves Survival in Unresectable or Recurrent Intrahepatic Cholangiocarcinoma, Gastroenterol Res Pract, 2016. 2016: p. 8732521., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4758109/pdf/GRP2016-8732521.pdf
602. Xu, C., Li, L., Xu, W., Du, C., Yang, L., Tong, J., et.al. Ultrasound-guided percutaneous microwave ablation versus surgical resection for recurrent intrahepatic cholangiocarcinoma: intermediate-term results, Int J Hyperthermia, 2019. 36(1): p. 351-358., https://www.tandfonline.com/doi/pdf/10.1080/02656736.2019.1571247?needAccess=true
603. Zhang, S. J., Hu, P., Wang, N., Shen, Q., Sun, A. X., Kuang, M., et.al. Thermal ablation versus repeated hepatic resection for recurrent intrahepatic cholangiocarcinoma, Ann Surg Oncol, 2013. 20(11): p. 3596-602., https://link.springer.com/content/pdf/10.1245/s10434-013-3035-1.pdf
604. Amini, N., Ejaz, A., Spolverato, G., Kim, Y., Herman, J. M., Pawlik, T. M., Temporal trends in liver-directed therapy of patients with intrahepatic cholangiocarcinoma in the United States: a population-based analysis, J Surg Oncol, 2014. 110(2): p. 163-70., https://www.ncbi.nlm.nih.gov/pubmed/24676600
605. Butros, S. R., Shenoy-Bhangle, A., Mueller, P. R., Arellano, R. S., Radiofrequency ablation of intrahepatic cholangiocarcinoma: feasability, local tumor control, and long-term outcome, Clin Imaging, 2014. 38(4): p. 490-494., https://www.clinicalimaging.org/article/S0899-7071(14)00040-0/fulltext
606. Fu, Y., Yang, W., Wu, W., Yan, K., Xing, B. C., Chen, M. H., Radiofrequency ablation in the management of unresectable intrahepatic cholangiocarcinoma, J Vasc Interv Radiol, 2012. 23(5): p. 642-9., https://www.jvir.org/article/S1051-0443(12)00208-4/fulltext
607. Han, K., Ko, H. K., Kim, K. W., Won, H. J., Shin, Y. M., Kim, P. N., Radiofrequency ablation in the treatment of unresectable intrahepatic cholangiocarcinoma: systematic review and meta-analysis, J Vasc Interv Radiol, 2015. 26(7): p. 943-8., https://www.jvir.org/article/S1051-0443(15)00250-X/fulltext
608. Kolarich, A. R., Shah, J. L., George, T. J., Jr., Hughes, S. J., Shaw, C. M., Geller, B. S., et.al. Non-surgical management of patients with intrahepatic cholangiocarcinoma in the United States, 2004-2015: an NCDB analysis, J Gastrointest Oncol, 2018. 9(3): p. 536-545., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6006029/pdf/jgo-09-03-536.pdf
609. Takahashi, E. A., Kinsman, K. A., Schmit, G. D., Atwell, T. D., Schmitz, J. J., Welch, B. T., et.al. Thermal ablation of intrahepatic cholangiocarcinoma: Safety, efficacy, and factors affecting local tumor progression, Abdom Radiol (NY), 2018. 43(12): p. 3487-3492., https://link.springer.com/content/pdf/10.1007/s00261-018-1656-3.pdf
610. Kim, J. H., Won, H. J., Shin, Y. M., Kim, P. N., Lee, S. G., Hwang, S., Radiofrequency ablation for recurrent intrahepatic cholangiocarcinoma after curative resection, Eur J Radiol, 2011. 80(3): p. e221-5., https://www.ejradiology.com/article/S0720-048X(10)00476-6/fulltext
611. Goldaracena, N., Gorgen, A., Sapisochin, G., Current status of liver transplantation for cholangiocarcinoma, Liver Transpl, 2018. 24(2): p. 294-303.
612. Facciuto, M. E., Singh, M. K., Lubezky, N., Selim, M. A., Robinson, D., Kim-Schluger, L., et.al. Tumors with intrahepatic bile duct differentiation in cirrhosis: implications on outcomes after liver transplantation, Transplantation, 2015. 99(1): p. 151-7.
613. Vilchez, V., Shah, M. B., Daily, M. F., Pena, L., Tzeng, C. W., Davenport, D., et.al. Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of the UNOS database, HPB (Oxford), 2016. 18(1): p. 29-34., https://www.hpbonline.org/article/S1365-182X(15)00002-7/pdf
614. Sapisochin, G., de Lope, C. R., Gastaca, M., de Urbina, J. O., López-Andujar, R., Palacios, F., et.al. Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: a Spanish matched cohort multicenter study, Ann Surg, 2014. 259(5): p. 944-52.
615. Sapisochin, G., Facciuto, M., Rubbia-Brandt, L., Marti, J., Mehta, N., Yao, F. Y., et.al. Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment, Hepatology, 2016. 64(4): p. 1178-88.
616. Lunsford, K. E., Javle, M., Heyne, K., Shroff, R. T., Abdel-Wahab, R., Gupta, N., et.al. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series, Lancet Gastroenterol Hepatol, 2018. 3(5): p. 337-348., https://www.thelancet.com/journals/langas/article/PIIS2468-1253(18)30045-1/fulltext
617. Becker, N. S., Rodriguez, J. A., Barshes, N. R., O'Mahony, C. A., Goss, J. A., Aloia, T. A., Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period, J Gastrointest Surg, 2008. 12(1): p. 117-22., https://link.springer.com/content/pdf/10.1007/s11605-007-0335-4.pdf
618. Darwish Murad, S., Kim, W. R., Harnois, D. M., Douglas, D. D., Burton, J., Kulik, L. M., et.al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers, Gastroenterology, 2012. 143(1): p. 88-98.e3; quiz e14., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846443/pdf/nihms507180.pdf
619. Rosen, C. B., Heimbach, J. K., Gores, G. J., Surgery for cholangiocarcinoma: the role of liver transplantation, HPB (Oxford), 2008. 10(3): p. 186-9., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2504373/pdf/MHPB10-186.pdf
620. Gulamhusein, A. F., Sanchez, W., Liver transplantation in the management of perihilar cholangiocarcinoma, Hepat Oncol, 2015. 2(4): p. 409-421., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095165/pdf/hep-02-409.pdf
621. Ethun, C. G., Lopez-Aguiar, A. G., Anderson, D. J., Adams, A. B., Fields, R. C., Doyle, M. B., et.al. Transplantation Versus Resection for Hilar Cholangiocarcinoma: An Argument for Shifting Treatment Paradigms for Resectable Disease, Ann Surg, 2018. 267(5): p. 797-805., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6002861/pdf/nihms955692.pdf
622. Mantel, H. T., Westerkamp, A. C., Adam, R., Bennet, W. F., Seehofer, D., Settmacher, U., et.al. Strict Selection Alone of Patients Undergoing Liver Transplantation for Hilar Cholangiocarcinoma Is Associated with Improved Survival, PLoS One, 2016. 11(6): p. e0156127., https://air.unimi.it/retrieve/handle/2434/465540/799026/journal.pone.0156127.PDF
623. Weber, S. M., Ribero, D., O'Reilly, E. M., Kokudo, N., Miyazaki, M., Pawlik, T. M., Intrahepatic cholangiocarcinoma: expert consensus statement, HPB (Oxford), 2015. 17(8): p. 669-80.
624. NCCN Guidelines® for Hepatobiliary Cancers Version 3, 2019.
625. Ray, C. E., Jr., Edwards, A., Smith, M. T., Leong, S., Kondo, K., Gipson, M., et.al. Metaanalysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma, J Vasc Interv Radiol, 2013. 24(8): p. 1218-26.
626. Koch, C., Franzke, C., Bechstein, W. O., Schnitzbauer, A. A., Filmann, N., Vogl, T., et.al. Poor Prognosis of Advanced Cholangiocarcinoma: Real-World Data from a Tertiary Referral Center, Digestion, 2019. p. 1-8.
627. Gusani, N. J., Balaa, F. K., Steel, J. L., Geller, D. A., Marsh, J. W., Zajko, A. B., et.al. Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience, J Gastrointest Surg, 2008. 12(1): p. 129-37., https://link.springer.com/content/pdf/10.1007/s11605-007-0312-y.pdf
628. Boehm, L. M., Jayakrishnan, T. T., Miura, J. T., Zacharias, A. J., Johnston, F. M., Turaga, K. K., et.al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma, J Surg Oncol, 2015. 111(2): p. 213-20., https://onlinelibrary.wiley.com/doi/full/10.1002/jso.23781
629. Kiefer, M. V., Albert, M., McNally, M., Robertson, M., Sun, W., Fraker, D., et.al. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study, Cancer, 2011. 117(7): p. 1498-505., https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.25625
630. Vogl, T. J., Naguib, N. N., Nour-Eldin, N. E., Bechstein, W. O., Zeuzem, S., Trojan, J., et.al. Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: Results and prognostic factors governing treatment success, Int J Cancer, 2012. 131(3): p. 733-40., https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.26407
631. Cucchetti, A., Cappelli, A., Mosconi, C., Zhong, J. H., Cescon, M., Pinna, A. D., et.al. Improving patient selection for selective internal radiation therapy of intra-hepatic cholangiocarcinoma: A meta-regression study, Liver Int, 2017. 37(7): p. 1056-1064., https://onlinelibrary.wiley.com/doi/full/10.1111/liv.13382
632. Gangi, A., Shah, J., Hatfield, N., Smith, J., Sweeney, J., Choi, J., et.al. Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective Study, J Vasc Interv Radiol, 2018. 29(8): p. 1101-1108., https://www.sciencedirect.com/science/article/pii/S1051044318310868?via%3Dihub
633. Manceau, V., Palard, X., Rolland, Y., Pracht, M., Le Sourd, S., Laffont, S., et.al. A MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy and (90)Y-loaded glass microsphere selective internal radiation therapy, Eur J Nucl Med Mol Imaging, 2018. 45(10): p. 1731-1741., https://link.springer.com/content/pdf/10.1007%2Fs00259-018-3990-7.pdf
634. Reimer, P., Virarkar, M. K., Binnenhei, M., Justinger, M., Schön, M. R., Tatsch, K., Prognostic Factors in Overall Survival of Patients with Unresectable Intrahepatic Cholangiocarcinoma Treated by Means of Yttrium-90 Radioembolization: Results in Therapy-Naïve Patients, Cardiovasc Intervent Radiol, 2018. 41(5): p. 744-752., https://link.springer.com/content/pdf/10.1007/s00270-017-1871-2.pdf
635. Yang, L., Shan, J., Shan, L., Saxena, A., Bester, L., Morris, D. L., Trans-arterial embolisation therapies for unresectable intrahepatic cholangiocarcinoma: a systematic review, J Gastrointest Oncol, 2015. 6(5): p. 570-88., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570915/pdf/jgo-06-05-570.pdf
636. Zhen, Y, Liu, B, Chang, Z, Ren, H, Liu, Z, Zheng, J, A pooled analysis of transarterial radioembolization with yttrium-90 microspheres for the treatment of unresectable intrahepatic cholangiocarcinoma., Onco Targets Ther, 2019. 12 (): p. 4489-4498., https://pubmed.ncbi.nlm.nih.gov/31239717/
637. Mosconi, C, Solaini, L, Vara, G, Brandi, N, Cappelli, A, Modestino, F, et.al. Transarterial Chemoembolization and Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma-a Systemic Review and Meta-Analysis., Cardiovasc Intervent Radiol, 2021. 44 (5)(5): p. 728-738., https://pubmed.ncbi.nlm.nih.gov/33709272/
638. Hyder, O., Marsh, J. W., Salem, R., Petre, E. N., Kalva, S., Liapi, E., et.al. Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis, Ann Surg Oncol, 2013. 20(12): p. 3779-86., https://link.springer.com/content/pdf/10.1245/s10434-013-3127-y.pdf
639. Marquardt, S., Kirstein, M. M., Brüning, R., Zeile, M., Ferrucci, P. F., Prevoo, W., et.al. Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival, Eur Radiol, 2019. 29(4): p. 1882-1892., https://link.springer.com/content/pdf/10.1007/s00330-018-5729-z.pdf
640. Edeline, J., Touchefeu, Y., Guiu, B., Farge, O., Tougeron, D., Baumgaertner, I., et.al. Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial, JAMA Oncol, 2019. 6(1): p. 51-9., https://jamanetwork.com/journals/jamaoncology/articlepdf/2753557/jamaoncology_edeline_2019_oi_190074.pdf
641. Konstantinidis, I. T., Groot Koerkamp, B., Do, R. K., Gönen, M., Fong, Y., Allen, P. J., et.al. Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone, Cancer, 2016. 122(5): p. 758-65., https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.29824?download=true
642. Al-Adra, D. P., Gill, R. S., Axford, S. J., Shi, X., Kneteman, N., Liau, S. S., Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis, Eur J Surg Oncol, 2015. 41(1): p. 120-7.
643. Wronka, K. M., Grąt, M., Stypułkowski, J., Bik, E., Patkowski, W., Krawczyk, M., et.al. Relevance of Preoperative Hyperbilirubinemia in Patients Undergoing Hepatobiliary Resection for Hilar Cholangiocarcinoma, J Clin Med, 2019. 8(4):, https://res.mdpi.com/d_attachment/jcm/jcm-08-00458/article_deploy/jcm-08-00458.pdf
644. Al Mahjoub, A., Menahem, B., Fohlen, A., Dupont, B., Alves, A., Launoy, G., et.al. Preoperative Biliary Drainage in Patients with Resectable Perihilar Cholangiocarcinoma: Is Percutaneous Transhepatic Biliary Drainage Safer and More Effective than Endoscopic Biliary Drainage? A Meta-Analysis, J Vasc Interv Radiol, 2017. 28(4): p. 576-582.
645. Hameed, A., Pang, T., Chiou, J., Pleass, H., Lam, V., Hollands, M., et.al. Percutaneous vs. endoscopic pre-operative biliary drainage in hilar cholangiocarcinoma - a systematic review and meta-analysis, HPB (Oxford), 2016. 18(5): p. 400-10., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4857062/pdf/main.pdf
646. Coelen, R. J. S., Roos, E., Wiggers, J. K., Besselink, M. G., Buis, C. I., Busch, O. R. C., et.al. Endoscopic versus percutaneous biliary drainage in patients with resectable perihilar cholangiocarcinoma: a multicentre, randomised controlled trial, Lancet Gastroenterol Hepatol, 2018. 3(10): p. 681-690., https://www.sciencedirect.com/science/article/abs/pii/S2468125318302346?via%3Dihub
647. Ba, Y., Yue, P., Leung, J. W., Wang, H., Lin, Y., Bai, B., et.al. Percutaneous transhepatic biliary drainage may be the preferred preoperative drainage method in hilar cholangiocarcinoma, Endosc Int Open, 2020. 8(2): p. E203-e210., https://www.thieme-connect.com/products/ejournals/pdf/10.1055/a-0990-9114.pdf
648. Maeda, T., Ebata, T., Yokoyama, Y., Mizuno, T., Yamaguchi, J., Onoe, S., et.al. Preoperative course of patients undergoing endoscopic nasobiliary drainage during the management of resectable perihilar cholangiocarcinoma, J Hepatobiliary Pancreat Sci, 2019. 26(8): p. 341-347., https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jhbp.640?download=true
649. Nakai, Y., Yamamoto, R., Matsuyama, M., Sakai, Y., Takayama, Y., Ushio, J., et.al. Multicenter study of endoscopic preoperative biliary drainage for malignant hilar biliary obstruction: E-POD hilar study, J Gastroenterol Hepatol, 2018. 33(5): p. 1146-1153., https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jgh.14050?download=true
650. Komaya, K., Ebata, T., Yokoyama, Y., Igami, T., Sugawara, G., Mizuno, T., et.al. Verification of the oncologic inferiority of percutaneous biliary drainage to endoscopic drainage: A propensity score matching analysis of resectable perihilar cholangiocarcinoma, Surgery, 2017. 161(2): p. 394-404.
651. Kim, K. M., Park, J. W., Lee, J. K., Lee, K. H., Lee, K. T., Shim, S. G., A Comparison of Preoperative Biliary Drainage Methods for Perihilar Cholangiocarcinoma: Endoscopic versus Percutaneous Transhepatic Biliary Drainage, Gut Liver, 2015. 9(6): p. 791-9., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4625710/pdf/gnl-09-791.pdf
652. Kennedy, T. J., Yopp, A., Qin, Y., Zhao, B., Guo, P., Liu, F., et.al. Role of preoperative biliary drainage of liver remnant prior to extended liver resection for hilar cholangiocarcinoma, HPB (Oxford), 2009. 11(5): p. 445-51., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2742615/pdf/hpb0011-0445.pdf
653. Miura, S., Kanno, A., Fukase, K., Tanaka, Y., Matsumoto, R., Nabeshima, T., et.al. Preoperative biliary drainage of the hepatic lobe to be resected does not affect liver hypertrophy after percutaneous transhepatic portal vein embolization, Surg Endosc, 2020. 34(2): p. 667-674., https://link.springer.com/content/pdf/10.1007/s00464-019-06813-y.pdf
654. Hintze, R. E., Abou-Rebyeh, H., Adler, A., Veltzke-Schlieker, W., Felix, R., Wiedenmann, B., Magnetic resonance cholangiopancreatography-guided unilateral endoscopic stent placement for Klatskin tumors, Gastrointest Endosc, 2001. 53(1): p. 40-6.
655. Abraham, N. S., Barkun, J. S., Barkun, A. N., Palliation of malignant biliary obstruction: a prospective trial examining impact on quality of life, Gastrointest Endosc, 2002. 56(6): p. 835-41.
656. Paik, W. H., Park, Y. S., Hwang, J. H., Lee, S. H., Yoon, C. J., Kang, S. G., et.al. Palliative treatment with self-expandable metallic stents in patients with advanced type III or IV hilar cholangiocarcinoma: a percutaneous versus endoscopic approach, Gastrointest Endosc, 2009. 69(1): p. 55-62.
657. Saluja, S. S., Gulati, M., Garg, P. K., Pal, H., Pal, S., Sahni, P., et.al. Endoscopic or percutaneous biliary drainage for gallbladder cancer: a randomized trial and quality of life assessment, Clin Gastroenterol Hepatol, 2008. 6(8): p. 944-950.e3., https://www.sciencedirect.com/science/article/abs/pii/S1542356508003418?via%3Dihub
658. Schima, W., Prokesch, R., Osterreicher, C., Thurnher, S., Függer, R., Schöfl, R., et.al. Biliary Wallstent endoprosthesis in malignant hilar obstruction: long-term results with regard to the type of obstruction, Clin Radiol, 1997. 52(3): p. 213-9.
659. Uberoi, R., Das, N., Moss, J., Robertson, I., British Society of Interventional Radiology: Biliary Drainage and Stenting Registry (BDSR), Cardiovasc Intervent Radiol, 2012. 35(1): p. 127-38., https://link.springer.com/content/pdf/10.1007/s00270-011-0103-4.pdf
660. Smith, A. C., Dowsett, J. F., Russell, R. C., Hatfield, A. R., Cotton, P. B., Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction, Lancet, 1994. 344(8938): p. 1655-60.
661. Speer, A. G., Cotton, P. B., Russell, R. C., Mason, R. R., Hatfield, A. R., Leung, J. W., et.al. Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice, Lancet, 1987. 2(8550): p. 57-62.
662. Almadi, M. A., Barkun, A., Martel, M., Plastic vs. Self-Expandable Metal Stents for Palliation in Malignant Biliary Obstruction: A Series of Meta-Analyses, Am J Gastroenterol, 2017. 112(2): p. 260-273.
663. Lee, T. H., Moon, J. H., Choi, J. H., Lee, S. H., Lee, Y. N., Paik, W. H., et.al. Prospective comparison of endoscopic bilateral stent-in-stent versus stent-by-stent deployment for inoperable advanced malignant hilar biliary stricture, Gastrointest Endosc, 2019. 90(2): p. 222-230., https://www.sciencedirect.com/science/article/abs/pii/S0016510719301737?via%3Dihub
664. Sharaiha, R. Z., Kumta, N. A., Desai, A. P., DeFilippis, E. M., Gabr, M., Sarkisian, A. M., et.al. Endoscopic ultrasound-guided biliary drainage versus percutaneous transhepatic biliary drainage: predictors of successful outcome in patients who fail endoscopic retrograde cholangiopancreatography, Surg Endosc, 2016. 30(12): p. 5500-5505., https://link.springer.com/content/pdf/10.1007/s00464-016-4913-y.pdf
665. Paik, W. H., Lee, T. H., Park, D. H., Choi, J. H., Kim, S. O., Jang, S., et.al. EUS-Guided Biliary Drainage Versus ERCP for the Primary Palliation of Malignant Biliary Obstruction: A Multicenter Randomized Clinical Trial, Am J Gastroenterol, 2018. 113(7): p. 987-997.
666. Bang, J. Y., Navaneethan, U., Hasan, M., Hawes, R., Varadarajulu, S., Stent placement by EUS or ERCP for primary biliary decompression in pancreatic cancer: a randomized trial (with videos), Gastrointest Endosc, 2018. 88(1): p. 9-17.
667. Dumonceau, J. M., Tringali, A., Papanikolaou, I. S., Blero, D., Mangiavillano, B., Schmidt, A., et.al. Endoscopic biliary stenting: indications, choice of stents, and results: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline - Updated October 2017, Endoscopy, 2018. 50(9): p. 910-930., https://www.thieme-connect.com/products/ejournals/pdf/10.1055/a-0659-9864.pdf
668. Moole, H., Dharmapuri, S., Duvvuri, A., Dharmapuri, S., Boddireddy, R., Moole, V., et.al. Endoscopic versus Percutaneous Biliary Drainage in Palliation of Advanced Malignant Hilar Obstruction: A Meta-Analysis and Systematic Review, Can J Gastroenterol Hepatol, 2016. 2016: p. 4726078., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014937/pdf/CJGH2016-4726078.pdf
669. Zhao, X. Q., Dong, J. H., Jiang, K., Huang, X. Q., Zhang, W. Z., Comparison of percutaneous transhepatic biliary drainage and endoscopic biliary drainage in the management of malignant biliary tract obstruction: a meta-analysis, Dig Endosc, 2015. 27(1): p. 137-45., https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/den.12320?download=true
670. Born, P., Rösch, T., Triptrap, A., Frimberger, E., Allescher, H. D., Ott, R., et.al. Long-term results of percutaneous transhepatic biliary drainage for benign and malignant bile duct strictures, Scand J Gastroenterol, 1998. 33(5): p. 544-9., https://www.tandfonline.com/doi/pdf/10.1080/00365529850172142?needAccess=true
671. De Palma, G. D., Galloro, G., Siciliano, S., Iovino, P., Catanzano, C., Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: results of a prospective, randomized, and controlled study, Gastrointest Endosc, 2001. 53(6): p. 547-53.
672. Chang, W. H., Kortan, P., Haber, G. B., Outcome in patients with bifurcation tumors who undergo unilateral versus bilateral hepatic duct drainage, Gastrointest Endosc, 1998. 47(5): p. 354-62.
673. Bulajic, M., Panic, N., Radunovic, M., Scepanovic, R., Perunovic, R., Stevanovic, P., et.al. Clinical outcome in patients with hilar malignant strictures type II Bismuth-Corlette treated by minimally invasive unilateral versus bilateral endoscopic biliary drainage, Hepatobiliary Pancreat Dis Int, 2012. 11(2): p. 209-14.
674. Cheng, J. L., Bruno, M. J., Bergman, J. J., Rauws, E. A., Tytgat, G. N., Huibregtse, K., Endoscopic palliation of patients with biliary obstruction caused by nonresectable hilar cholangiocarcinoma: efficacy of self-expandable metallic Wallstents, Gastrointest Endosc, 2002. 56(1): p. 33-9.
675. Vienne, A., Hobeika, E., Gouya, H., Lapidus, N., Fritsch, J., Choury, A. D., et.al. Prediction of drainage effectiveness during endoscopic stenting of malignant hilar strictures: the role of liver volume assessment, Gastrointest Endosc, 2010. 72(4): p. 728-35.
676. Rees, J., Mytton, J., Evison, F., Mangat, K. S., Patel, P., Trudgill, N., The outcomes of biliary drainage by percutaneous transhepatic cholangiography for the palliation of malignant biliary obstruction in England between 2001 and 2014: a retrospective cohort study, BMJ Open, 2020. 10(1): p. e033576., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045186/pdf/bmjopen-2019-033576.pdf
677. Harvey, P. R., Baldwin, S., Mytton, J., Dosanjh, A., Evison, F., Patel, P., et.al. Higher volume providers are associated with improved outcomes following ERCP for the palliation of malignant biliary obstruction, EClinicalMedicine, 2020. 18: p. 100212., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6948226/pdf/main.pdf
678. Tal, A. O., Vermehren, J., Friedrich-Rust, M., Bojunga, J., Sarrazin, C., Zeuzem, S., et.al. Intraductal endoscopic radiofrequency ablation for the treatment of hilar non-resectable malignant bile duct obstruction, World J Gastrointest Endosc, 2014. 6(1): p. 13-9., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3921441/pdf/WJGE-6-13.pdf
679. Moole, H., Tathireddy, H., Dharmapuri, S., Moole, V., Boddireddy, R., Yedama, P., et.al. Success of photodynamic therapy in palliating patients with nonresectable cholangiocarcinoma: A systematic review and meta-analysis, World J Gastroenterol, 2017. 23(7): p. 1278-1288., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323453/pdf/WJG-23-1278.pdf
680. Zoepf, T., Jakobs, R., Rosenbaum, A., Apel, D., Arnold, J. C., Riemann, J. F., Photodynamic therapy with 5-aminolevulinic acid is not effective in bile duct cancer, Gastrointest Endosc, 2001. 54(6): p. 763-6.
681. Ortner, M. E., Caca, K., Berr, F., Liebetruth, J., Mansmann, U., Huster, D., et.al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study, Gastroenterology, 2003. 125(5): p. 1355-63., https://www.sciencedirect.com/science/article/abs/pii/S0016508503013623?via%3Dihub
682. Zoepf, T., Jakobs, R., Arnold, J. C., Apel, D., Riemann, J. F., Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy, Am J Gastroenterol, 2005. 100(11): p. 2426-30.
683. Pereira, S. P., Jitlal, M., Duggan, M., Lawrie, E., Beare, S., O'Donoghue, P., et.al. PHOTOSTENT-02: porfimer sodium photodynamic therapy plus stenting versus stenting alone in patients with locally advanced or metastatic biliary tract cancer, ESMO Open, 2018. 3(5): p. e000379., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069917/pdf/esmoopen-2018-000379.pdf
684. Gonzalez-Carmona, M. A., Bolch, M., Jansen, C., Vogt, A., Sampels, M., Mohr, R. U., et.al. Combined photodynamic therapy with systemic chemotherapy for unresectable cholangiocarcinoma, Aliment Pharmacol Ther, 2019. 49(4): p. 437-447., https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/apt.15050?download=true
685. Wentrup, R., Winkelmann, N., Mitroshkin, A., Prager, M., Voderholzer, W., Schachschal, G., et.al. Photodynamic Therapy Plus Chemotherapy Compared with Photodynamic Therapy Alone in Hilar Nonresectable Cholangiocarcinoma, Gut Liver, 2016. 10(3): p. 470-5., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4849702/pdf/gnl-10-470.pdf
686. Strand, D. S., Cosgrove, N. D., Patrie, J. T., Cox, D. G., Bauer, T. W., Adams, R. B., et.al. ERCP-directed radiofrequency ablation and photodynamic therapy are associated with comparable survival in the treatment of unresectable cholangiocarcinoma, Gastrointest Endosc, 2014. 80(5): p. 794-804.
687. Dolak, W., Schwaighofer, H., Hellmich, B., Stadler, B., Spaun, G., Plieschnegger, W., et.al. Photodynamic therapy with polyhematoporphyrin for malignant biliary obstruction: A nationwide retrospective study of 150 consecutive applications, United European Gastroenterol J, 2017. 5(1): p. 104-110., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384559/pdf/10.1177_2050640616654037.pdf
688. Kahaleh, M., Mishra, R., Shami, V. M., Northup, P. G., Berg, C. L., Bashlor, P., et.al. Unresectable cholangiocarcinoma: comparison of survival in biliary stenting alone versus stenting with photodynamic therapy, Clin Gastroenterol Hepatol, 2008. 6(3): p. 290-7., https://www.sciencedirect.com/science/article/abs/pii/S1542356507011469?via%3Dihub
689. Ben-Josef, E., Normolle, D., Ensminger, W. D., Walker, S., Tatro, D., Ten Haken, R. K., et.al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies, J Clin Oncol, 2005. 23(34): p. 8739-47.
690. Brunner, T. B., Blanck, O., Lewitzki, V., Abbasi-Senger, N., Momm, F., Riesterer, O., et.al. Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma, Radiother Oncol, 2019. 132: p. 42-47., https://www.sciencedirect.com/science/article/abs/pii/S0167814018336089?via%3Dihub
691. Tao, R., Krishnan, S., Bhosale, P. R., Javle, M. M., Aloia, T. A., Shroff, R. T., et.al. Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis, J Clin Oncol, 2016. 34(3): p. 219-26., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980564/pdf/JCO613778.pdf
692. Lee, J., Yoon, W. S., Koom, W. S., Rim, C. H., Efficacy of stereotactic body radiotherapy for unresectable or recurrent cholangiocarcinoma: a meta-analysis and systematic review, Strahlenther Onkol, 2019. 195(2): p. 93-102., https://link.springer.com/content/pdf/10.1007/s00066-018-1367-2.pdf
693. Frakulli, R., Buwenge, M., Macchia, G., Cammelli, S., Deodato, F., Cilla, S., et.al. Stereotactic body radiation therapy in cholangiocarcinoma: a systematic review, Br J Radiol, 2019. 92(1097): p. 20180688., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580923/pdf/bjr.20180688.pdf
694. Barney, B. M., Olivier, K. R., Miller, R. C., Haddock, M. G., Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma, Radiat Oncol, 2012. 7: p. 67., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464963/pdf/1748-717X-7-67.pdf
695. Tse, R. V., Hawkins, M., Lockwood, G., Kim, J. J., Cummings, B., Knox, J., et.al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma, J Clin Oncol, 2008. 26(4): p. 657-64.
696. Weiner, A. A., Olsen, J., Ma, D., Dyk, P., DeWees, T., Myerson, R. J., et.al. Stereotactic body radiotherapy for primary hepatic malignancies - Report of a phase I/II institutional study, Radiother Oncol, 2016. 121(1): p. 79-85., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543719/pdf/nihms872134.pdf
697. Kopek, N., Holt, M. I., Hansen, A. T., Høyer, M., Stereotactic body radiotherapy for unresectable cholangiocarcinoma, Radiother Oncol, 2010. 94(1): p. 47-52.
698. Schnapauff, D., Denecke, T., Grieser, C., Collettini, F., Seehofer, D., Sinn, M., et.al. Computed tomography-guided interstitial HDR brachytherapy (CT-HDRBT) of the liver in patients with irresectable intrahepatic cholangiocarcinoma, Cardiovasc Intervent Radiol, 2012. 35(3): p. 581-7., https://link.springer.com/content/pdf/10.1007/s00270-011-0249-0.pdf
699. Jeong, H, Kim, KP, Jeong, JH, Hwang, DW, Lee, JH, Kim, KH, et.al. Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial., Hepatology, 2023. 77 (5)(5): p. 1540-1549., https://pubmed.ncbi.nlm.nih.gov/37070950/
700. Vogel, A., Wege, H., Caca, K., Nashan, B., Neumann, U., The diagnosis and treatment of cholangiocarcinoma, Dtsch Arztebl Int, 2014. 111(44): p. 748-54., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239580/pdf/Dtsch_Arztebl_Int-111-0748.pdf
701. Horgan, A. M., Amir, E., Walter, T., Knox, J. J., Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis, J Clin Oncol, 2012. 30(16): p. 1934-40.
702. Bridgewater, J, Fletcher, P, Palmer, DH, Malik, HZ, Prasad, R, Mirza, D, et.al. Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study., J Clin Oncol, 2022. 40 (18)(18): p. 2048-2057., https://pubmed.ncbi.nlm.nih.gov/35316080/
703. Edeline, Julien, Bonnetain, Franck, Phelip, Jean Marc, Watelet, Jérôme, Hammel, Pascal, Joly, Jean-Paul, et.al. Gemox versus surveillance following surgery of localized biliary tract cancer: Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial, Journal of Clinical Oncology, 2017. 35(4_suppl): p. 225-225., http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.4_suppl.225
704. Edeline, J, Hirano, S, Bertaut, A, Konishi, M, Benabdelghani, M, Uesaka, K, et.al. Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studies., Eur J Cancer, 2022. 164 (): p. 80-87., https://pubmed.ncbi.nlm.nih.gov/35182925/
705. Luvira, V, Satitkarnmanee, E, Pugkhem, A, Kietpeerakool, C, Lumbiganon, P, Pattanittum, P, Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma., Cochrane Database Syst Rev, 2021. 9 (9)(9): p. CD012814., https://pubmed.ncbi.nlm.nih.gov/34515993/
706. Oh, Do-Youn, Ruth He, Aiwu, Qin, Shukui, Chen, Li-Tzong, Okusaka, Takuji, Vogel, Arndt, et.al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer, NEJM Evidence, 2022. 1(8): p. EVIDoa2200015., https://doi.org/10.1056/EVIDoa2200015
707. Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., et.al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer, N Engl J Med, 2010. 362(14): p. 1273-81., https://www.nejm.org/doi/pdf/10.1056/NEJMoa0908721?articleTools=true
708. Okusaka, T., Nakachi, K., Fukutomi, A., Mizuno, N., Ohkawa, S., Funakoshi, A., et.al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan, Br J Cancer, 2010. 103(4): p. 469-74., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2939781/pdf/6605779a.pdf
709. Valle, J. W., Furuse, J., Jitlal, M., Beare, S., Mizuno, N., Wasan, H., et.al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials, Ann Oncol, 2014. 25(2): p. 391-8.
710. Park, J. O., Oh, D. Y., Hsu, C., Chen, J. S., Chen, L. T., Orlando, M., et.al. Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review, Cancer Res Treat, 2015. 47(3): p. 343-61., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4509359/pdf/crt-2014-308.pdf
711. Markussen, A, Jensen, LH, Diness, LV, Larsen, FO, Treatment of Patients with Advanced Biliary Tract Cancer with Either Oxaliplatin, Gemcitabine, and Capecitabine or Cisplatin and Gemcitabine-A Randomized Phase II Trial., Cancers (Basel), 2020. 12 (7)(7):, https://pubmed.ncbi.nlm.nih.gov/32698410/
712. Valle, J. W., Borbath, I., Khan, S. A., Huguet, F., Gruenberger, T., Arnold, D., et.al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 2016. 27(suppl 5): p. v28-v37., https://www.ncbi.nlm.nih.gov/pubmed/27664259
713. Kelley, RK, Ueno, M, Yoo, C, Finn, RS, Furuse, J, Ren, Z, et.al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial., Lancet, 2023. ():, https://pubmed.ncbi.nlm.nih.gov/37075781/
714. Abou-Alfa, Ghassan K., Macarulla, Teresa, Javle, Milind M., Kelley, Robin K., Lubner, Sam J., Adeva, Jorge, et.al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study, The Lancet Oncology, 2020. 21(6): p. 796-807.
715. Abou-Alfa, Ghassan K., Sahai, Vaibhav, Hollebecque, Antoine, Vaccaro, Gina, Melisi, Davide, Al-Rajabi, Raed, et.al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study, The Lancet Oncology, 2020. 21(5): p. 671-684.
716. Goyal, L, Meric-Bernstam, F, Hollebecque, A, Valle, JW, Morizane, C, Karasic, TB, et.al. Futibatinib for , N Engl J Med, 2023. 388 (3)(3): p. 228-239., https://pubmed.ncbi.nlm.nih.gov/36652354/
717. Valle, J. W., Lamarca, A., Goyal, L., Barriuso, J., Zhu, A. X., New Horizons for Precision Medicine in Biliary Tract Cancers, Cancer Discov, 2017. 7(9): p. 943-962., https://cancerdiscovery.aacrjournals.org/content/candisc/7/9/943.full.pdf
718. Cocco, E., Scaltriti, M., Drilon, A., NTRK fusion-positive cancers and TRK inhibitor therapy, Nat Rev Clin Oncol, 2018. 15(12): p. 731-747., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419506/pdf/nihms-1016874.pdf
719. Solomon, J. P., Linkov, I., Rosado, A., Mullaney, K., Rosen, E. Y., Frosina, D., et.al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls, Mod Pathol, 2019., https://www.ncbi.nlm.nih.gov/pubmed/31375766
720. Ross, J. S., Wang, K., Gay, L., Al-Rohil, R., Rand, J. V., Jones, D. M., et.al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing, Oncologist, 2014. 19(3): p. 235-42., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958461/pdf/theoncologist_13352.pdf
721. Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., et.al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children, N Engl J Med, 2018. 378(8): p. 731-739., https://www.nejm.org/doi/pdf/10.1056/NEJMoa1714448?articleTools=true
722. Oh, D. Y., Bang, Y. J., HER2-targeted therapies - a role beyond breast cancer, Nat Rev Clin Oncol, 2019., https://www.ncbi.nlm.nih.gov/pubmed/31548601
723. Javle, M, Borad, MJ, Azad, NS, Kurzrock, R, Abou-Alfa, GK, George, B, et.al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study., Lancet Oncol, 2021. 22 (9)(9): p. 1290-1300., https://pubmed.ncbi.nlm.nih.gov/34339623/
724. Nakamura, Y, Mizuno, N, Sunakawa, Y, Canon, JL, Galsky, MD, Hamilton, E, et.al. Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study., J Clin Oncol, 2023. 41 (36)(36): p. 5569-5578., https://pubmed.ncbi.nlm.nih.gov/37751561/
725. Meric-Bernstam, F, Makker, V, Oaknin, A, Oh, DY, Banerjee, S, González-Martín, A, et.al. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial., J Clin Oncol, 2024. 42 (1)(1): p. 47-58., https://pubmed.ncbi.nlm.nih.gov/37870536/
726. Harding, JJ, Piha-Paul, SA, Shah, RH, Murphy, JJ, Cleary, JM, Shapiro, GI, et.al. Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers., Nat Commun, 2023. 14 (1)(1): p. 630., https://pubmed.ncbi.nlm.nih.gov/36746967/
727. Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J. Y., et.al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations, N Engl J Med, 2015. 373(8): p. 726-36., https://www.nejm.org/doi/pdf/10.1056/NEJMoa1502309?articleTools=true
728. Salama, A. K. S., Li, S. L., Macrae, E. R., Park, J. I., Mitchell, E. P., Zwiebel, J. A., et.al. Dabrafenib and trametinib in patients with tumors with BRAF V600E/K mutations: Results from the molecular analysis for therapy choice (MATCH) Arm H., Journal of Clinical Oncology, 2019. 37(15):, , to, ISI>://WOS:000487345804592
729. Lavingia, V., Fakih, M., Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma-2 case reports and a brief review, J Gastrointest Oncol, 2016. 7(6): p. E98-e102., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5177579/pdf/jgo-07-06-E98.pdf
730. Kocsis, J., Árokszállási, A., András, C., Balogh, I., Béres, E., Déri, J., et.al. Combined dabrafenib and trametinib treatment in a case of chemotherapy-refractory extrahepatic BRAF V600E mutant cholangiocarcinoma: dramatic clinical and radiological response with a confusing synchronic new liver lesion, J Gastrointest Oncol, 2017. 8(2): p. E32-e38., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5401859/pdf/jgo-08-02-E32.pdf
731. Bunyatov, T., Zhao, A., Kovalenko, J., Gurmikov, B., Vishnevsky, V., Personalised approach in combined treatment of cholangiocarcinoma: a case report of healing from cholangiocellular carcinoma at stage IV, J Gastrointest Oncol, 2019. 10(4): p. 815-820., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657318/pdf/jgo-10-04-815.pdf
732. Subbiah, V, Lassen, U, Élez, E, Italiano, A, Curigliano, G, Javle, M, et.al. Dabrafenib plus trametinib in patients with BRAF, Lancet Oncol, 2020. 21 (9)(9): p. 1234-1243., https://pubmed.ncbi.nlm.nih.gov/32818466/
733. Abou-Alfa, GK, Sahai, V, Hollebecque, A, Vaccaro, G, Melisi, D, Al-Rajabi, R, et.al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study., Lancet Oncol, 2020. 21 (5)(5): p. 671-684., https://pubmed.ncbi.nlm.nih.gov/32203698/
734. Wu, Q, Ellis, H, Siravegna, G, Michel, AG, Norden, BL, Fece de la Cruz, F, et.al. Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma., Clin Cancer Res, 2024. 30 (1)(1): p. 198-208., https://pubmed.ncbi.nlm.nih.gov/37843855/
735. Rengan, AK, Denlinger, CS, Robust Response to Futibatinib in a Patient With Metastatic FGFR-Addicted Cholangiocarcinoma Previously Treated Using Pemigatinib., J Natl Compr Canc Netw, 2022. 20 (5)(5): p. 430-435., https://pubmed.ncbi.nlm.nih.gov/35378504/
736. Meric-Bernstam, F, Bahleda, R, Hierro, C, Sanson, M, Bridgewater, J, Arkenau, HT, et.al. Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring , Cancer Discov, 2022. 12 (2)(2): p. 402-415., https://pubmed.ncbi.nlm.nih.gov/34551969/
737. Mazzaferro, V., El-Rayes, B. F., Droz Dit Busset, M., Cotsoglou, C., Harris, W. P., Damjanov, N., et.al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma, Br J Cancer, 2019. 120(2): p. 165-171., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6342954/pdf/41416_2018_Article_334.pdf
738. Bahleda, R., Italiano, A., Hierro, C., Mita, A., Cervantes, A., Chan, N., et.al. Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors, Clin Cancer Res, 2019. 25(16): p. 4888-4897., https://clincancerres.aacrjournals.org/content/clincanres/25/16/4888.full.pdf
739. Subbiah, V, Sahai, V, Maglic, D, Bruderek, K, Touré, BB, Zhao, S, et.al. RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations., Cancer Discov, 2023. 13 (9)(9): p. 2012-2031., https://pubmed.ncbi.nlm.nih.gov/37270847/
740. Cleary, JM, Raghavan, S, Wu, Q, Li, YY, Spurr, LF, Gupta, HV, et.al. None, Cancer Discov, 2021. 11 (10)(10): p. 2488-2505., https://pubmed.ncbi.nlm.nih.gov/33926920/
741. Katoh, M., Fibroblast growth factor receptors as treatment targets in clinical oncology, Nat Rev Clin Oncol, 2018., https://www.ncbi.nlm.nih.gov/pubmed/30367139
742. Maio, M, Ascierto, PA, Manzyuk, L, Motola-Kuba, D, Penel, N, Cassier, PA, et.al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study., Ann Oncol, 2022. 33 (9)(9): p. 929-938., https://pubmed.ncbi.nlm.nih.gov/35680043/
743. Lamarca, A, Palmer, DH, Wasan, HS, Ross, PJ, Ma, YT, Arora, A, et.al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial., Lancet Oncol, 2021. 22 (5)(5): p. 690-701., https://pubmed.ncbi.nlm.nih.gov/33798493/
744. Marabelle, Aurelien, Le, Dung T., Ascierto, Paolo A., Giacomo, Anna Maria Di, Jesus-Acosta, Ana De, Delord, Jean-Pierre, et.al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study, Journal of Clinical Oncology 0(0): p. JCO.19.02105., https://ascopubs.org/doi/abs/10.1200/JCO.19.02105
745. Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., et.al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade, Science, 2017. 357(6349): p. 409-413., https://science.sciencemag.org/content/sci/357/6349/409.full.pdf
746. Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., et.al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency, N Engl J Med, 2015. 372(26): p. 2509-20., https://www.nejm.org/doi/pdf/10.1056/NEJMoa1500596?articleTools=true
747. Goeppert, B., Roessler, S., Renner, M., Singer, S., Mehrabi, A., Vogel, M. N., et.al. Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma, Br J Cancer, 2019. 120(1): p. 109-114., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325153/pdf/41416_2018_Article_199.pdf
748. Cloyd, JM, Chun, YS, Ikoma, N, Vauthey, JN, Aloia, TA, Cuddy, A, et.al. Clinical and Genetic Implications of DNA Mismatch Repair Deficiency in Biliary Tract Cancers Associated with Lynch Syndrome., J Gastrointest Cancer, 2018. 49 (1)(1): p. 93-96., https://pubmed.ncbi.nlm.nih.gov/29238914/
749. Zhu, AX, Macarulla, T, Javle, MM, Kelley, RK, Lubner, SJ, Adeva, J, et.al. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial., JAMA Oncol, 2021. 7 (11)(11): p. 1669-1677., https://pubmed.ncbi.nlm.nih.gov/34554208/
750. Choi, IS, Kim, KH, Lee, JH, Suh, KJ, Kim, JW, Park, JH, et.al. A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy., Eur J Cancer, 2021. 154 (): p. 288-295., https://pubmed.ncbi.nlm.nih.gov/34303267/
751. Yoo, C, Kim, KP, Jeong, JH, Kim, I, Kang, MJ, Cheon, J, et.al. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study., Lancet Oncol, 2021. ():, https://pubmed.ncbi.nlm.nih.gov/34656226/
752. Zheng, Y, Tu, X, Zhao, P, Jiang, W, Liu, L, Tong, Z, et.al. A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin., Br J Cancer, 2018. 119 (3)(3): p. 291-295., https://pubmed.ncbi.nlm.nih.gov/29955136/
753. Vogel, A., Wenzel, P., Folprecht, G., Schütt, P., Wege, H., Kretzschmar, A., et.al. 53MO Nal-IRI and 5-FU/LV compared to 5-FU/LV in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies (NALIRICC – AIO-HEP-0116)Elsevier, Annals of Oncology, 2022. 33: p. S563 - S564., https://doi.org/10.1016/j.annonc.2022.07.081
754. Ramaswamy, A, Ostwal, V, Sharma, A, Bhargava, P, Srinivas, S, Goel, M, et.al. Efficacy of Capecitabine Plus Irinotecan vs Irinotecan Monotherapy as Second-line Treatment in Patients With Advanced Gallbladder Cancer: A Multicenter Phase 2 Randomized Clinical Trial (GB-SELECT)., JAMA Oncol, 2021. 7 (3)(3): p. 436-439., https://pubmed.ncbi.nlm.nih.gov/33270098/
755. Schütte, K., Tippelt, B., Schulz, C., Röhl, F. W., Feneberg, A., Seidensticker, R., et.al. Malnutrition is a prognostic factor in patients with hepatocellular carcinoma (HCC), Clin Nutr, 2015. 34(6): p. 1122-7.
756. Huang, T. H., Hsieh, C. C., Kuo, L. M., Chang, C. C., Chen, C. H., Chi, C. C., et.al. Malnutrition associated with an increased risk of postoperative complications following hepatectomy in patients with hepatocellular carcinoma, HPB (Oxford), 2019. 21(9): p. 1150-1155.
757. Arends, J., Bachmann, P., Baracos, V., Barthelemy, N., Bertz, H., Bozzetti, F., et.al. ESPEN guidelines on nutrition in cancer patients, Clin Nutr, 2017. 36(1): p. 11-48.
758. Ciuni, R., Biondi, A., Grosso, G., Nunnari, G., Panascia, E., Randisi, L., et.al. Nutritional aspects in patient undergoing liver resection, Updates Surg, 2011. 63(4): p. 249-52., https://link.springer.com/content/pdf/10.1007/s13304-011-0121-4.pdf
759. Cederholm, T., Jensen, G. L., Correia, Mitd, Gonzalez, M. C., Fukushima, R., Higashiguchi, T., et.al. GLIM criteria for the diagnosis of malnutrition - A consensus report from the global clinical nutrition community, J Cachexia Sarcopenia Muscle, 2019. 10(1): p. 207-217., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438340/pdf/JCSM-10-207.pdf
760. Badran, H., Elsabaawy, M. M., Ragab, A., Aly, R. A., Alsebaey, A., Sabry, A., Baseline Sarcopenia is Associated with Lack of Response to Therapy, Liver Decompensation and High Mortality in Hepatocellular Carcinoma Patients, Asian Pac J Cancer Prev, 2020. 21(11): p. 3285-3290., http://journal.waocp.org/article_89349_cc643ce4770cf7eeca5890c5d5c453d5.pdf
761. Fujiwara, N., Nakagawa, H., Kudo, Y., Tateishi, R., Taguri, M., Watadani, T., et.al. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma, J Hepatol, 2015. 63(1): p. 131-40.
762. Kim, N., Yu, J. I., Park, H. C., Yoo, G. S., Choi, C., Hong, J. Y., et.al. Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab, Cancer Immunol Immunother, 2020., https://link.springer.com/content/pdf/10.1007/s00262-020-02794-3.pdf
763. Mardian, Y., Yano, Y., Ratnasari, N., Choridah, L., Wasityastuti, W., Setyawan, N. H., et.al. "Sarcopenia and intramuscular fat deposition are associated with poor survival in Indonesian patients with hepatocellular carcinoma: a retrospective study", BMC Gastroenterol, 2019. 19(1): p. 229., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937974/pdf/12876_2019_Article_1152.pdf
764. Voron, T., Tselikas, L., Pietrasz, D., Pigneur, F., Laurent, A., Compagnon, P., et.al. Sarcopenia Impacts on Short- and Long-term Results of Hepatectomy for Hepatocellular Carcinoma, Ann Surg, 2015. 261(6): p. 1173-83.
765. Plauth, M., Bernal, W., Dasarathy, S., Merli, M., Plank, L. D., Schütz, T., et.al. ESPEN guideline on clinical nutrition in liver disease, Clin Nutr, 2019. 38(2): p. 485-521., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6686849/pdf/nihms-1529826.pdf
766. Haun, M. W., Estel, S., Rucker, G., Friederich, H. C., Villalobos, M., Thomas, M., et.al. Early palliative care for adults with advanced cancer, Cochrane Database Syst Rev, 2017. 6: p. CD011129., http://www.ncbi.nlm.nih.gov/pubmed/28603881
767. Adler, K., Schlieper, D., Kindgen-Milles, D., Meier, S., Schwartz, J., van Caster, P., et.al. [Integration of palliative care into intensive care : Systematic review], Anaesthesist, 2017. 66(9): p. 660-666., http://www.ncbi.nlm.nih.gov/pubmed/28589374
768. Dalgaard, K. M., Bergenholtz, H., Nielsen, M. E., Timm, H., Early integration of palliative care in hospitals: A systematic review on methods, barriers, and outcome, Palliat Support Care, 2014. 12(6): p. 495-513., http://www.ncbi.nlm.nih.gov/pubmed/24621947
769. Davis, M. P., Temel, J. S., Balboni, T., Glare, P., A review of the trials which examine early integration of outpatient and home palliative care for patients with serious illnesses, Ann Palliat Med, 2015. 4(3): p. 99-121., http://www.ncbi.nlm.nih.gov/pubmed/26231807
770. Hui, D., Kim, Y. J., Park, J. C., Zhang, Y., Strasser, F., Cherny, N., et.al. Integration of oncology and palliative care: a systematic review, Oncologist, 2015. 20(1): p. 77-83., http://www.ncbi.nlm.nih.gov/pubmed/25480826
771. Hui, D., Meng, Y. C., Bruera, S., Geng, Y., Hutchins, R., Mori, M., et.al. Referral Criteria for Outpatient Palliative Cancer Care: A Systematic Review, Oncologist, 2016. 21(7): p. 895-901., http://www.ncbi.nlm.nih.gov/pubmed/27185614
772. Tassinari, D., Drudi, F., Monterubbianesi, M. C., Stocchi, L., Ferioli, I., Marzaloni, A., et.al. Early Palliative Care in Advanced Oncologic and Non-Oncologic Chronic Diseases: A Systematic Review of Literature, Rev Recent Clin Trials, 2016. 11(1): p. 63-71., http://www.ncbi.nlm.nih.gov/pubmed/26464077
773. Gärtner, U., Braun, G. D., Held, K., Friedrich, H., Reimers, H. J., Schmidt, J., et.al. [Physical complaints, stress and quality of life of oncologic patients. Effects and patient assessment in inpatient rehabilitation], Med Klin (Munich), 1996. 91(8): p. 501-8.
774. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), Palliativmedizin für Patienten mit einer nicht-heilbaren Krebserkrankung, Version 2.2, 2020., https://www.leitlinienprogramm-onkologie.de/leitlinien/palliativmedizin/
775. Hamano, J., Morita, T., Inoue, S., Ikenaga, M., Matsumoto, Y., Sekine, R., et.al. Surprise Questions for Survival Prediction in Patients With Advanced Cancer: A Multicenter Prospective Cohort Study, Oncologist, 2015. 20(7): p. 839-44., http://www.ncbi.nlm.nih.gov/pubmed/26054631
776. Moroni, M., Zocchi, D., Bolognesi, D., Abernethy, A., Rondelli, R., Savorani, G., et.al. The 'surprise' question in advanced cancer patients: A prospective study among general practitioners, Palliat Med, 2014. 28(7): p. 959-964., http://www.ncbi.nlm.nih.gov/pubmed/24662237
777. Moss, A. H., Lunney, J. R., Culp, S., Auber, M., Kurian, S., Rogers, J., et.al. Prognostic significance of the "surprise" question in cancer patients, J Palliat Med, 2010. 13(7): p. 837-40., http://www.ncbi.nlm.nih.gov/pubmed/20636154
778. Murray, S., Boyd, K., Using the 'surprise question' can identify people with advanced heart failure and COPD who would benefit from a palliative care approach, Palliat Med, 2011. 25(4): p. 382., http://www.ncbi.nlm.nih.gov/pubmed/21610113
779. Kremer, A. E., Beuers, U., Oude-Elferink, R. P., Pusl, T., Pathogenesis and treatment of pruritus in cholestasis, Drugs, 2008. 68(15): p. 2163-82., http://www.ncbi.nlm.nih.gov/pubmed/18840005
780. Stander, S., Raap, U., Weisshaar, E., Schmelz, M., Mettang, T., Handwerker, H., et.al. Pathogenesis of pruritus, J Dtsch Dermatol Ges, 2011. 9(6): p. 456-63., http://www.ncbi.nlm.nih.gov/pubmed/21208378
781. Stander, S., Zeidler, C., Augustin, M., Bayer, G., Kremer, A. E., Legat, F. J., et.al. S2k-Leitlinie zur Diagnostik und Therapie des chronischen Pruritus - Update - Kurzversion, J Dtsch Dermatol Ges, 2017. 15(8): p. 860-873., http://www.ncbi.nlm.nih.gov/pubmed/28763608
782. Bachs, L., Pares, A., Elena, M., Piera, C., Rodes, J., Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis, Lancet, 1989. 1(8638): p. 574-6., http://www.ncbi.nlm.nih.gov/pubmed/2564110
783. Ghent, C. N., Carruthers, S. G., Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial, Gastroenterology, 1988. 94(2): p. 488-93., http://www.ncbi.nlm.nih.gov/pubmed/3275568
784. Terg, R., Coronel, E., Sorda, J., Munoz, A. E., Findor, J., Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study, J Hepatol, 2002. 37(6): p. 717-22., http://www.ncbi.nlm.nih.gov/pubmed/12445410
785. Bergasa, N. V., Talbot, T. L., Alling, D. W., Schmitt, J. M., Walker, E. C., Baker, B. L., et.al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis, Gastroenterology, 1992. 102(2): p. 544-9., http://www.ncbi.nlm.nih.gov/pubmed/1732125
786. Mayo, M. J., Handem, I., Saldana, S., Jacobe, H., Getachew, Y., Rush, A. J., Sertraline as a first-line treatment for cholestatic pruritus, Hepatology, 2007. 45(3): p. 666-74., http://www.ncbi.nlm.nih.gov/pubmed/17326161
787. Lindor, K. D., Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group, N Engl J Med, 1997. 336(10): p. 691-5., http://www.ncbi.nlm.nih.gov/pubmed/9041099
788. Talwalkar, J. A., Souto, E., Jorgensen, R. A., Lindor, K. D., Natural history of pruritus in primary biliary cirrhosis, Clin Gastroenterol Hepatol, 2003. 1(4): p. 297-302., http://www.ncbi.nlm.nih.gov/pubmed/15017671
789. Zapata, R., Sandoval, L., Palma, J., Hernandez, I., Ribalta, J., Reyes, H., et.al. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. A 12-year experience, Liver Int, 2005. 25(3): p. 548-54., http://www.ncbi.nlm.nih.gov/pubmed/15910492
790. Lemyze, M., Dharancy, S., Nevière, R., Pruvot, F. R., Declerck, N., Wallaert, B., Aerobic capacity in patients with chronic liver disease: Very modest effect of liver transplantation, Presse Med, 2010. 39(7-8): p. e174-81.
791. Epstein, S. K., Freeman, R. B., Khayat, A., Unterborn, J. N., Pratt, D. S., Kaplan, M. M., Aerobic capacity is associated with 100-day outcome after hepatic transplantation, Liver Transpl, 2004. 10(3): p. 418-24., https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lt.20088?download=true
792. van Ginneken, B. T., van den Berg-Emons, R. J., Kazemier, G., Metselaar, H. J., Tilanus, H. W., Stam, H. J., Physical fitness, fatigue, and quality of life after liver transplantation, Eur J Appl Physiol, 2007. 100(3): p. 345-53., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1914221/pdf/421_2007_Article_435.pdf
793. van den Berg-Emons, R., van Ginneken, B., Wijffels, M., Tilanus, H., Metselaar, H., Stam, H., et.al. Fatigue is a major problem after liver transplantation, Liver Transpl, 2006. 12(6): p. 928-33., https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lt.20684?download=true
794. van Ginneken, B. T., van den Berg-Emons, H. J., Metselaar, H. J., Tilanus, H. W., Kazemier, G., Stam, H. J., Effects of a rehabilitation programme on daily functioning, participation, health-related quality of life, anxiety and depression in liver transplant recipients, Disabil Rehabil, 2010. 32(25): p. 2107-12., https://www.tandfonline.com/doi/abs/10.3109/09638288.2010.482174
795. Schwibbe, G., [Changes in quality of life in oncological patients in the course of an inpatient after-care program], Rehabilitation (Stuttg), 1991. 30(2): p. 55-62.
796. Fan, S. Y., Eiser, C., Ho, M. C., Lin, C. Y., Health-related quality of life in patients with hepatocellular carcinoma: the mediation effects of illness perceptions and coping, Psychooncology, 2013. 22(6): p. 1353-60., https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pon.3146?download=true
797. Fan, S. Y., Eiser, C., Ho, M. C., Health-related quality of life in patients with hepatocellular carcinoma: a systematic review, Clin Gastroenterol Hepatol, 2010. 8(7): p. 559-64.e1-10., https://www.sciencedirect.com/science/article/abs/pii/S1542356510002533?via%3Dihub
798. Qiao, C. X., Zhai, X. F., Ling, C. Q., Lang, Q. B., Dong, H. J., Liu, Q., et.al. Health-related quality of life evaluated by tumor node metastasis staging system in patients with hepatocellular carcinoma, World J Gastroenterol, 2012. 18(21): p. 2689-94., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3370007/pdf/WJG-18-2689.pdf
799. Steel, J. L., Geller, D. A., Gamblin, T. C., Olek, M. C., Carr, B. I., Depression, immunity, and survival in patients with hepatobiliary carcinoma, J Clin Oncol, 2007. 25(17): p. 2397-405.
800. Lee, H. H., Chiu, C. C., Lin, J. J., Wang, J. J., Lee, K. T., Sun, D. P., et.al. Impact of preoperative anxiety and depression on quality of life before and after resection of hepatocellular carcinoma, J Affect Disord, 2019. 246: p. 361-367., https://www.sciencedirect.com/science/article/abs/pii/S0165032718318639?via%3Dihub
801. Huang, T. W., Lin, C. C., The mediating effects of depression on sleep disturbance and fatigue: symptom clusters in patients with hepatocellular carcinoma, Cancer Nurs, 2009. 32(5): p. 398-403.
802. Ahn, M. H., Park, S., Lee, H. B., Ramsey, C. M., Na, R., Kim, S. O., et.al. Suicide in cancer patients within the first year of diagnosis, Psychooncology, 2015. 24(5): p. 601-7., https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pon.3705?download=true
803. Chiu, C. C., Lee, K. T., Wang, J. J., Sun, D. P., Lee, H. H., Shi, H. Y., Health-Related Quality of Life before and after Surgical Resection of Hepatocellular Carcinoma: A Prospective Study, Asian Pac J Cancer Prev, 2018. 19(1): p. 65-72., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844638/pdf/APJCP-19-65.pdf
804. Shun, S. C., Chen, C. H., Sheu, J. C., Liang, J. D., Yang, J. C., Lai, Y. H., Quality of life and its associated factors in patients with hepatocellular carcinoma receiving one course of transarterial chemoembolization treatment: a longitudinal study, Oncologist, 2012. 17(5): p. 732-9., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3360913/pdf/onc732.pdf
805. Shun, S. C., Lai, Y. H., Hung, H., Chen, C. H., Liang, J. D., Chou, Y. J., The Role of Age in Change in Unmet Supportive Care Needs in Hepatocellular Carcinoma Patients During Transition From Hospital to Home, Cancer Nurs, 2017. 40(3): p. 245-254.
806. Wang, Z. X., Liu, S. L., Sun, C. H., Wang, Q., Psychological intervention reduces postembolization pain during hepatic arterial chemoembolization therapy: a complementary approach to drug analgesia, World J Gastroenterol, 2008. 14(6): p. 931-5., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687062/pdf/WJG-14-931.pdf
807. Sanson-Fisher, R., Girgis, A., Boyes, A., Bonevski, B., Burton, L., Cook, P., The unmet supportive care needs of patients with cancer. Supportive Care Review Group, Cancer, 2000. 88(1): p. 226-37., https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/%28SICI%291097-0142%2820000101%2988%3A1%3C226%3A%3AAID-CNCR30%3E3.0.CO%3B2-P?download=true
808. Kleeberg, U. R., Tews, J. T., Ruprecht, T., Höing, M., Kuhlmann, A., Runge, C., Patient satisfaction and quality of life in cancer outpatients: results of the PASQOC study, Support Care Cancer, 2005. 13(5): p. 303-10., https://link.springer.com/content/pdf/10.1007/s00520-004-0727-x.pdf
809. Fallowfield, L., Jenkins, V., Communicating sad, bad, and difficult news in medicine, Lancet, 2004. 363(9405): p. 312-9.
810. de Haes, H., Teunissen, S., Communication in palliative care: a review of recent literature, Curr Opin Oncol, 2005. 17(4): p. 345-50.
811. Ong, L. M., Visser, M. R., Lammes, F. B., de Haes, J. C., Doctor-patient communication and cancer patients' quality of life and satisfaction, Patient Educ Couns, 2000. 41(2): p. 145-56.
812. Fukui, S., Ogawa, K., Ohtsuka, M., Fukui, N., A randomized study assessing the efficacy of communication skill training on patients' psychologic distress and coping: nurses' communication with patients just after being diagnosed with cancer, Cancer, 2008. 113(6): p. 1462-70., https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.23710?download=true
813. Lienard, A., Merckaert, I., Libert, Y., Delvaux, N., Marchal, S., Boniver, J., et.al. Factors that influence cancer patients' and relatives' anxiety following a three-person medical consultation: impact of a communication skills training program for physicians, Psychooncology, 2008. 17(5): p. 488-96., https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pon.1262?download=true
814. Razavi, D., Merckaert, I., Marchal, S., Libert, Y., Conradt, S., Boniver, J., et.al. How to optimize physicians' communication skills in cancer care: results of a randomized study assessing the usefulness of posttraining consolidation workshops, J Clin Oncol, 2003. 21(16): p. 3141-9.
815. Butow, P., Juraskova, I., Chang, S., Lopez, A. L., Brown, R., Bernhard, J., Shared decision making coding systems: how do they compare in the oncology context?, Patient Educ Couns, 2010. 78(2): p. 261-8.
816. Edwards, A., Elwyn, G., Inside the black box of shared decision making: distinguishing between the process of involvement and who makes the decision, Health Expect, 2006. 9(4): p. 307-20., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5060371/pdf/HEX-9-307.pdf
817. Gordon, E. J., Bergeron, A., McNatt, G., Friedewald, J., Abecassis, M. M., Wolf, M. S., Are informed consent forms for organ transplantation and donation too difficult to read?, Clin Transplant, 2012. 26(2): p. 275-83., https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1399-0012.2011.01480.x?download=true
818. Rodrigue, J. R., Hanto, D. W., Curry, M. P., Patients' expectations and success criteria for liver transplantation, Liver Transpl, 2011. 17(11): p. 1309-17., https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lt.22355?download=true
819. Volk, M. L., Tocco, R. S., Pelletier, S. J., Zikmund-Fisher, B. J., Lok, A. S., Patient decision making about organ quality in liver transplantation, Liver Transpl, 2011. 17(12): p. 1387-93., https://deepblue.lib.umich.edu/bitstream/handle/2027.42/88081/22437_ftp.pdf?sequence=1
820. Butow, P. N., Tattersall, M. H., Goldstein, D., Communication with cancer patients in culturally diverse societies, Ann N Y Acad Sci, 1997. 809: p. 317-29., https://nyaspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1749-6632.1997.tb48095.x?download=true
821. Dowsett, S. M., Saul, J. L., Butow, P. N., Dunn, S. M., Boyer, M. J., Findlow, R., et.al. Communication styles in the cancer consultation: preferences for a patient-centred approach, Psychooncology, 2000. 9(2): p. 147-56., https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/%28SICI%291099-1611%28200003/04%299%3A2%3C147%3A%3AAID-PON443%3E3.0.CO%3B2-X?download=true
822. Epstein, R. M., Making communication research matter: what do patients notice, what do patients want, and what do patients need?, Patient Educ Couns, 2006. 60(3): p. 272-8.
823. Zachariae, R., Pedersen, C. G., Jensen, A. B., Ehrnrooth, E., Rossen, P. B., von der Maase, H., Association of perceived physician communication style with patient satisfaction, distress, cancer-related self-efficacy, and perceived control over the disease, Br J Cancer, 2003. 88(5): p. 658-65., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376357/pdf/88-6600798a.pdf
824. Fogarty, L. A., Curbow, B. A., Wingard, J. R., McDonnell, K., Somerfield, M. R., Can 40 seconds of compassion reduce patient anxiety?, J Clin Oncol, 1999. 17(1): p. 371-9.
825. Strasser, F., Palmer, J. L., Willey, J., Shen, L., Shin, K., Sivesind, D., et.al. Impact of physician sitting versus standing during inpatient oncology consultations: patients' preference and perception of compassion and duration. A randomized controlled trial, J Pain Symptom Manage, 2005. 29(5): p. 489-97.
826. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), Entwicklung von leitlinienbasierten Qualitätsindikatoren. Methodenpapier für das Leitlinienprogramm Onkologie, Version 2.1, 2017., https://www.leitlinienprogramm-onkologie.de/methodik/grundlegende-informationen-zur-methodik
827. Ashoori, N., Bamberg, F., Paprottka, P., Rentsch, M., Kolligs, F. T., Siegert, S., et.al. Multimodality treatment for early-stage hepatocellular carcinoma: a bridging therapy for liver transplantation, Digestion, 2012. 86(4): p. 338-48.
828. Boteon, Apcds, Boteon, Y. L., Vinuela, E. F., Derosas, C., Mergental, H., Isaac, J. R., et.al. The impact of transarterial chemoembolization induced complications on outcomes after liver transplantation: A propensity-matched study, Clin Transplant, 2018. 32(5): p. e13255.
829. Habibollahi, P., Shamchi, S. P., Choi, J. M., Gade, T. P., Stavropoulos, S. W., Hunt, S. J., et.al. Association of Complete Radiologic and Pathologic Response following Locoregional Therapy before Liver Transplantation with Long-Term Outcomes of Hepatocellular Carcinoma: A Retrospective Study, J Vasc Interv Radiol, 2019. 30(3): p. 323-329., https://www.sciencedirect.com/science/article/pii/S105104431831741X?via%3Dihub
830. Lu, D. S., Yu, N. C., Raman, S. S., Lassman, C., Tong, M. J., Britten, C., et.al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation, Hepatology, 2005. 41(5): p. 1130-7.
831. Nicolini, A., Martinetti, L., Crespi, S., Maggioni, M., Sangiovanni, A., Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma, J Vasc Interv Radiol, 2010. 21(3): p. 327-32.
832. Sandow, T., Pavlus, J., Field, D., Lacayo, E., Cohen, E., Lynskey, G., et.al. Bridging Hepatocellular Carcinoma to Transplant: Transarterial Chemoembolization Response, Tumor Biology, and Recurrence after Transplantation in a 12-Year Transplant Cohort, J Vasc Interv Radiol, 2019. 30(7): p. 995-1003.
833. Tan, C. H. N., Yu, Y., Tan, Y. R. N., Lim, B. L. K., Iyer, S. G., Madhavan, K., et.al. Bridging therapies to liver transplantation for hepatocellular carcinoma: A bridge to nowhere?, Ann Hepatobiliary Pancreat Surg, 2018. 22(1): p. 27-35.
834. Werner, J. D., Frangakis, C., Ruck, J. M., Hong, K., Philosophe, B., Cameron, A. M., et.al. Neoadjuvant Transarterial Chemoembolization Improves Survival After Liver Transplant in Patients With Hepatocellular Carcinoma, Exp Clin Transplant, 2019. 17(5): p. 638-643.
835. Sapisochin, G., Barry, A., Doherty, M., Fischer, S., Goldaracena, N., Rosales, R., et.al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis, J Hepatol, 2017. 67(1): p. 92-99.
836. Wang, J. H., Wang, C. C., Hung, C. H., Chen, C. L., Lu, S. N., Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma, J Hepatol, 2012. 56(2): p. 412-8., https://www.journal-of-hepatology.eu/article/S0168-8278(11)00524-1/fulltext
837. Peng, Z. W., Lin, X. J., Zhang, Y. J., Liang, H. H., Guo, R. P., Shi, M., et.al. Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: a retrospective comparative study, Radiology, 2012. 262(3): p. 1022-33.
838. Hasegawa, K., Kokudo, N., Makuuchi, M., Izumi, N., Ichida, T., Kudo, M., et.al. Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey, J Hepatol, 2013. 58(4): p. 724-9., https://www.sciencedirect.com/science/article/pii/S016882781200877X?via%3Dihub
839. Fang, Y., Chen, W., Liang, X., Li, D., Lou, H., Chen, R., et.al. Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma, J Gastroenterol Hepatol, 2014. 29(1): p. 193-200., https://onlinelibrary.wiley.com/doi/abs/10.1111/jgh.12441
840. Miura, J. T., Johnston, F. M., Tsai, S., Eastwood, D., Banerjee, A., Christians, K. K., et.al. Surgical resection versus ablation for hepatocellular carcinoma ≤ 3 cm: a population-based analysis, HPB (Oxford), 2015. 17(10): p. 896-901., https://www.hpbonline.org/article/S1365-182X(15)31122-9/pdf
841. Zhang, M., Ma, H., Zhang, J., He, L., Ye, X., Li, X., Comparison of microwave ablation and hepatic resection for hepatocellular carcinoma: a meta-analysis, Onco Targets Ther, 2017. 10: p. 4829-4839., https://pubmed.ncbi.nlm.nih.gov/29042794/
842. Zhang, Q. B., Zhang, X. G., Jiang, R. D., Hu, C. X., Sun, D., Ran, L., et.al. Microwave ablation versus hepatic resection for the treatment of hepatocellular carcinoma and oesophageal variceal bleeding in cirrhotic patients, Int J Hyperthermia, 2017. 33(3): p. 255-262., https://www.tandfonline.com/doi/pdf/10.1080/02656736.2016.1257824?needAccess=true
843. Liu, P. H., Hsu, C. Y., Hsia, C. Y., Lee, Y. H., Huang, Y. H., Chiou, Y. Y., et.al. Surgical Resection Versus Radiofrequency Ablation for Single Hepatocellular Carcinoma ≤ 2 cm in a Propensity Score Model, Ann Surg, 2016. 263(3): p. 538-45., https://www.ingentaconnect.com/content/wk/sla/2016/00000263/00000003/art00040;jsessionid=1n53m5b4ljd7b.x-ic-live-01
844. Takayasu, K., Arii, S., Sakamoto, M., Matsuyama, Y., Kudo, M., Kaneko, S., et.al. Impact of resection and ablation for single hypovascular hepatocellular carcinoma ≤2 cm analysed with propensity score weighting, Liver Int, 2018. 38(3): p. 484-493., https://onlinelibrary.wiley.com/doi/abs/10.1111/liv.13670
845. Hung, H. H., Chiou, Y. Y., Hsia, C. Y., Su, C. W., Chou, Y. H., Chiang, J. H., et.al. Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas, Clin Gastroenterol Hepatol, 2011. 9(1): p. 79-86., https://www.cghjournal.org/article/S1542-3565(10)00847-5/pdf
846. Ogihara, M., Wong, L. L., Machi, J., Radiofrequency ablation versus surgical resection for single nodule hepatocellular carcinoma: long-term outcomes, HPB (Oxford), 2005. 7(3): p. 214-21.
847. Lü, M. D., Kuang, M., Liang, L. J., Xie, X. Y., Peng, B. G., Liu, G. J., et.al. [Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: a randomized clinical trial], Zhonghua Yi Xue Za Zhi, 2006. 86(12): p. 801-5.
848. Lupo, L., Panzera, P., Giannelli, G., Memeo, M., Gentile, A., Memeo, V., Single hepatocellular carcinoma ranging from 3 to 5 cm: radiofrequency ablation or resection?, HPB (Oxford), 2007. 9(6): p. 429-34.
849. Abu-Hilal, M., Primrose, J. N., Casaril, A., McPhail, M. J., Pearce, N. W., Nicoli, N., Surgical resection versus radiofrequency ablation in the treatment of small unifocal hepatocellular carcinoma, J Gastrointest Surg, 2008. 12(9): p. 1521-6.
850. Tashiro, H., Aikata, H., Waki, K., Amano, H., Oshita, A., Kobayashi, T., et.al. Treatment strategy for early hepatocellular carcinomas: comparison of radiofrequency ablation with or without transcatheter arterial chemoembolization and surgical resection, J Surg Oncol, 2011. 104(1): p. 3-9.
851. Kim, J. W., Shin, S. S., Kim, J. K., Choi, S. K., Heo, S. H., Lim, H. S., et.al. Radiofrequency ablation combined with transcatheter arterial chemoembolization for the treatment of single hepatocellular carcinoma of 2 to 5 cm in diameter: comparison with surgical resection, Korean J Radiol, 2013. 14(4): p. 626-35.
852. Tang, C., Shen, J., Feng, W., Bao, Y., Dong, X., Dai, Y., et.al. Combination Therapy of Radiofrequency Ablation and Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Retrospective Study, Medicine (Baltimore), 2016. 95(20): p. e3754., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902444/pdf/medi-95-e3754.pdf
853. Bholee, A. K., Peng, K., Zhou, Z., Chen, J., Xu, L., Zhang, Y., et.al. Radiofrequency ablation combined with transarterial chemoembolization versus hepatectomy for patients with hepatocellular carcinoma within Milan criteria: a retrospective case-control study, Clin Transl Oncol, 2017. 19(7): p. 844-852.
854. Pan, T., Mu, L. W., Wu, C., Wu, X. Q., Xie, Q. K., Li, X. S., et.al. Comparison of Combined Transcatheter Arterial Chemoembolization and CT-guided Radiofrequency Ablation with Surgical Resection in Patients with Hepatocellular Carcinoma within the Up-to-seven Criteria: A Multicenter Case-matched Study, J Cancer, 2017. 8(17): p. 3506-3513., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687165/pdf/jcav08p3506.pdf
855. Zhang, R., Shen, L., Zhao, L., Guan, Z., Chen, Q., Li, W., Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma, Diagn Interv Radiol, 2018. 24(4): p. 219-224., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6045511/pdf/dir-24-4-219.pdf
856. Lin, D. Y., Liaw, Y. F., Lee, T. Y., Lai, C. M., Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma--a randomized controlled trial, Gastroenterology, 1988. 94(2): p. 453-6., https://www.sciencedirect.com/science/article/abs/pii/0016508588904362?via%3Dihub
857. Pelletier, G., Roche, A., Ink, O., Anciaux, M. L., Derhy, S., Rougier, P., et.al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma, J Hepatol, 1990. 11(2): p. 181-4.
858. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma, N Engl J Med, 1995. 332(19): p. 1256-61., https://www.nejm.org/doi/pdf/10.1056/NEJM199505113321903?articleTools=true
859. Bruix, J., Llovet, J. M., Castells, A., Montañá, X., Brú, C., Ayuso, M. C., et.al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution, Hepatology, 1998. 27(6): p. 1578-83., https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.510270617?download=true
860. Pelletier, G., Ducreux, M., Gay, F., Luboinski, M., Hagège, H., Dao, T., et.al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC, J Hepatol, 1998. 29(1): p. 129-34.
861. Stefanini, G. F., Amorati, P., Biselli, M., Mucci, F., Celi, A., Arienti, V., et.al. Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma. An Italian experience, Cancer, 1995. 75(10): p. 2427-34., https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/1097-0142%2819950515%2975%3A10%3C2427%3A%3AAID-CNCR2820751007%3E3.0.CO%3B2-J?download=true
862. Bronowicki, J. P., Vetter, D., Dumas, F., Boudjema, K., Bader, R., Weiss, A. M., et.al. Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year study of 127 French patients, Cancer, 1994. 74(1): p. 16-24., https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/1097-0142%2819940701%2974%3A1%3C16%3A%3AAID-CNCR2820740105%3E3.0.CO%3B2-V?download=true
863. Kim, J. H., Yoon, H. K., Kim, S. Y., Kim, K. M., Ko, G. Y., Gwon, D. I., et.al. Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis, Aliment Pharmacol Ther, 2009. 29(12): p. 1291-8., https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2036.2009.04016.x?download=true
864. Herber, S., Otto, G., Schneider, J., Manzl, N., Kummer, I., Kanzler, S., et.al. Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma, Cardiovasc Intervent Radiol, 2007. 30(6): p. 1156-65., https://link.springer.com/content/pdf/10.1007/s00270-007-9032-7.pdf
865. Chung, G. E., Lee, J. H., Kim, H. Y., Hwang, S. Y., Kim, J. S., Chung, J. W., et.al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival, Radiology, 2011. 258(2): p. 627-34.
866. Georgiades, C. S., Hong, K., D'Angelo, M., Geschwind, J. F., Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis, J Vasc Interv Radiol, 2005. 16(12): p. 1653-9., https://www.sciencedirect.com/science/article/pii/S1051044307607933?via%3Dihub
867. Okazaki, M, Higashihara, H, Koganemaru, HE, Ono, H, Fujimitsu, R, Nakamura, T, et.al. Transcatheter arterial embolization for inoperable hepatocellular carcinoma, Jpn J Clin Radiol, 1991. 36: p. 535-539.
868. Sacco, R., Bargellini, I., Bertini, M., Bozzi, E., Romano, A., Petruzzi, P., et.al. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma, J Vasc Interv Radiol, 2011. 22(11): p. 1545-52.
869. van Malenstein, H., Maleux, G., Vandecaveye, V., Heye, S., Laleman, W., van Pelt, J., et.al. A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma, Onkologie, 2011. 34(7): p. 368-76., https://www.karger.com/Article/Pdf/329602
870. Dhanasekaran, R., Kooby, D. A., Staley, C. A., Kauh, J. S., Khanna, V., Kim, H. S., Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC), J Surg Oncol, 2010. 101(6): p. 476-80., https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jso.21522?download=true
871. Ferrer Puchol, M. D., la Parra, C., Esteban, E., Vaño, M., Forment, M., Vera, A., et.al. [Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma], Radiologia, 2011. 53(3): p. 246-53., https://www.sciencedirect.com/science/article/abs/pii/S0033833810003449?via%3Dihub
872. Wiggermann, P., Sieron, D., Brosche, C., Brauer, T., Scheer, F., Platzek, I., et.al. Transarterial Chemoembolization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs. TACE with cisplatin/lipiodol (cTACE), Med Sci Monit, 2011. 17(4): p. Cr189-95., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539521/pdf/medscimonit-17-4-cr189.pdf
873. Song, M. J., Chun, H. J., Song, D. S., Kim, H. Y., Yoo, S. H., Park, C. H., et.al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma, J Hepatol, 2012. 57(6): p. 1244-50.
874. Megías Vericat, J. E., García Marcos, R., López Briz, E., Gómez Muñoz, F., Ramos Ruiz, J., Martínez Rodrigo, J. J., et.al. Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs, Radiologia, 2015. 57(6): p. 496-504., https://www.sciencedirect.com/science/article/abs/pii/S0033833815000764?via%3Dihub
875. Kloeckner, R., Weinmann, A., Prinz, F., Pinto dos Santos, D., Ruckes, C., Dueber, C., et.al. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma, BMC Cancer, 2015. 15: p. 465., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4460638/pdf/12885_2015_Article_1480.pdf
876. Facciorusso, A., Mariani, L., Sposito, C., Spreafico, C., Bongini, M., Morosi, C., et.al. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma, J Gastroenterol Hepatol, 2016. 31(3): p. 645-53., https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jgh.13147?download=true
877. Baur, J., Ritter, C. O., Germer, C. T., Klein, I., Kickuth, R., Steger, U., Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma, Hepat Med, 2016. 8: p. 69-74., https://pubmed.ncbi.nlm.nih.gov/27382341/
878. Gao, S., Yang, Z., Zheng, Z., Yao, J., Deng, M., Xie, H., et.al. Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: a meta-analysis, Hepatogastroenterology, 2013. 60(124): p. 813-20.
879. Huang, K., Zhou, Q., Wang, R., Cheng, D., Ma, Y., Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma, J Gastroenterol Hepatol, 2014. 29(5): p. 920-5., https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jgh.12439?download=true
880. Zhou, X., Tang, Z., Wang, J., Lin, P., Chen, Z., Lv, L., et.al. Doxorubicin-eluting beads versus conventional transarterialchemoembolization for the treatment of hepatocellular carcinoma: a meta-analysis, Int J Clin Exp Med, 2014. 7(11): p. 3892-903.
881. Zou, J. H., Zhang, L., Ren, Z. G., Ye, S. L., Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis, J Dig Dis, 2016. 17(8): p. 510-517., https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1751-2980.12380?download=true
882. Facciorusso, A., Di Maso, M., Muscatiello, N., Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: A meta-analysis, Dig Liver Dis, 2016. 48(6): p. 571-7.
883. Chiesa, C, Maccauro, M, Romito, R, Spreafico, C, Pellizzari, S, Negri, A, et.al. Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan., Q J Nucl Med Mol Imaging, 2011. 55 (2)(2): p. 168-97., https://pubmed.ncbi.nlm.nih.gov/21386789/
884. Garin, E, Lenoir, L, Rolland, Y, Edeline, J, Mesbah, H, Laffont, S, et.al. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results., J Nucl Med, 2012. 53 (2)(2): p. 255-63., https://pubmed.ncbi.nlm.nih.gov/22302962/
885. Garin, E, Rolland, Y, Pracht, M, Le Sourd, S, Laffont, S, Mesbah, H, et.al. High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with , Liver Int, 2017. 37 (1)(1): p. 101-110., https://pubmed.ncbi.nlm.nih.gov/27514012/
886. Kappadath, SC, Mikell, J, Balagopal, A, Baladandayuthapani, V, Kaseb, A, Mahvash, A, Hepatocellular Carcinoma Tumor Dose Response After , Int J Radiat Oncol Biol Phys, 2018. 102 (2)(2): p. 451-461., https://pubmed.ncbi.nlm.nih.gov/30191875/
887. Chan, KT, Alessio, AM, Johnson, GE, Vaidya, S, Kwan, SW, Monsky, W, et.al. Prospective Trial Using Internal Pair-Production Positron Emission Tomography to Establish the Yttrium-90 Radioembolization Dose Required for Response of Hepatocellular Carcinoma., Int J Radiat Oncol Biol Phys, 2018. 101 (2)(2): p. 358-365., https://pubmed.ncbi.nlm.nih.gov/29559288/
888. d'Abadie, P, Walrand, S, Hesse, M, Annet, L, Borbath, I, Van den Eynde, M, et.al. Prediction of tumor response and patient outcome after radioembolization of hepatocellular carcinoma using 90Y-PET-computed tomography dosimetry., Nucl Med Commun, 2021. 42 (7)(7): p. 747-754., https://pubmed.ncbi.nlm.nih.gov/33741864/
889. Nodari, G, Popoff, R, Riedinger, JM, Lopez, O, Pellegrinelli, J, Dygai-Cochet, I, et.al. Impact of contouring methods on pre-treatment and post-treatment dosimetry for the prediction of tumor control and survival in HCC patients treated with selective internal radiation therapy., EJNMMI Res, 2021. 11 (1)(1): p. 24., https://pubmed.ncbi.nlm.nih.gov/33687596/
890. Allimant, C, Kafrouni, M, Delicque, J, Ilonca, D, Cassinotto, C, Assenat, E, et.al. Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma., J Vasc Interv Radiol, 2018. 29 (12)(12): p. 1662-1670.e4., https://pubmed.ncbi.nlm.nih.gov/30217745/
891. Son, MH, Ha, LN, Bang, MH, Bae, S, Giang, DT, Thinh, NT, et.al. Diagnostic and prognostic value of , Sci Rep, 2021. 11 (1)(1): p. 3207., https://pubmed.ncbi.nlm.nih.gov/33547398/
892. Celotti, A., Solaini, L., Montori, G., Coccolini, F., Tognali, D., Baiocchi, G., Preoperative biliary drainage in hilar cholangiocarcinoma: Systematic review and meta-analysis, Eur J Surg Oncol, 2017. 43(9): p. 1628-1635.
893. Ramanathan, R., Borrebach, J., Tohme, S., Tsung, A., Preoperative Biliary Drainage Is Associated with Increased Complications After Liver Resection for Proximal Cholangiocarcinoma, J Gastrointest Surg, 2018. 22(11): p. 1950-1957., https://link.springer.com/content/pdf/10.1007/s11605-018-3861-3.pdf
894. Cai, Y., Tang, Q., Xiong, X., Li, F., Ye, H., Song, P., et.al. Preoperative biliary drainage versus direct surgery for perihilar cholangiocarcinoma: A retrospective study at a single center, Biosci Trends, 2017. 11(3): p. 319-325., https://www.jstage.jst.go.jp/article/bst/11/3/11_2017.01107/_pdf
895. Farges, O., Regimbeau, J. M., Fuks, D., Le Treut, Y. P., Cherqui, D., Bachellier, P., et.al. Multicentre European study of preoperative biliary drainage for hilar cholangiocarcinoma, Br J Surg, 2013. 100(2): p. 274-83., https://bjssjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/bjs.8950?download=true
896. Xiong, J. J., Nunes, Q. M., Huang, W., Pathak, S., Wei, A. L., Tan, C. L., et.al. Preoperative biliary drainage in patients with hilar cholangiocarcinoma undergoing major hepatectomy, World J Gastroenterol, 2013. 19(46): p. 8731-9., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3870521/pdf/WJG-19-8731.pdf
897. Wang, L., Lin, N., Xin, F., Ke, Q., Zeng, Y., Liu, J., A systematic review of the comparison of the incidence of seeding metastasis between endoscopic biliary drainage and percutaneous transhepatic biliary drainage for resectable malignant biliary obstruction, World J Surg Oncol, 2019. 17(1): p. 116., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612106/pdf/12957_2019_Article_1656.pdf
898. Kishi, Y., Shimada, K., Nara, S., Esaki, M., Kosuge, T., The type of preoperative biliary drainage predicts short-term outcome after major hepatectomy, Langenbecks Arch Surg, 2016. 401(4): p. 503-11., https://link.springer.com/content/pdf/10.1007/s00423-016-1427-y.pdf
899. Sangchan, A., Kongkasame, W., Pugkhem, A., Jenwitheesuk, K., Mairiang, P., Efficacy of metal and plastic stents in unresectable complex hilar cholangiocarcinoma: a randomized controlled trial, Gastrointest Endosc, 2012. 76(1): p. 93-9.